<SEC-DOCUMENT>0001104659-24-054084.txt : 20240429
<SEC-HEADER>0001104659-24-054084.hdr.sgml : 20240429
<ACCEPTANCE-DATETIME>20240429163031
ACCESSION NUMBER:		0001104659-24-054084
CONFORMED SUBMISSION TYPE:	DEF 14A
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20240627
FILED AS OF DATE:		20240429
DATE AS OF CHANGE:		20240429

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Protalix BioTherapeutics, Inc.
		CENTRAL INDEX KEY:			0001006281
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				650643773
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEF 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33357
		FILM NUMBER:		24891458

	BUSINESS ADDRESS:	
		STREET 1:		2 UNIVERSITY PLAZA
		STREET 2:		SUITE 100
		CITY:			HACKENSACK
		STATE:			NJ
		ZIP:			07601
		BUSINESS PHONE:		201-696-9345

	MAIL ADDRESS:	
		STREET 1:		2 UNIVERSITY PLAZA
		STREET 2:		SUITE 100
		CITY:			HACKENSACK
		STATE:			NJ
		ZIP:			07601

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ORTHODONTIX INC
		DATE OF NAME CHANGE:	19980422

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EMBASSY ACQUISITION CORP
		DATE OF NAME CHANGE:	19960124
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEF 14A
<SEQUENCE>1
<FILENAME>tm2412127-1_def14a.htm
<DESCRIPTION>DEF 14A
<TEXT>
<html>
  <head>
    <title>tm2412127-1_def14a - none - 5.765656s</title>
  </head>
  <body style="margin-left:auto;margin-right:auto;width:595.31pt;">
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">&#8203;</div>
      <div style="margin-top:27.85pt;min-height:706pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:14pt;font-weight:bold;font-size:12pt;">
          <font style="letter-spacing:-0.24pt;">UNITED STATES </font>
          <br >
          <font style="letter-spacing:-0.24pt;">SECURITIES AND EXCHANGE COMMISSION </font>
        </div>
        <div style="margin-top:2pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Washington, D.C. 20549</font><font style="font-weight:normal;font-size:12pt;">&#8203;<font style="letter-spacing:0.24pt;"> </font></font>
        </div>
        <div style="margin-top:10pt; text-align:center; width:456pt; line-height:14pt;font-weight:bold;font-size:12pt;">
          <font style="letter-spacing:-0.24pt;">SCHEDULE 14A </font>
        </div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Proxy Statement Pursuant to Section&#160;14(a) of the Securities Exchange Act of 1934</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Filed by the Registrant&nbsp;&nbsp;&nbsp;&#9746; </font>
        </div>
        <div style="margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Filed by a Party other than the Registrant&nbsp;&nbsp;&nbsp;&#9744; </font>
        </div>
        <div style="margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Check the appropriate box: </font>
        </div>
        <div style=" float:left; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#9744;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Preliminary Proxy Statement </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#9744;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Confidential, for Use of the Commission Only (as permitted by Rule&#160;14a-6(e)(2))</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#9746;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Definitive Proxy Statement </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#9744;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Definitive Additional Materials </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#9744;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Soliciting Material Pursuant to &#167;240.14a-12 </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:16pt;font-weight:bold;font-size:14pt;">
          <font style="letter-spacing:-0.28pt;">Protalix BioTherapeutics, Inc. </font>
        </div>
        <div style="margin-top:1.167pt; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="text-align:center; width:456pt; line-height:10pt;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">(Name of Registrant as Specified In Its Charter)</font><font style="font-size:10pt;">&#8203;<font style="letter-spacing:0.2pt;"> </font></font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp; </font>
        </div>
        <div style="margin-top:2.5pt; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:-1pt; text-align:center; width:456pt; line-height:10pt;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">(Name of Person(s) Filing Proxy Statement, if other than the Registrant)</font><font style="font-size:10pt;">&#8203;<font style="letter-spacing:0.2pt;"> </font></font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Payment of Filing Fee (Check the appropriate box): </font>
        </div>
        <div style=" float:left; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#9746;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">No fee required. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#9744;</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Fee paid previously with preliminary materials. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#9744;</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Fee computed on table in exhibit required by Item&#160;25(b) per Exchange Act Rules 14a6(i)(1) and 0-11</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">&#8203;</div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:3pt;height:660pt;margin-left:69.66pt;width:456pt;">
        <div style="position:relative;width:456pt;">
          <img src="lg_protalix-4c.jpg" alt="[MISSING IMAGE: lg_protalix-4c.jpg]" height="51" width="164" >
        </div>
        <div style="margin-top:13pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">April&#160;29, 2024 </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Dear Stockholder, </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We cordially invite you to attend the 2024 Annual Meeting of Stockholders of Protalix BioTherapeutics, Inc. to be held at 11:30 A.M. EDT on June&#160;27, 2024 in the Garrison Room of the Lotte New York Palace Hotel, 455&#160;Madison Avenue, New York, NY 10022. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The attached notice of annual meeting and proxy statement describe the business we will conduct at the meeting and provide information about us that you should consider when you vote your shares. As set forth in the attached proxy statement, the meeting will be held to: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">consider the election of directors; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">approve an advisory vote on executive compensation; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">adopt amendments to the Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended, to increase the number of shares of common stock available under the plan from 12,475,171 shares to 17,475,171 shares and to amend certain other terms of said plan; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">ratify the appointment of our independent registered public accounting firm for the fiscal year ending December&#160;31, 2024. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Please take the time to carefully read each of the proposals stockholders are being asked to consider and vote on. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Please promptly vote your shares either via the Internet, by telephone or by marking, signing, dating and returning the proxy card in the enclosed envelope. Your vote is important, whether or not you attend the meeting in person. We encourage you to vote by proxy so that your shares will be represented and voted at the meeting. If you decide to attend the meeting and vote in person, your proxy may be revoked at your request. </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We appreciate your support and look forward to your attending the meeting. </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Sincerely, </font>
        </div>
        <div style="position:relative;margin-top:10pt; width:456pt;">
          <img src="sg_eyalrubin-bw.jpg" alt="[MISSING IMAGE: sg_eyalrubin-bw.jpg]" height="39" width="123" >
        </div>
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Eyal Rubin </font> <br ><font style="letter-spacing:0.2pt;">Sr. Vice President and Chief Financial Officer</font></div>
      </div>
      <div style="margin-top:2.00000000000002pt;margin-bottom:35.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">&#8203;</div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;height:660pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt;">
          <div style="margin-left: 38.158%; margin-right: 38.158%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">NOTICE OF 2024 ANNUAL MEETING OF STOCKHOLDERS </font>
          <br >
          <font style="letter-spacing:-0.2pt;">TO BE HELD ON JUNE 27, 2024</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:10.5pt; text-align:center; width:456pt;">
          <div style="margin-left: 38.158%; margin-right: 38.158%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">To the Stockholders of Protalix BioTherapeutics, Inc.: </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The 2024 Annual Meeting of Stockholders of Protalix BioTherapeutics, Inc. (the &#8220;Company&#8221;) will be held at the following time, date and place for the following purposes: </font>
        </div>
        <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:60pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">TIME:</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">11:30 A.M. EDT </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:60pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">DATE:</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">June&#160;27, 2024 </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:60pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">PLACE:</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">The Garrison Room of the Lotte New York Palace Hotel, 455 Madison Avenue, New York, NY 10022 </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">PURPOSES: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">1.</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">To elect or re-elect seven members to the Board of Directors to serve for the ensuing year or until their respective successors have been duly elected; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">2.</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">To approve, on a non-binding advisory basis, the compensation of the Company&#8217;s named executive officers as disclosed in the proxy statement that accompanies this notice; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">3.</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">To adopt amendments to the Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended, to increase the number of shares of common stock available under the plan from 12,475,171 shares to 17,475,171 shares and to amend certain other terms of said plan; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">4.</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">To ratify the appointment of Kesselman &amp; Kesselman, Certified Public Accountant (lsr.), a member of PricewaterhouseCoopers International Limited, as our independent registered public accounting firm for the fiscal year ending December&#160;31, 2024; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">5.</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">To transact such other business that is properly presented at the meeting or any adjournment.</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">All of these proposals are more fully described in the proxy statement that follows. You may vote at the meeting and any adjournments if you were the record owner of the Company&#8217;s common stock at the close of business on April&#160;29, 2024. A list of stockholders of record will be available at the meeting and, during the 10&#160;days prior to the meeting, at the office of the Company&#8217;s Corporate Secretary at 2 University Plaza, Suite 100, Hackensack, NJ 07601. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Please sign, date and promptly return the enclosed proxy card in the enclosed envelope, or vote by telephone or Internet (instructions are on your proxy card), so that your shares will be represented whether or not you attend the annual meeting.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:98pt;margin-top:14pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:10pt;min-height:11pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:222pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:222pt;">
              <font style="letter-spacing:0.2pt;">BY ORDER OF THE BOARD OF DIRECTORS </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="min-height:49pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:16pt 0pt 0.5pt 0pt; width:222pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:16pt 0pt 4pt 0pt; width:222pt;white-space:normal;">
              <div style="position:relative;">
                <img src="sg_eyalrubin-bw.jpg" alt="[MISSING IMAGE: sg_eyalrubin-bw.jpg]" height="39" width="123" >
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;min-height:43pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 11pt 0pt; width:222pt;">
              <font style="letter-spacing:0.2pt;">Carmiel, Israel </font>
              <br >
              <font style="letter-spacing:0.2pt;">April&#160;29, 2024 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 11pt 0pt; width:222pt;white-space:normal;">
              <font style="letter-spacing:0.2pt;">Eyal Rubin </font>
              <br >
              <font style="letter-spacing:0.2pt;">Sr. Vice President and Chief Financial Officer and Corporate Secretary</font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;margin-bottom:35.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">&#8203;</div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Protalix BioTherapeutics, Inc. </font>
          <br >
          <font style="letter-spacing:-0.2pt;">2 University Plaza, Suite 100 </font>
          <br >
          <font style="letter-spacing:-0.2pt;">Hackensack, NJ 07601 </font>
          <br >
          <font style="letter-spacing:-0.2pt;">201-696-9345</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:10.5pt; text-align:center; width:456pt;">
          <div style="margin-left: 38.158%; margin-right: 38.158%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:7.1pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">PROXY STATEMENT FOR PROTALIX BIOTHERAPEUTICS, INC. </font>
          <br >
          <font style="letter-spacing:-0.2pt;">2024 ANNUAL MEETING OF STOCKHOLDERS </font>
          <br >
          <font style="letter-spacing:-0.2pt;">TO BE HELD ON JUNE 27, 2024</font>
        </div>
        <div style="margin-top:7.5pt; text-align:center; width:456pt;">
          <div style="margin-left: 38.158%; margin-right: 38.158%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:7.1pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">GENERAL INFORMATION ABOUT THE ANNUAL MEETING</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Why Did You Send Me This Proxy Statement?</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We sent you this proxy statement and the enclosed proxy card because the Board of Directors of Protalix BioTherapeutics, Inc. is soliciting your proxy to vote at the 2024 Annual Meeting of Stockholders and any adjournments of the meeting to be held on June&#160;27, 2024 in the Garrison Room of the Lotte New York Palace Hotel, 455 Madison Avenue, New York, NY 10022. This proxy statement, along with the accompanying Notice of Annual Meeting of Stockholders, summarizes the purposes of the meeting and the information you need to know to vote at the meeting. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We anticipate that on or about May&#160;13, 2024, we will begin sending this proxy statement, the attached Notice of Annual Meeting and the form of proxy enclosed to all stockholders entitled to vote at the meeting. Although not part of this proxy statement, we are also sending along with this proxy statement our Annual Report on Form 10-K which includes financial statements for the fiscal year ended December&#160;31, 2023 (the &#8220;FY2023 Annual Report&#8221;). You can also find a copy of our FY2023 Annual Report on the Internet through the electronic data system called EDGAR provided by the Securities and Exchange Commission, or the SEC, at http://www.sec.gov or through the Investor Relations section of our website at http://www.protalix.com. Our FY2023 Annual Report and the information on the website other than the proxy statement are not part of our proxy soliciting materials. Additional copies of the FY2023 Annual Report are available upon request. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Who Can Vote?</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Only holders of record of our common stock, par value $0.001 per share, on April&#160;29, 2024 (the &#8220;Record Date&#8221;), are entitled to vote at the meeting. On the Record Date, there were 73,316,084 shares of common stock outstanding and entitled to vote. The common stock is currently our only outstanding class of voting stock. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">You do not need to attend the meeting to vote your shares. Shares represented by valid proxies, received in time for the meeting and not revoked prior to the meeting, will be voted at the meeting. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">How Many Votes Do I Have?</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Each share of common stock that you own entitles you to one vote. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">How Do I Vote?</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Whether you plan to attend the meeting or not, we urge you to vote by proxy. Voting by proxy will not affect your right to attend the meeting. If your shares are registered directly in your name through our stock transfer agent, Equiniti Trust Company, LLC, or you have stock certificates, you may vote: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="font-weight:bold;letter-spacing:-0.2pt;">By mail.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Complete, date, sign and mail the enclosed proxy card in the enclosed postage prepaid envelope. Your proxy will be voted in accordance with your instructions. If you sign the proxy card but do not specify how you want your shares voted, they will be voted as recommended by our Board of Directors. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="font-weight:bold;letter-spacing:-0.2pt;">By Internet or by telephone.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Follow the instructions attached to the proxy card to vote by Internet or telephone. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">1</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">&#8203;</div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="font-weight:bold;letter-spacing:-0.2pt;">In person at the meeting.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;If you attend the meeting, you may deliver your completed proxy card in person or you may vote by completing a ballot, which will be available at the meeting. We recommend arriving early to the meeting as there may be delays at the entrance to the meeting venue. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If your shares are held in &#8220;street name&#8221; &#8203;(held in the name of a bank, broker or other nominee), you must provide the bank, broker or other nominee with instructions on how to vote your shares and can generally do so as follows: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="font-weight:bold;letter-spacing:-0.2pt;">By mail.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Complete, date, sign and mail the enclosed proxy card in the enclosed postage prepaid envelope. Your proxy will be voted in accordance with your instructions. If you sign the proxy card but do not specify how you want your shares voted, they will be voted as recommended by our Board of Directors. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="font-weight:bold;letter-spacing:-0.2pt;">By Internet or by telephone.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Follow the instructions attached to the proxy card to vote by Internet or telephone. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="font-weight:bold;letter-spacing:-0.2pt;">In person at the meeting.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;If you attend the meeting, you may deliver your completed proxy card in person or you may vote by completing a ballot, which will be available at the meeting. We recommend arriving early to the meeting as there may be delays at the entrance to the meeting venue. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If you need assistance in voting by telephone or over the Internet or completing your proxy card or have questions regarding the meeting, please contact our proxy advisor: </font>
        </div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Alliance Advisors, LLC</font>
          <br >
          <font style="letter-spacing:0.2pt;">200 Broadacres Drive, 3rd Floor</font>
          <br >
          <font style="letter-spacing:0.2pt;">Bloomfield, NJ 07003</font>
          <br >
          <font style="letter-spacing:0.2pt;">+1 (855) 200-7892 (toll free in the United States) </font>
          <br >
          <font style="letter-spacing:0.2pt;">PLX@AllianceAdvisors.com </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">What Am I Voting On?</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">You are voting on: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">The election or re-election of seven members to our Board of Directors to serve for the ensuing year or until their respective successors have been duly elected (Eliot Richard Forster, Ph.D., Dror Bashan, Amos Bar Shalev, Shmuel &#8220;Muli&#8221; Ben Zvi, Ph.D., Pol F. Boudes, M.D., Gwen A. Melincoff and Aharon Schwartz, Ph.D.). </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">To approve, on a non-binding advisory basis, the compensation of our named executive officers as disclosed in this proxy statement. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">To adopt amendments to the Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended (the &#8220;Plan&#8221;), to increase the number of shares of common stock available under the plan from 12,475,171 shares to 17,475,171 shares and to amend certain other terms of said plan. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">The ratification of the appointment of Kesselman and Kesselman, Certified Public Accountant (Isr.), a member of PricewaterhouseCoopers International Limited, as our independent registered public accounting firm for the fiscal year ending December&#160;31, 2024. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">How Does The Board Of Directors Recommend That I Vote At The Meeting?</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Board of Directors recommends that you vote as follows: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">FOR</font><font style="letter-spacing:0.2pt;">&#8221; the election or re-election of all director nominees named in &#8220;Proposal 1: Election of Directors&#8221; of this proxy statement. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">FOR</font><font style="letter-spacing:0.2pt;">&#8221; the approval, on a non-binding advisory basis, of our executive compensation as disclosed in the proxy statement that accompanies this notice and as described in &#8220;Proposal 2: Advisory Vote on Executive Compensation&#8221; of this proxy statement. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">FOR</font><font style="letter-spacing:0.2pt;">&#8221; the adoption of amendments to the Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended, to increase the number of shares of common stock available under the plan from </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">2</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">&#8203;</div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:30pt; width:426pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">12,475,171 shares to 17,475,171 shares and to amend certain other terms of said plan as disclosed in the proxy statement that accompanies this notice and as described in &#8220;Proposal 3: Advisory Vote on Executive Compensation&#8221; of this proxy statement; and </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">FOR</font><font style="letter-spacing:0.2pt;">&#8221; the ratification of Kesselman and Kesselman as our independent registered public accounting firm for the 2024 fiscal year, as named in &#8220;Proposal 4: Ratification of Independent Registered Public Accounting Firm&#8221; of this proxy statement. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If any other matter is properly presented at the meeting or any adjournment, the proxy card provides that your shares will be voted by the proxy holder listed on the proxy card in accordance with his or her best judgment. At the time this proxy statement was printed, we knew of no matters that needed to be acted on at the meeting, other than those discussed in this proxy statement. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">What Constitutes A Quorum For The Meeting?</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Of the 73,316,084 shares of common stock outstanding as of the Record Date, the holders of at least one-third (1/3) of those shares, or at least 24,438,695 shares, must be present at the meeting in person or represented by proxy to hold the meeting and conduct business. Once a quorum is established at a meeting, it shall not be broken by the withdrawal of enough votes to leave less than a quorum. Shares held by stockholders of record who are present at the meeting in person or by proxy are counted for purposes of determining whether a quorum exists. Abstentions and &#8220;broker non-votes&#8221; are also counted as present and entitled to vote for purposes of determining whether a quorum exists. If a quorum is not present, the meeting will be adjourned until a quorum is obtained. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">What Are The Voting Requirements To Approve A Proposal?</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Election of directors</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Director nominees will be elected by a plurality of votes cast, which means that the director nominees receiving the highest number of votes will be elected. In voting to elect nominees to the Board of Directors, stockholders may vote in favor of all the nominees or any individual nominee or withhold their votes as to all the nominees or any individual nominee. Only &#8220;FOR&#8221; and &#8220;WITHHOLD&#8221; votes will affect the outcome. Abstentions and broker non-votes will have no effect on Proposal 1. </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Approval of non-binding advisory resolution on executive compensation</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">You may vote &#8220;FOR,&#8221; &#8220;AGAINST&#8221; or &#8220;ABSTAIN&#8221; on the advisory vote to approve executive compensation. Approval requires the affirmative vote of the majority of shares present in person or represented by proxy at the meeting and entitled to vote on the resolution. The outcome of this vote is not binding; however, the Board of Directors and the Compensation Committee will consider the outcome of the vote when developing and reviewing the future executive compensation plans. Abstentions and broker non-votes will have no effect on Proposal 2. </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Adoption of amendments to the Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended, to increase the number of authorized shares of common stock reserved for issuance under the plan and to amend certain other terms of the plan</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">You may vote &#8220;FOR,&#8221; &#8220;AGAINST&#8221; or &#8220;ABSTAIN&#8221; on the adoption of an amendment to the Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended, to increase the number of authorized shares of common stock reserved for issuance under the plan. If a quorum is present, adoption of the amendment requires that the number of votes cast at the meeting in favor of adoption exceeds the number of votes cast opposing adoption. Abstentions and broker non-votes will have no effect on Proposal 3. </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Ratification of the selection of Kesselman &amp; Kesselman as our independent auditor</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">You may vote &#8220;FOR,&#8221; &#8220;AGAINST&#8221; or &#8220;ABSTAIN&#8221; on the ratification of the selection of Kesselman&#160;&amp; Kesselman to serve as our principal independent registered public accounting firm for the fiscal year ending December&#160;31, 2024. Ratification of the appointment of our independent registered public accounting </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">3</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">&#8203;</div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">firm requires the affirmative vote of the majority of shares present in person or represented by proxy at the meeting and entitled to vote on the proposal. Abstentions will have no effect on Proposal 4. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">How Are My Votes Cast When I Sign And Return A Proxy Card?</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">When you sign the proxy card or submit your proxy by telephone or over the Internet, you appoint Dror Bashan, our President and Chief Executive Officer, and Eyal Rubin, our Sr. Vice President and Chief Financial Officer, as your representatives at the meeting. Either Mr.&#160;Bashan or Mr.&#160;Rubin will vote your shares at the meeting as you have instructed them on the proxy card. Each such person may appoint a substitute for himself. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Even if you plan to attend the meeting, it is a good idea to complete, sign and return your proxy card or submit your proxy by telephone or over the Internet in advance of the meeting in case your plans change. This way, your shares will be voted by you whether or not you actually attend the meeting. We recommend arriving early to the meeting as there may be delays at the entrance to the meeting venue. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">May I Revoke My Proxy?</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If you give us your proxy, you may revoke it at any time before it is voted at the meeting. There will be no double counting of votes. You may revoke your proxy in any one of the following ways: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">entering a new vote or by granting a new proxy card or new voting instruction bearing a later date (which automatically revokes the earlier instructions); </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.71pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.71pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">if your shares are held in street name, re-voting by Internet or by telephone as instructed above (only your latest Internet or telephone vote will be counted); </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">notifying our Corporate Secretary, Eyal Rubin, in writing before the meeting that you have revoked your proxy; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">attending the meeting in person and voting in person. Attending the meeting in person will not in and of itself revoke a previously submitted proxy unless you specifically request it. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Can My Broker Vote My Shares For Me?</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">A broker &#8220;non-vote&#8221; occurs when a broker or nominee holding shares for a beneficial owner does not vote on a particular matter because the matter is not routine and such broker or nominee does not have the discretionary voting authority to vote the shares for which it is the holder of record with respect to a particular matter at the meeting and such broker or nominee has not received instructions from the beneficial owner. Broker &#8220;non-votes,&#8221; and shares as to which proxy authority has been withheld with respect to any matter, are generally not deemed to be entitled to vote for purposes of determining whether stockholders&#8217; approval of that matter has been obtained. Pursuant to New York Stock Exchange (&#8220;NYSE&#8221;) Rule&#160;452, the uncontested election of directors (Proposal No. 1), the approval of a non-binding advisory resolution on executive compensation (Proposal No. 2) and the adoption of amendments to the Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended, which increase the number of shares of common stock authorized for issuance under the plan and amend certain other terms of the plan (Proposal No. 3) are non-routine matters and, therefore, may not be voted upon by brokers without instructions from beneficial owners. Consequently, proxies submitted by brokers for shares beneficially owned by other persons may not, in the absence of specific instructions from such beneficial owners, vote the shares in favor of or withhold votes from such proposals at the brokers&#8217; discretion. The ratification of the selection of Kesselman &amp; Kesselman to serve as our principal independent registered public accounting firm for the fiscal year ending December&#160;31, 2024 (Proposal No. 4) is a routine matter. </font><font style="font-weight:bold;letter-spacing:-0.2pt;">Please complete your proxy and return it as instructed so your vote can be counted.</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">What If I Receive More Than One Proxy Card?</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">You may receive more than one proxy card or voting instruction form if you hold shares of our common stock in more than one account, which may be in registered form or held in street name. Please vote in the manner described under &#8220;How Do I Vote?&#8221; for each account to ensure that all of your shares are voted. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">4</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">&#8203;</div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">What If I Do Not Vote For Some Of The Matters Listed On My Proxy Card?</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If you return your proxy card without indicating your vote, your shares will be voted </font><font style="font-style:italic;letter-spacing:0.2pt;">for</font><font style="letter-spacing:0.2pt;"> all of the nominees listed on the card; </font><font style="font-style:italic;letter-spacing:0.2pt;">for</font><font style="letter-spacing:0.2pt;"> the approval, on an advisory basis, of the executive compensation; </font><font style="font-style:italic;letter-spacing:0.2pt;">for</font><font style="letter-spacing:0.2pt;"> the adoption of amendments to the Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended, which increase the number of shares of common stock authorized for issuance under the plan and amend certain other terms of the plan; and </font><font style="font-style:italic;letter-spacing:0.2pt;">for</font><font style="letter-spacing:0.2pt;"> the ratification of the appointment of Kesselman &amp; Kesselman. </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Will My Shares Be Voted If I Do Not Return My Proxy Card And Do Not Attend The Annual Meeting?</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If your shares are registered in your name or if you have stock certificates, they will not be voted if you do not return your proxy card by mail or vote at the meeting as described above under &#8220;How Do I Vote?&#8221;. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If your shares are held in street name and you do not provide voting instructions to the bank, broker or other nominee that holds your shares as described above under &#8220;How Do I Vote?,&#8221; the bank, broker or other nominee has the authority to vote your shares on certain routine matters scheduled to come before the meeting even if it does not receive instructions from you. We encourage you to provide voting instructions. This ensures your shares will be voted at the meeting in the manner you desire. </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Is Voting Confidential?</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Yes. Only the inspector of elections and our employees who have been assigned the responsibility for overseeing the legal aspects of the meeting and our proxy solicitors will have access to your proxy card. The inspector of elections will tabulate and certify the vote. Any comments written on the proxy card will remain confidential unless you ask that your name be disclosed. </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">What Are The Costs Of Soliciting These Proxies?</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-size:9.9pt;">
          <font style="font-size:10pt;letter-spacing:0.198pt;">We will pay all of the costs of soliciting these proxies. Our officers, directors and employees may solicit proxies in person or by telephone, fax or email. We will pay these officers, employees and directors no additional compensation for these services. We will ask banks, brokers and other institutions, nominees and fiduciaries to forward these proxy materials to their principals and to obtain authority to execute proxies. We will then reimburse them for their expenses. We have engaged Alliance Advisors LLC to assist us in soliciting proxies for the meeting. We will pay Alliance Advisors a base fee of $10,000, plus reasonable out-of-pocket expenses, plus an additional fee based upon the number of contacts with stockholders made and work performed. We estimate the total amount payable to Alliance Advisors will be approximately $100,000.</font><font style="font-size:10pt;">&#8203;<font style="letter-spacing:0.2pt;"> </font></font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Could Other Matters Be Decided At The Annual Meeting?</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We do not know of any other matters that will be considered at the meeting. If any other matters arise at the meeting at or by the direction of the Board of Directors, the proxies will be voted at the discretion of the proxy holders. </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">What Happens If The Annual Meeting Is Postponed Or Adjourned?</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Your proxy will still be valid and may be voted at the postponed or adjourned meeting. You will still be able to change or revoke your proxy until it is voted. </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Do I Need A Ticket To Attend The Annual Meeting?</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Yes, you will need an admission ticket or proof of ownership of common stock to enter the meeting. If you are a stockholder of record, your admission ticket is the bottom half of the proxy card sent to you. If you plan to attend the meeting, please so indicate when you vote and bring the ticket with you to the meeting. If your shares are held in the name of a bank, broker or other holder of record, your admission ticket is the left side of your voting information form. If you do not bring your admission ticket, you will need proof of ownership to be admitted to the meeting. A recent brokerage statement or letter from a bank or broker is an example of proof of ownership. If you arrive at the meeting without an admission ticket, we will admit you only if we are able to verify that you are a stockholder of our Company. We recommend arriving early to the meeting as there may be delays at the entrance to the meeting venue.</font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">5</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">&#8203;</div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following table sets forth information, as of April&#160;29, 2024, regarding beneficial ownership of our common stock: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">each person who is known by us to own beneficially more than 5% of our common stock; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.01pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.01pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">each director; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">each of our executive officers; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.01pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.01pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">all of our directors and executive officers collectively. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Unless otherwise noted, we believe that all persons named in the table have sole voting and investment power with respect to all shares of our common stock beneficially owned by each of them. For purposes of this table, a person is deemed to be the beneficial owner of securities that can be acquired by such person within 60&#160;days from April&#160;29, 2024 upon exercise of options, warrants and convertible securities. Each beneficial owner&#8217;s&#160;percentage ownership is determined by assuming that options, warrants and convertible securities that are held by such person (but not those held by any other person) and that are exercisable or convertible within 60&#160;days from such date have been exercised. The information set forth below is based upon information obtained from the beneficial owners, upon information in our possession regarding their respective holdings and upon information filed by the holders with the SEC. The&#160;percentages of beneficial ownership are based on 73,316,084 shares of our common stock outstanding as of April&#160;29, 2024. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The address for all directors and officers is c/o&#160;Protalix BioTherapeutics, Inc., 2 Snunit Street, Science Park, P.O. Box 455, Carmiel 2161401, Israel. </font>
        </div>
        <table style="width:416pt;height:242.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:272.28pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Name and Address of Beneficial Owner </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Amount and Nature of</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Beneficial Ownership </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Percentage of</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Class (%) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:272.28pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Board of Directors and Executive Officers</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.265pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.265pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:272.28pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Eliot Richard Forster, Ph.D.</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(1)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.04pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">21,428</td>
            <td style="padding:0pt;padding-left:17.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.265pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:16.265pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:272.28pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Dror Bashan</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(2)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.04pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">2,770,059</td>
            <td style="padding:0pt;padding-left:17.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.265pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">3.8</td>
            <td style="padding:0pt;padding-left:16.265pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:272.28pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Amos Bar Shalev</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(3)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.04pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">72,322</td>
            <td style="padding:0pt;padding-left:17.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.265pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:16.265pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:272.28pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Shmuel &#8220;Muli&#8221; Ben Zvi, Ph.D.</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(4)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.04pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">32,154</td>
            <td style="padding:0pt;padding-left:17.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.265pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:16.265pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:272.28pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Pol F. Boudes, M.D.</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(5)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.04pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">72,194</td>
            <td style="padding:0pt;padding-left:17.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.265pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:16.265pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:272.28pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Gwen A. Melincoff</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(6)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.04pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">72,154</td>
            <td style="padding:0pt;padding-left:17.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.265pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:16.265pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:272.28pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Aharon Schwartz, Ph.D.</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(7)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.04pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">246,154</td>
            <td style="padding:0pt;padding-left:17.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.265pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:16.265pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:272.28pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Yaron Naos</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(8)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.04pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">536,039</td>
            <td style="padding:0pt;padding-left:17.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.265pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:16.265pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:272.28pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Eyal Rubin</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(9)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.04pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">803,125</td>
            <td style="padding:0pt;padding-left:17.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.265pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">1.1</td>
            <td style="padding:0pt;padding-left:16.265pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:272.28pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">All executive officers and directors as a group (9 persons)</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(10)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.04pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">4,625,629</td>
            <td style="padding:0pt;padding-left:17.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.265pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">6.3</td>
            <td style="padding:0pt;padding-left:16.265pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:272.28pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">5% Holders</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.265pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.265pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:272.28pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Alfred Akirov</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(11)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.04pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">4,517,192</td>
            <td style="padding:0pt;padding-left:17.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.265pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">6.0</td>
            <td style="padding:0pt;padding-left:16.265pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:272.28pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Highbridge Capital Management LLC</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(12)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.04pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">8,137,181</td>
            <td style="padding:0pt;padding-left:17.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.265pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">9.9</td>
            <td style="padding:0pt;padding-left:16.265pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:272.28pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">HIR Investments Ltd.</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(13)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.04pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">6,724,845 </td>
            <td style="padding:0pt;padding-left:17.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.265pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">8.9</td>
            <td style="padding:0pt;padding-left:16.265pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.3pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:7.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">*</font>
          <br >
        </div>
        <div style=" margin-top:7.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Less than 1%. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.41pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:3.41pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Consists of 21,428 shares of our common stock issuable upon exercise of outstanding options within 60&#160;days of April&#160;29, 2024. Does not include 64,287 shares of our common stock underlying options that will not vest within 60&#160;days of April&#160;29, 2024. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(2)</font>
          <br >
        </div>
        <div style=" margin-top:3.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Consists of 132,516 outstanding shares of our common stock, 1,746,422 outstanding restricted shares of our common stock that are not subject to forfeiture within 60&#160;days of April&#160;29, 2024, 402,996 outstanding restricted shares of our common stock that are subject to forfeiture as of April&#160;29, 2024 and 488,125 shares of our common stock issuable upon exercise of outstanding options within 60&#160;days of April&#160;29, 2024. Does not include 421,875 shares of our common stock underlying options that will not vest within 60&#160;days of April&#160;29, 2024. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">6</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">&#8203;</div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(3)</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Consists of 168 outstanding shares of our common stock and 72,154 shares of our common stock issuable upon exercise of outstanding options within 60&#160;days of April&#160;29, 2024. Does not include 79,522 shares of our common stock underlying options that will not vest within 60&#160;days of April&#160;29, 2024. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(4)</font>
          <br >
        </div>
        <div style=" margin-top:4.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Consists of 32,154 shares of our common stock issuable upon exercise of outstanding options within 60&#160;days of April&#160;29, 2024. Does not include 79,522 shares of our common stock underlying options that will not vest within 60&#160;days of April&#160;29, 2024. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(5)</font>
          <br >
        </div>
        <div style=" margin-top:4.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Consists of 40 outstanding shares of our common stock and 72,154 shares of our common stock issuable upon exercise of outstanding options within 60&#160;days of April&#160;29, 2024. Does not include 79,522 shares of our common stock underlying options that will not vest within 60&#160;days of April&#160;29, 2024. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4.09pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(6)</font>
          <br >
        </div>
        <div style=" margin-top:4.09pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Consists of 72,154 shares of our common stock issuable upon exercise of outstanding options within 60&#160;days of April&#160;29, 2024. Does not include 79,522 shares of our common stock underlying options that will not vest within 60&#160;days of April&#160;29, 2024. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(7)</font>
          <br >
        </div>
        <div style=" margin-top:4.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Consists of 174,000 outstanding shares of our common stock and 72,154 shares of our common stock issuable upon exercise of outstanding options within 60&#160;days of April&#160;29, 2024. Does not include 79,522 shares of our common stock underlying options that will not vest within 60&#160;days of April&#160;29, 2024. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(8)</font>
          <br >
        </div>
        <div style=" margin-top:4.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Consists of 12,955 outstanding shares of our common stock, 53,836 outstanding restricted shares of our common stock that are not subject to forfeiture within 60&#160;days of April&#160;29, 2024, 140,508 outstanding restricted shares of our common stock that are subject to forfeiture within 60&#160;days of April&#160;29, 2024, 328,740 shares of our common stock issuable upon exercise of outstanding options within 60&#160;days of April&#160;29, 2024. Does not include 198,916 shares of our common stock underlying options that will not vest within 60&#160;days of April&#160;29, 2024. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(9)</font>
          <br >
        </div>
        <div style=" margin-top:4.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Consists of 404,928 outstanding restricted shares of our common stock that are not subject to forfeiture within 60&#160;days of April&#160;29, 2024, 165,072 outstanding restricted shares of our common stock that are subject to forfeiture as of April&#160;29, 2024 and 233,125 shares of our common stock issuable upon exercise of outstanding options within 60&#160;days of April&#160;29, 2024. Does not include 196,875 shares of our common stock underlying options that will not vest within 60&#160;days of April&#160;29, 2024. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4.09pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(10)</font>
          <br >
        </div>
        <div style=" margin-top:4.09pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Consists of 319,679 outstanding shares of our common stock, 2,205,186 outstanding restricted shares of our common stock that are not subject to forfeiture within 60&#160;days of April&#160;29, 2024, 708,576 outstanding restricted shares of our common stock that are subject to forfeiture as of April&#160;29, 2024 and 1,392,188 shares of our common stock issuable upon exercise of outstanding options within 60&#160;days of April&#160;29, 2024. Does not include 1,279,563 shares of our common stock underlying options that will not vest within 60&#160;days of April&#160;29, 2024. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(11)</font>
          <br >
        </div>
        <div style=" margin-top:4.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Based on information provided by Alfred Akirov. Consists of 2,505,120 outstanding shares of our common stock and 2,012,072 shares of our common stock issuable upon exercise of outstanding warrants within 60&#160;days of April&#160;29, 2024, in the aggregate, held by Alrov Properties &amp; Lodgings Ltd., or Alrov Properties, Technorov Holdings (1993) Ltd., or Technorov, and Alrov Ventures Ltd., or Alrov Ventures. Mr.&#160;Akirov is the majority shareholder, and Chairman of the Board of each of Alrov Properties, which is listed on the Tel Aviv Stock Exchange, and the subsidiaries of Alrov Properties, Technorov and Alrov Ventures, and, accordingly, in the normal course of business has the power to direct the voting and disposition decisions of such entities, all subject to the Israeli law provision in regards to a public company. Mr.&#160;Akirov&#8217;s principal business office is at The Alrov Tower, 46 Rothschild Boulevard, Tel Aviv 66883, Israel. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(12)</font>
          <br >
        </div>
        <div style=" margin-top:4.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Based on a Schedule&#160;13F-HR filed on February&#160;12, 2024 for December&#160;31, 2023 by Highbridge Capital Management LLC, or Highbridge and other information provided by Highbridge. Consists of 8,137,181 shares of our common stock issuable upon conversion of convertible notes and exercise of outstanding warrants within 60&#160;days of April&#160;29, 2024, held by Highbridge Tactical Credit Master Fund, L.P., or the Highbridge Fund. Highbridge, as the trading manager of the Highbridge Fund, and the Highbridge Fund may each be deemed to be the beneficial owner of such shares. The convertible notes and the warrants are subject to blocker provisions pursuant to which the holders thereof cannot convert the notes or exercise the warrants to the extent that the reporting persons would beneficially own, after any such exercise, more than 9.99% of the outstanding shares of our common stock. The </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">7</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">&#8203;</div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:400pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">disclosed holdings do not include all of the shares underlying all of the notes and the warrants due to the blocker provisions. The principal business office of Highbridge is 277 Park Avenue, 23rd Floor, New York, New York 10172. </font>
        </div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(13)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Based on information provided by the holder. Consists of 4,676,341 outstanding shares of our common stock and 2,012,072 shares of our common stock issuable upon exercise of outstanding warrants within 60&#160;days of April&#160;29, 2024, in the aggregate, held by HIR Investments Ltd., or HIR, and 36,432 outstanding shares of our common stock held directly or indirectly by Chinar Shah. Mr.&#160;Shah has the power to direct the voting and disposition decisions of, and thus may be deemed to have beneficial ownership (as determined under Section&#160;13(d) of the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;)) of, all such shares and warrants. The principal business office of HIR is Flat No. 303, Al-Shamal Building, Al-Khor Street, Goldsuq, Deira, Dubai, UAE. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Section&#160;16(a) Beneficial Ownership Reporting Compliance</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;16(a) of the Exchange Act requires our directors, executive officers and holders of more than 10% of our common stock to file with the SEC reports regarding their ownership and changes in ownership of our equity securities. We believe that all Section&#160;16 filings requirements were met by our officers and directors during 2023. In making this statement, we have relied solely upon examination of the copies of Forms 3, 4 and 5, and written representations of our former and current officers and directors.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">8</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">&#8203;</div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">PROPOSAL 1: ELECTION OF DIRECTORS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">At the meeting, our stockholders will be asked to elect or re-elect seven directors for a one-year term expiring at the next meeting of stockholders. Each director will hold office until his or her successor has been elected and qualified or until the director&#8217;s earlier resignation or removal. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our Board of Directors recommends that the persons named below be elected or re-elected as directors of our Company and it is intended that the accompanying proxy will be voted for their election as directors, unless the proxy contains contrary instructions. Shares of common stock represented by all proxies received by the Board of Directors and not so marked as to withhold authority to vote for any individual nominee or for all nominees will be voted (unless one or more nominees are unable to serve) for the election of the nominees named below. The Board of Directors knows of no reason why any such nominee should be unable or unwilling to serve, but if such should be the case, proxies will be voted for the election of some other person or the size of the Board of Directors will be fixed at a lower number. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Each of the nominees currently serves as a member of our Board of Directors. The directors are elected by a plurality of the votes cast by the stockholders present or represented by proxy and entitled to vote at the Annual Meeting. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Nominees for Election to the Board of Directors</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The names of the nominees for election or re-election to the Board of Directors and certain information about such nominees are set forth below. For information concerning the number of shares of common stock beneficially owned by each nominee, see &#8220;Security Ownership of Certain Beneficial Owners and Management&#8221; above. </font>
        </div>
        <table style="width:416pt;height:113.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:156pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Name </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:13.25pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Age </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:222.75pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Position </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:156pt;">
              <font style="letter-spacing:0.2pt;">Eliot Richard Forster, Ph.D. </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:13.25pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">58 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:222.75pt;">
              <font style="letter-spacing:0.2pt;">Chairman of the Board </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:156pt;">
              <font style="letter-spacing:0.2pt;">Dror Bashan </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:13.25pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">57 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:222.75pt;">
              <font style="letter-spacing:0.2pt;">President and Chief Executive Officer, Director </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:156pt;">
              <font style="letter-spacing:0.2pt;">Amos Bar Shalev </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:13.25pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">71 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:222.75pt;">
              <font style="letter-spacing:0.2pt;">Director </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:156pt;">
              <font style="letter-spacing:0.2pt;">Shmuel &#8220;Muli&#8221; Ben Zvi, Ph.D. </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:13.25pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">64 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:222.75pt;">
              <font style="letter-spacing:0.2pt;">Director </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:156pt;">
              <font style="letter-spacing:0.2pt;">Pol F. Boudes, M.D. </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:13.25pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">67 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:222.75pt;">
              <font style="letter-spacing:0.2pt;">Director </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:156pt;">
              <font style="letter-spacing:0.2pt;">Gwen A. Melincoff </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:13.25pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">72 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:222.75pt;">
              <font style="letter-spacing:0.2pt;">Director </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:156pt;">
              <font style="letter-spacing:0.2pt;">Aharon Schwartz, Ph.D. </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:13.25pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">81 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:222.75pt;">
              <font style="letter-spacing:0.2pt;">Director</font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Eliot Richard Forster, Ph.D.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Dr.&#160;Forster joined our Board of Directors as its Chairman in September&#160;2023. Dr.&#160;Forster has served as the Chief Executive Officer of Levicept Ltd., a privately-held, UK-based biotechnology company since November 2023. He also has served as a Non-Executive Chairman of Avacta Group PLC (AIM:AVCT) since June 2018, and as a Non-Executive Director of Immatics NV (NASDAQ:IMTX) since September 2020. In addition he has served as the Non-Executive Chairman of Ochre Bio, Ltd., a UK-based private biotechnology company since May 2023, and Non-Executive Chairman of Tessellate BIO NV., a Netherlands-based private biotechnology company, since September 2023. He served, from September&#160;2018, as the Chief Executive Officer of F-Star Therapeutics Ltd. (NASDAQ:FSTX) until its March&#160;2023 sale to invoX Ltd. Prior to that, he served as Chief Executive Officer of Immunocure Ltd. from January 2015 to February 2018, Chief Executive Officer of Creabilis SA from May 2010 to January 2015 and President and Chief Executive Officer of Solace Pharmaceuticals Inc. from May 2007 to May 2010. Earlier in his career, he held positions at Pfizer Global Research &amp; Development and Glaxo/</font>&#8203;<font style="letter-spacing:0.2pt;">GlaxoWellcome. Dr.&#160;Forster holds a B.Sc. (Hons) and a Ph.D. from the University of Liverpool and an MBA from the Henley Management College. He is an Honorary Visiting Professor at the University of Liverpool and at the University of Pavia. We believe Dr.&#160;Forster&#8217;s qualifications to serve on our Board of Directors include his established reputation for management and leadership in the life sciences field and his successful experience and industry relationships in the United States, European Union and Asia. </font></div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Dror Bashan.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Mr.&#160;Bashan has served as our President and Chief Executive Officer and as our director since June&#160;2019. He has over 20&#160;years of experience in the pharmaceutical industry with roles ranging from business development, marketing, sales and finance providing him with both cross regional and cross discipline </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">9</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">&#8203;</div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">experience and a deep knowledge of the global pharmaceutical and health industries. From 1998 through 2018, he served in a number of senior positions at Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; TASE:TEVA). Most recently, he served as Teva&#8217;s Senior Vice President, Global Business Development, and was involved in strategic alliances, cross-company strategic projects and the acquisition and divestiture of assets. Mr.&#160;Bashan holds a BA in Economics and Business Management and an MBA from the Tel Aviv University. We believe Mr.&#160;Bashan&#8217;s qualifications to serve on our Board of Directors includes his service as our President and Chief Executive Officer as well as his extensive experience in the life sciences and pharmaceutical industry on a global scale. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Amos Bar Shalev.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Mr.&#160;Bar Shalev joined our Board of Directors in July&#160;2008. Previously, Mr.&#160;Bar Shalev served as a director of Protalix Ltd. from 2005 through January&#160;2008, and as our director from 2006 through January&#160;2008. Mr.&#160;Bar Shalev brings to us extensive experience in managing technology companies. Currently, Mr.&#160;Bar Shalev serves on the Board of Directors of the following privately-held Israeli companies: Aposense Ltd. and Sirvir Ltd. From 2004 through 2012, Mr.&#160;Bar Shalev served as a director of Technorov Holdings (1993) Ltd. and managed its portfolio. From 1997 through 2004, he was a Managing Director of TDA Capital Partners, a management company of the TGF (Templeton Tadiran) Fund. From 2004 through 2007, he was the President of Win Buyer Ltd. He has served on the Board of Directors of a number of Israeli publicly traded and privately-held Israeli companies including, among others, Steam CC Ltd., Velox Ltd., NESS Ltd. (acquired by BioNess Inc.), Idanit (acquired by Scitex Corporation Ltd.), Objet Geometrix (merged with Stratasys, Inc. (NASDAQ:SSYS)), Verisity, Scitex Vision (acquired by Hewlett Packard (NYSE:HPE), Golden Wings Investment Company Ltd., the venture capital fund of the Israeli Air Force Veterans Business Club, Win Buyer Ltd. and Sun Light Ltd. He received his B.Sc. in Electrical Engineering from the Technion, Israel in 1978 and M.B.A. from the Tel Aviv University in 1981. He holds the highest award from the Israeli Air Force for technological achievements. We believe Mr.&#160;Bar Shalev&#8217;s qualifications to serve on our Board of Directors include his&#160;years of experience in the management of Israeli businesses. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Shmuel &#8220;Muli&#8221; Ben Zvi, Ph.D.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Dr.&#160;Ben Zvi joined our Board of Directors in June&#160;2022. In November&#160;2023, he was appointed to serve as the Chairman of the Board of Directors of Bank Leumi of Israel (TASE:LUMI). He joined Bank Leumi&#8217;s Board of Directors in August&#160;2015 and serves as the Chairman of the credit, technology and strategy committees thereof. He served on the Board of Directors of Vascular Biogenics Ltd. (NASDAQ:VBLT) from 2018 until its acquisition by Notable Labs, Inc. (NASDAQ:NTBL) in October&#160;2023, and on the Board of Directors of Sol-Gel Technologies Ltd. (NASDAQ:SLGL), from February&#160;2018 through November&#160;2023. From 2004 through 2014, Dr.&#160;Ben Zvi served in a number of managerial positions at Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; TASE:TEVA), the last two being Vice President, Strategy and Vice President, Finance. From 2000 to 2004, Dr.&#160;Ben Zvi was the financial advisor to the chief of general staff of the Israeli Defense Forces and head of the Israeli Defense Ministry budget department. Dr.&#160;Ben Zvi holds a B.A. and an M.A., both Cum Laude, and a Ph.D. in economics, all from the Tel Aviv University, Israel. He also participated in the Harvard Business School Advanced Management Program (AMP) and in National Security &amp; Political Science programs at the National Security College, Israel and Haifa University, Israel. Dr.&#160;Ben Zvi performed post-doctoral studies in Economics at the Massachusetts Institute of Technology. We believe Dr.&#160;Ben Zvi&#8217;s qualifications to serve on our Board of Directors include his&#160;years of experience in the management of public Israeli companies, including life science companies, and in particular his experience in financial and investment matters and participation on audit committees. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Pol F. Boudes, M.D.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Dr.&#160;Boudes joined our Board of Directors in January&#160;2020. He is a senior physician and chief medical officer with more than 25&#160;years of experience in research and development, with a special emphasis on orphan drugs and translational medicine. In March&#160;2020, Dr.&#160;Boudes was appointed Chief Medical Officer of Galectin Therapeutics Inc. (NASDAQ:GALT). He also serves as a research and development consultant. From April&#160;2014 through October&#160;2019, he served as the Chief Medical Officer of CymaBay Therapeutics, Inc. (NASDAQ:CBAY) where he led the development of treatments for rare liver diseases. Dr.&#160;Boudes was also Chief Medical Officer at Amicus Therapeutics Inc. (NASDAQ:FOLD) from 2009 to 2013 where he was instrumental in the development of migalastat (Galafold</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;">) for the treatment of Fabry disease, as well as treatments for Pompe disease and Gaucher disease. He has served in various roles at Berlex Laboratories (acquired by Bayer HealthCare Pharmaceuticals), Wyeth-Ayerst Research, Hoffmann-La Roche and Pasteur-Merieux Serums &amp; Vaccines. Dr.&#160;Boudes holds an M.D. from the University </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">10</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">&#8203;</div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">of Aix-Marseilles, France and has specialized in Endocrinology and Metabolic Diseases, Internal Medicine, and Geriatric diseases. We believe Dr.&#160;Boudes&#8217; qualifications to serve on our Board of Directors include his vast experience and knowledge of the research and development of pharmaceuticals. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Gwen A. Melincoff.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Ms.&#160;Melincoff joined our Board of Directors in January&#160;2020. She is a seasoned business development and venture professional with over 25&#160;years of deal-making and management experience in the biotechnology and pharmaceutical industries. Her experience has spanned public and private company boards, venture financing, business development, licensing, mergers and acquisitions, research operations, marketing, product management and project management. Ms.&#160;Melincoff currently serves on the Board of Directors of Gain Therapeutics, Inc. (NASDAQ:GANX), Soleno Therapeutics, Inc. (NASDAQ:SOLN) and Collegium Pharmaceutical, Inc. (NASDAQ:COLL). She also serves in an advisory capacity at a number of pharmaceutical companies. From April&#160;2017 through June&#160;2020, she served on the Board of Directors of Photocure ASA, from January&#160;2017 through January&#160;2019, she served on the Board of Directors of Kamada Ltd. (NASDAQ:KMDA, TASE:KMDA), and from June&#160;2014 through November&#160;2016, she served on the Board of Directors of Tobira Therapeutics Inc. (acquired by Allergan plc). From August&#160;2014 through September&#160;2016, Ms.&#160;Melincoff served as Vice President of Business Development at BTG International Inc. Prior to that, she was Senior Vice President of Corporate Development at Shire Plc. Additionally, she led the Shire Strategic Investment Group, the venture capital arm of Shire Plc. Ms.&#160;Melincoff was Vice President of Business Development at Adolor Corporation and held executive positions at Eastman Kodak for over ten&#160;years in a number of their health care companies. Ms.&#160;Melincoff holds a B.S. in Biology from The George Washington University and an M.S. in Management and Health Care Administration from Pennsylvania State University. Ms.&#160;Melincoff has also attained the designation of Certified Licensing Professional (CLP&#8482;) and was named to the &#8220;Top Women in Biotech 2013&#8221; by Fierce Biotech and to the Powerlist 100 of Corporate Venture Capital in 2012 and 2013. We believe Ms.&#160;Melincoff&#8217;s qualifications to serve on our Board of Directors include her&#160;years of experience at pharmaceutical companies, particularly with respect to business development. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Aharon Schwartz, Ph.D.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Dr.&#160;Schwartz joined our Board of Directors in November&#160;2014. He retired from Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; TASE:TEVA) in 2011 where he served in a number of positions from 1975 through 2011, the most recent being Vice President, Head of Teva Innovative Ventures. Dr.&#160;Schwartz is currently chairman of the Board of Directors of BiolineRx Ltd. (NASDAQ:BLRX, TASE:BLRX) and works as an independent consultant. From May&#160;2015 through March&#160;2020, he served as a member of the Board of Directors of Foamix Pharmaceuticals Ltd. (Nasdaq:FOMX), which was acquired by Menlo Therapeutics Inc. (Nasdaq:MNLO), and from January&#160;2013 through November&#160;2017, he served as a member of the Board of Directors of Alcobra Ltd., which is now called Arcturus Therapeutics&#160;Ltd. Dr.&#160;Schwartz received his Ph.D. in organic chemistry in 1978 from the Weizmann Institute of Science, his M.Sc. in organic chemistry from the Technion, Israel Institute of Technology and a B.Sc. in chemistry and physics from the Hebrew University of Jerusalem. Dr.&#160;Schwartz received a second Ph.D. in 2014 from the Hebrew University of Jerusalem in the history and philosophy of science. We believe Dr.&#160;Schwartz&#8217;s qualifications to serve on our Board of Directors include his&#160;years of experience at life science companies. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our Board of Directors recommends that stockholders vote &#8220;FOR&#8221; the election or re-election of all director nominees named in this &#8220;Proposal 1: Election of Directors.&#8221;</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Corporate Governance and Independent Directors</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In compliance with the listing requirements of the NYSE American, we have a comprehensive plan of corporate governance for the purpose of defining responsibilities, setting high standards of professional and personal conduct and assuring compliance with such responsibilities and standards. We currently regularly monitor developments in the area of corporate governance to ensure we are in compliance with the standards and regulations required by the NYSE American. A summary of our corporate governance measures follows. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Independent Directors</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We believe a majority of the members of our Board of Directors are independent from management. When making determinations from time to time regarding independence, the Board of Directors will </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">11</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">&#8203;</div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">reference the listing standards adopted by the NYSE American as well as the independence standards set forth in the Sarbanes-Oxley Act of 2002, or the SOX, and the rules and regulations promulgated by the SEC under that Act, as well as other factors which could assist our Board of Directors and its committees in determining that a director will have no material relationship with us that could compromise that director&#8217;s independence. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Under the rules of the NYSE American, a director of our Company will only qualify as an &#8220;independent director&#8221; if, among other things, in the opinion of our Board of Directors, that person does not have a material relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. The Board of Directors has determined that neither Dr.&#160;Forster, Mr.&#160;Bar Shalev, Dr.&#160;Ben Zvi, Dr.&#160;Boudes, Ms.&#160;Melincoff nor Dr.&#160;Schwartz has a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director, and that each such non-employee director is an &#8220;independent director&#8221; as defined under the rules of the NYSE American and the SEC. In addition, the Board of Directors has determined that all members of the Audit and Finance Committee meet the independence requirements set forth in Section&#160;803B(2) of the NYSE American Company Guide and Section&#160;10A(m)(3) of the Exchange Act, and that all members of the Compensation Committee meet the independence requirements set forth in Rule&#160;805(c) of the NYSE American Listed Company Guide. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The position of Chairman of the Board is not held by our chief executive officer at this time. The Board of Directors does not have a policy mandating the separation of these functions. We believe it is in our best interest that Dr.&#160;Forster serve as the chairman of our Board of Directors. This decision was based on Dr.&#160;Forster&#8217;s established reputation for management and leadership in the life sciences field and his successful experience and industry relationships in the United States, Europe and Asia. Our non-management directors hold formal meetings, separate from management, at least twice per year. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The Board&#8217;s Role in Risk Oversight</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our Board of Directors oversees an enterprise-wide approach to risk management, designed to support the achievement of business objectives, including organizational and strategic objectives, to improve long-term organizational performance and enhance stockholder value. The involvement of our Board of Directors in setting our business strategy is a key part of its assessment of management&#8217;s plans for risk management and its determination of what constitutes an appropriate level of risk for the Company. The participation of our Board of Directors in our risk oversight process includes receiving regular reports from members of senior management on areas of material risk to the Company, including operational, financial, legal and regulatory, and strategic and reputational risks. While the full Board of Directors has the ultimate oversight responsibility for the risk management process, various committees of the Board of Directors also have responsibility for risk management. For example, financial risks, including internal controls, are overseen by the Audit and Finance Committee and risks that may be implicated by our executive compensation programs are overseen by the Compensation Committee. Upon identification of a risk, the assigned committee or our full Board of Directors discuss or review risk management and risk mitigation strategies. Additional review or reporting on enterprise risks is conducted as needed or as requested by our Board of Directors or a committee thereof. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Board and Committee Meetings</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our Board of Directors has an Audit and Finance Committee, Compensation Committee and Nominating Committee. The membership of each committee is as follows: </font>
        </div>
        <table style="width:456pt;height:86.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:146.67pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Committee </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:146.67pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Chairman </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:146.66pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Membership </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.917pt 0pt 0.5pt 0pt; width:146.67pt;">
              <font style="letter-spacing:0.2pt;">Audit and Finance Committee </font>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; width:146.67pt;">
              <font style="letter-spacing:0.2pt;">Shmuel &#8220;Muli&#8221; Ben Zvi, Ph.D. </font>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; width:146.66pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">Shmuel &#8220;Muli&#8221; Ben Zvi, Ph.D.,</font>
                <br >
                <font style="letter-spacing:0.2pt;">Amos Bar Shalev</font>
                <br >
                <font style="letter-spacing:0.2pt;">and Aharon Schwartz, Ph.D. </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:146.67pt;">
              <font style="letter-spacing:0.2pt;">Compensation Committee </font>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:146.67pt;">
              <font style="letter-spacing:0.2pt;">Amos Bar Shalev </font>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:146.66pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">Amos Bar Shalev,</font>
                <br >
                <font style="letter-spacing:0.2pt;">Shmuel &#8220;Muli&#8221; Ben Zvi, Ph.D.</font>
                <br >
                <font style="letter-spacing:0.2pt;">and Aharon Schwartz, Ph.D. </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">12</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">&#8203;</div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;height:47.5pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:146.67pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Committee </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:146.67pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Chairman </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:146.66pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Membership </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.917pt 0pt 2.5pt 0pt; width:146.67pt;">
              <font style="letter-spacing:0.2pt;">Nominating Committee </font>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 2.5pt 0pt; width:146.67pt;">
              <font style="letter-spacing:0.2pt;">Amos Bar Shalev </font>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 2.5pt 0pt; width:146.66pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">Amos Bar Shalev,</font>
                <br >
                <font style="letter-spacing:0.2pt;">Eliot Richard Forster, Ph.D.</font>
                <br >
                <font style="letter-spacing:0.2pt;">and Aharon Schwartz, Ph.D.</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-left:20pt; margin-top:15.9pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The primary functions of each committee are as follows: </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Audit and Finance Committee</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our Board of Directors has determined that Dr.&#160;Ben Zvi, Mr.&#160;Bar Shalev and Dr.&#160;Schwartz are &#8220;independent&#8221; for purposes of membership on the Audit and Finance Committee pursuant to Section&#160;803B(2) of the NYSE American Company Guide and Section&#160;10A(m)(3) of the Exchange Act. We require that all Audit and Finance Committee members possess the required level of financial literacy and at least one member of the Audit and Finance Committee meet the current standard of requisite financial management expertise as required by the NYSE American and applicable rules and regulations of the SEC. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our Audit and Finance Committee operates under a formal charter that governs its duties and conduct. A current copy of the Audit and Finance Committee Charter is available on our website at http://www.protalix.com. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">All members of the Audit and Finance Committee are independent from our executive officers and management. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our independent registered public accounting firm reports directly to the Audit and Finance Committee. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our Audit and Finance Committee meets with management and representatives of our registered public accounting firm prior to the filing of officers&#8217; certifications with the SEC to receive information concerning, among other things, effectiveness of the design or operation of our internal controls over financial reporting, as required by Section&#160;404 of SOX. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our Audit and Finance Committee has adopted a Policy for Reporting Questionable Accounting and Auditing Practices and Policy Prohibiting Retaliation against Reporting employees to enable confidential and anonymous reporting of improper activities to the Audit and Finance Committee. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Dr.&#160;Ben Zvi, Mr.&#160;Bar Shalev and Dr.&#160;Schwartz each qualify as &#8220;audit committee financial experts&#8221; under the applicable rules of the SEC. In making the determination as to these individuals&#8217; status as audit committee financial experts, our Board of Directors determined they have accounting and related financial management expertise within the meaning of the aforementioned rules, as well as the listing standards of the NYSE American. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Compensation Committee</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our Board of Directors has determined that Mr.&#160;Bar Shalev, Dr.&#160;Ben Zvi, and Dr.&#160;Schwartz are &#8220;independent&#8221; for purposes of membership on the Compensation Committee pursuant to Section&#160;805(c) of the NYSE American Company Guide. The Compensation Committee reviews and approves the compensation of executive officers and key employees and administers our Plan. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our Compensation Committee operates under a formal charter that governs its duties and conduct. A current copy of the Compensation Committee Charter is available on our website at http://www.protalix.com. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Nominating Committee</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Nominating Committee is responsible for assisting our Board of Directors in selecting nominees for election to the Board of Directors and monitoring the composition of the Board of Directors. A current copy of the Nominating Committee Charter is available on our website at http://www.protalix.com. Although our Board of Directors does not have a formal policy requiring the Nominating Committee to consider the diversity of directors in its nomination process, in considering potential new directors, the Nominating Committee will review individuals from various disciplines and backgrounds, and consider the following qualifications: broad experience in business, finance or administration; familiarity with national </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">13</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">&#8203;</div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">business matters; familiarity with our industry; independence; and prominence and reputation. The committee seeks nominees with a broad diversity of experience, professions, education, skills and backgrounds with a view to having a Board of Directors that represents a diversity of views, experiences, and backgrounds. After making such a review, the Nominating Committee submits the nomination to the full Board of Directors for approval. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Nominating Committee will consider any nominees submitted by stockholders of record at the time of any such nomination in compliance with applicable rules of the SEC and our By-Laws. The Nominating Committee will determine whether any stockholder nominee meets the qualifications for candidacy described above and in the Nominating Committee Charter. Stockholders&#8217; nominations for election at the 2025 Annual Meeting of Stockholders must be submitted in writing to Eyal Rubin, Corporate Secretary, not less than 45&#160;days nor more than 75&#160;days prior to the date on which we first mailed this proxy statement. Such written notice must include the following information: (i)&#160;name, age, business address and residence address of the nominee; (ii)&#160;the principal occupation or employment of the nominee; (iii)&#160;the class and number of shares of our Company beneficially owned by the nominee; and (iv)&#160;any other information relating to the nominee that would be required to be disclosed in solicitations for proxies for elections of directors pursuant to Regulation&#160;14A of the Exchange Act. The written notice must also include the following information with respect to each stockholder delivering such notice: (i)&#160;the name and record address of such stockholder; and (ii)&#160;the class and number of shares of our Company beneficially owned by the stockholder. Lastly, the written notice must include certain information relating to any derivative or hedging transactions by the stockholder delivering such notice and its Stockholder Associated Persons, as defined in our By-Laws, and other arrangements with other parties regarding our securities, as presented in detail in our By-Laws. Stockholders can mail any such recommendations, including the criteria outlined above, to Eyal Rubin, Corporate Secretary, Protalix BioTherapeutics, Inc., 2 University Plaza, Suite 100, Hackensack, NJ 07601. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Contacting the Board of Directors</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Stockholders who wish to communicate with the Board of Directors may do so by mailing any such communications to Eyal Rubin, Corporate Secretary, Protalix BioTherapeutics, Inc., 2 University Plaza, Suite 100, Hackensack, NJ 07601. All communications are distributed to the Board of Directors, as appropriate, depending upon the facts and circumstances outlined in the communications received. For example, if any complaints regarding accounting and/or auditing matters are received, they may be forwarded by our Corporate Secretary to the Audit and Finance Committee for review. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Policy Governing Director Attendance at Annual Meetings of Stockholders</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have no formal policy regarding attendance by our directors at annual stockholders meetings, although we encourage such attendance and anticipate most of our directors will attend these meetings. Mr.&#160;Bashan participated in our 2023 annual meeting of stockholders. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">During the year ended December&#160;31, 2023, there were eight meetings of our Board of Directors, four meetings of the Audit and Finance Committee, five meetings of the Compensation Committee and one meeting of the Nominating Committee. Our non-management directors hold meetings separate from management at least twice per year. All of our current directors that served on our Board of Directors during the year ended December&#160;31, 2023 attended at least 75% of the aggregate number of meetings of the Board of Directors and the committees of the Board of Directors on which they served. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Compensation of Directors</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following table sets forth information with respect to compensation of our non-employee directors during fiscal year 2023. </font>
        </div>
        <table style="width:456pt;height:47.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:233.32pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Name </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Fees Earned or</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Paid in Cash ($) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Option</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Award(s) ($) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:47.33pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">All Other</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Compensation </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Total ($) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:233.32pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Zeev Bronfeld</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(1)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.97pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(49,216<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.97pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:47.33pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(49,216<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:233.32pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Eliot Richard Forster, Ph.D.</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(2)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">20,806</td>
            <td style="padding:0pt;padding-left:12.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.97pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">27,182</td>
            <td style="padding:0pt;padding-left:4.97pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:47.33pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">47,988</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">14</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">&#8203;</div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;height:92.5pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:233.32pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Name </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Fees Earned or</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Paid in Cash ($) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Option</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Award(s) ($) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">All Other</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Compensation </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Total ($) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:233.32pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Amos Bar Shalev </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">41,250</td>
            <td style="padding:0pt;padding-left:12.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.97pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">38,660</td>
            <td style="padding:0pt;padding-left:4.97pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.81pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.81pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">79,910</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:233.32pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Shmuel &#8220;Muli&#8221; Ben Zvi, Ph.D. </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">41,250</td>
            <td style="padding:0pt;padding-left:12.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.97pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">33,455</td>
            <td style="padding:0pt;padding-left:4.97pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.81pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.81pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">74,705</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:233.32pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Pol F. Boudes, M.D.</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(3)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">41,250</td>
            <td style="padding:0pt;padding-left:12.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.97pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">38,660</td>
            <td style="padding:0pt;padding-left:4.97pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.81pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">35,475</td>
            <td style="padding:0pt;padding-left:9.81pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">115,385</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:233.32pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Gwen A. Melincoff </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">41,250</td>
            <td style="padding:0pt;padding-left:12.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.97pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">38,660</td>
            <td style="padding:0pt;padding-left:4.97pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.81pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.81pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">79,910</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:233.32pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Aharon Schwartz, Ph.D. </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">41,250</td>
            <td style="padding:0pt;padding-left:12.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.97pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">38,660</td>
            <td style="padding:0pt;padding-left:4.97pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.81pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.81pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">79,910</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.4pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:7.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:7.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Zeev Bronfeld&#8217;s tenure on our Board of Directors ended on September&#160;13, 2023. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(2)</font>
          <br >
        </div>
        <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Dr.&#160;Forster&#8217;s tenure on our Board of Directors commenced on September&#160;14, 2023. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(3)</font>
          <br >
        </div>
        <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">From time to time Dr.&#160;Boudes performs consulting services regarding business development and licensing efforts for the Company with the consent of the Audit and Finance Committee of the Board of Directors. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In September&#160;2023, the Board of Directors approved a new compensation program for our non-employee, non-chairman directors effective as of October&#160;1, 2023. In addition, each non-employee director, other than our Chairman, received a grant of options to purchase 61,676 shares of our common stock with an exercise price equal to $1.66 per share. The options vest quarterly in 12 equal increments over a three-year period. In addition, as of October&#160;1, 2023, such directors are entitled to an annual cash payment equal to $45,000 per year, payable quarterly. The options vest quarterly in 12 equal increments over a three-year period. Upon the appointment to Dr.&#160;Forster to our Board of Directors, the Compensation Committee resolved that Dr.&#160;Forster is entitled to an annual cash payment equal to $70,000, payable quarterly and he received a grant to purchase 85,715 shares of our common stock with an exercise price equal to $1.75 per share. The options vest quarterly in 12 equal increments over a three-year period. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Compensation Committee Interlocks and Insider Participation</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">No member of our Compensation Committee or any executive officer of the Company or of Protalix&#160;Ltd. has a relationship that would constitute an interlocking relationship with executive officers or directors of another entity. No Compensation Committee member is or was an officer or employee of ours or of Protalix Ltd. or had any relationship that constituted a related party transaction. Further, none of our executive officers serves on the Board of Directors or compensation committee of any entity that has one or more executive officers serving as a member of our Board of Directors or Compensation Committee. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Code of Business Conduct and Ethics</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our Code of Business Conduct and Ethics includes provisions ranging from restrictions on gifts to conflicts of interest. All of our employees and directors are bound by this Code of Business Conduct and Ethics. Violations of our Code of Business Conduct and Ethics may be reported to the Audit and Finance Committee. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Code of Business Conduct and Ethics includes provisions applicable to all of our employees, including senior financial officers and members of our Board of Directors and is posted on our website (www.protalix.com). We intend to post amendments to or waivers from any such Code of Business Conduct and Ethics. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Insider Trading, Prohibition on Short-term, Speculative Transactions</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our Insider Trading and Blackout Policy includes restrictions regarding the timing and types of transactions in our securities by our directors, officers, including our Named Executive officers, and other employees. Our directors, officers and certain other designated other employees are prohibited from trading during blackout periods (during the period from and including the close of business on the seventh day prior to the end of the third month of each quarter and ends on the opening of the second business day following our filing with the SEC of the Company&#8217;s quarterly or annual financial reports or earlier public release of quarterly or annual financial information) and without the clearance of our Compliance Officer. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">15</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">&#8203;</div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:580pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">In addition, the policy provides that none of our directors, officers or other employees may engage in the following transactions: (i)&#160;purchasing our securities on margin; (ii)&#160;pledging our securities; (iii)&#160;short sales; (d)&#160;buying or selling puts or calls in connection with our securities; and (v)&#160;engaging in derivative transactions relating to our securities (e.g., exchange traded options, etc.). </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">16</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">&#8203;</div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">MANAGEMENT</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our 2023 executive officers, their ages and positions, and other information are as follows: </font>
        </div>
        <table style="width:416pt;height:65.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:120pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Name </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:13.25pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Age </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:258.75pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Position </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:120pt;">
              <font style="letter-spacing:0.2pt;">Dror Bashan </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:13.25pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">57 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:258.75pt;">
              <font style="letter-spacing:0.2pt;">President and Chief Executive Officer </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:120pt;">
              <font style="letter-spacing:0.2pt;">Eyal Rubin </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:13.25pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">48 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:258.75pt;white-space:normal;">
              <font style="letter-spacing:0.2pt;">Sr. Vice President, Chief Financial Officer, Treasurer and Secretary </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.833pt 0pt; width:120pt;">
              <font style="letter-spacing:0.2pt;">Yaron Naos </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.833pt 0pt; width:13.25pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">60 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.833pt 0pt; width:258.75pt;">
              <font style="letter-spacing:0.2pt;">Sr. Vice President, Operations</font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The biographical information for Mr.&#160;Bashan is set forth above under &#8220;Proposal 1: Election of Directors.&#8221; </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Eyal Rubin.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Mr.&#160;Rubin has served as our Senior Vice President and Chief Financial Officer since September&#160;2019. He brings to Protalix more than 20&#160;years of finance and capital markets experience, an extensive background in financial planning and operations, management and strategy and a deep knowledge of the biotechnology and pharmaceutical industries. Prior to joining Protalix, he served as Executive Vice President and Chief Financial Officer of BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a publicly traded biotechnology company, where he was responsible for all corporate finance, accounting and investor relations activities. Prior to his role at BrainStorm, Mr.&#160;Rubin served at Teva Pharmaceutical Industries&#160;Ltd. (NYSE:TEVA; TASE:TEVA) in several roles, most recently as Vice President, Head of Corporate Treasury. In this role, Mr.&#160;Rubin was responsible for Teva&#8217;s cash operations and cash management, as well as Teva&#8217;s equity and debt capital markets transactions. Mr.&#160;Rubin holds a BA in Financing and IT Systems from the College of Management, Israel, where he graduated Summa Cum Laude with a specialization in Financing and IT Systems, and an MBA from Bar-Ilan University, Israel, where he graduated Summa Cum Laude with a specialization in Finance. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Yaron Naos.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Mr.&#160;Naos joined Protalix in 2004, originally as a Senior Director for Operations and later as Vice President for Production, and became our Senior Vice President, Operations in 2018. He has a wealth of hands-on experience and knowledge in the field of pharmaceutical development. Prior to joining Protalix, he served for a decade as R&amp;D Product Manager at Dexxon Pharmaceutical Co., one of Israel&#8217;s largest pharmaceutical companies, where he was responsible for technology transfer from R&amp;D to production, and in charge of R&amp;D activities that led to the commercialization of many products. Later, Mr.&#160;Naos was plant manager of Medibrands Pharmaceutical Company, as well as logistics manager of Mediline for period of four&#160;years, where he was responsible for all operational activities, from procurement to distribution. Mr.&#160;Naos holds a B.Sc. in Food Engineering and Biotechnology from the Technion-Israel Technology Institute and an MBA from Haifa University. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Family Relationships</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">There are no family relationships among directors or executive officers of our Company. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Executive Compensation</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The primary goals of the Compensation Committee of our Board of Directors with respect to executive compensation are to attract and retain the most talented and dedicated executives possible, to tie annual and long-term cash and stock incentives to achievement of specified performance objectives, and to align executives&#8217; incentives with stockholder value creation. To achieve these goals, the Compensation Committee implements and maintains compensation plans that tie a portion of executive officers&#8217; overall compensation to key strategic goals such as developments in our clinical path, the establishment of key strategic collaborations, the build-up of our pipeline and the strengthening of our financial position. The Compensation Committee evaluates individual executive performance with a goal of setting compensation at levels the committee believes are comparable with executives in other companies of similar size and stage of development operating in the biotechnology industry while taking into account our relative performance and our own strategic goals. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">17</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">&#8203;</div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Elements of Compensation</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Executive compensation consists of following elements: </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Base Salary.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Base salaries for our executive officers are established based on the scope of their responsibilities taking into account competitive market compensation paid by other companies for similar positions. Generally, we believe that executive base salaries should be targeted near the median of the range of salaries for executives in similar positions with similar responsibilities at comparable companies. The Compensation Committee convenes from time to time to evaluate present and future executive compensation, which evaluation generally includes an evaluation of the peer group considered in analyzing executive compensation. The Compensation Committee intends to continue reviewing and revising the peer group periodically to ensure that it continues to reflect companies similar to the Company in size and development stage. The Compensation Committee also reviews executive compensation reports and an analysis of publicly-traded biotechnology companies prepared by third party experts from a well-known consulting firm for additional data and other information regarding executive compensation for comparative purposes. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Base salaries are usually reviewed annually, and adjusted from time to time to realign salaries with market levels after taking into account individual responsibilities, performance and experience. The base salaries of each of our President and Chief Executive Officer, our Senior Vice President and Chief Financial Officer our Senior Vice President, Operations, who we refer to collectively as the &#8220;Named Executive Officers,&#8221; are discussed herein. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Annual Bonus</font><font style="font-weight:bold;letter-spacing:-0.2pt;">.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The Compensation Committee has the authority to award discretionary annual bonuses to our executive officers. The discretionary annual bonus awards were intended to compensate officers for achieving financial, clinical, regulatory and operational goals and for achieving individual annual performance objectives. For any given year, the compensation objectives vary, but relate generally to strategic factors such as developments in our clinical path, the execution of a license agreement for the commercialization of product candidates, the establishment of key strategic collaborations, the build-up of our pipeline and financial factors such as capital raising. Bonuses are awarded generally based on corporate performance, with adjustments made within a range for individual performance, at the discretion of the Compensation Committee. The Compensation Committee determines, on a discretionary basis, the size of the entire bonus pool and\or the amount of the actual award to each Named Executive Officer. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Compensation Committee selects, in its discretion, the executive officers of the Company or our subsidiary who are eligible to receive bonuses for any given year. Any bonus granted by the Compensation Committee will generally be paid upon the achievement of a specific milestone, subject to certain terms and conditions. The Compensation Committee has not fixed a minimum or maximum award for any executive officer&#8217;s annual discretionary bonus. Each of our executive officers is eligible for a discretionary annual bonus under his or her employment agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">During the year ended December&#160;31, 2023, our Board of Directors determined that the Named Executive Officers and other officers and employees of the Company were entitled to certain cash bonuses as compensation for their efforts and executions during calendar year 2022. Important milestones underlying the Company&#8217;s efforts during calendar year 2022 included the following: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Submission of marketing authorization submissions to the U.S. Food and Drug Administration (&#8220;FDA&#8221;) and the European Medicines Agency (the &#8220;EMA&#8221;) for pegunigalsidase alfa for the treatment of adults patients with Fabry disease </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Advancement of the Company&#8217;s product candidate pipeline </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Transfer of the Company&#8217;s open-label expansion studies of pegunigalsidase alfa to the Company&#8217;s commercialization partner </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Maintaining and strengthening the Company&#8217;s financial position </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Based on the foregoing, the Board of Directors resolved to grant certain cash bonuses to the Named Executive Officers and other officers and employees of the Company including NIS 760,000, or eight monthly salaries, to Mr.&#160;Bashan; NIS 480,000, or six monthly salaries, to Mr.&#160;Rubin; and NIS 393,300, or six monthly salaries, to Mr.&#160;Naos. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">18</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">&#8203;</div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">During the year ended December&#160;31, 2023, the Compensation Committee determined that the Named Executive Officers and other officers and employees of the Company were entitled to certain special cash bonuses and equity incentives in consideration of the Company-wide, long-term efforts resulting in the approvals by the FDA and the EMA of pegunigalsidase alfa for the treatment of adults patients of Fabry disease. In particular, the Compensation Committee granted to Mr.&#160;Bashan a special cash bonus equal to $350,000 in consideration of the EMA approval of the marketing authorization application for pegunigalsidase alfa for the treatment of adult patients with Fabry disease in May&#160;2023 and a special cash bonus equal to $350,000 in consideration of the FDA approval of the biologics license application for pegunigalsidase alfa for the treatment of adult patients with Fabry disease in May&#160;2023. In addition, the Compensation Committee resolved to grant NIS 640,000, or eight monthly salaries, to Mr.&#160;Rubin; and NIS&#160;393,300, or six monthly salaries, to Mr.&#160;Naos. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition to the foregoing, during the year ended December&#160;31, 2023, the Compensation Committee resolved to increase Mr.&#160;Bashan&#8217;s salary by 15%. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Options and Share-Based Compensation.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Our Amended and Restated 2006 Stock Incentive Plan (the &#8220;Plan&#8221;) authorizes us to grant options to purchase shares of common stock, restricted stock and other securities to our employees, directors and consultants. Our Compensation Committee is the administrator of the stock incentive plan. Stock option or other grants are generally made at the commencement of employment and following a significant change in job responsibilities or to meet other special retention or performance objectives. The Compensation Committee reviews and approves stock option and other awards to executive officers based upon a review of competitive compensation data, its assessment of individual performance, a review of each executive&#8217;s existing long-term incentives, and retention considerations. The exercise price of stock options granted under the Plan must be equal to at least 100% of the fair market value of our common stock on the date of grant; however, in certain circumstances, grants may be made at a lower price to Israeli grantees who are residents of the State of Israel. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">During the year ended December&#160;31, 2023, the Compensation Committee granted to Mr.&#160;Bashan 800,000 restricted shares of the Company&#8217;s common stock, to Mr.&#160;Rubin 201,903 restricted shares of the Company&#8217;s common stock and to Mr.&#160;Naos 187,344 restricted shares of the Company&#8217;s common stock. All such restricted shares of common stock vest in 12 equal increments on a quarterly basis over a three-year period commencing upon the date of grant, subject to certain terms and conditions, except that 25% of the restricted shares of common stock granted to Mr.&#160;Bashan vested upon grant with the remaining 75% vesting on a quarterly basis over the following two-year period in eight equal tranches, subject to certain terms and conditions. The grant of restricted shares to Mr.&#160;Bashan was intended to compensate him for the FDA and EMA approvals. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Severance and Change in Control Benefits.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The Compensation Committee granted the following payments that would be payable in connection with a change of control: $1.0&#160;million to the President and Chief Executive Officer and $400,000 to each of the other executive Vice Presidents. Such payments are subject to certain terms and conditions. In addition to the foregoing, pursuant to the employment agreements entered into with each of our executive officers, the executive officer is entitled to be insured by Protalix Ltd. under a Manager&#8217;s Policy in lieu of severance. The intention of such Manager&#8217;s Policies is to provide the Israel-based officers with severance protection of one month&#8217;s salary for each year of employment. In addition, the stock options and restricted stock granted to each of our Named Executive Officers provide that all of such instruments are subject to accelerated vesting immediately upon a change in control of the Company. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Other Compensation.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Consistent with our compensation philosophy, we intend to continue to maintain our current benefits for our executive officers; however, the Compensation Committee in its discretion may revise, amend, or add to the officer&#8217;s executive benefits if it deems it advisable. As an additional benefit to all of our Israel-based Named Executive Officers and for most of our employees, we contribute to certain funds amounts equaling a total of approximately 15% of their respective gross salaries for certain pension and other savings plans for the benefit of the Named Executive Officers and other employees. In addition, in accordance with customary practice in Israel, our Israel-based executives&#8217; agreements require us to contribute towards their vocational studies, and to provide annual recreational allowances, a company car and a company phone. We believe these benefits are currently equivalent with median competitive levels for comparable companies. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">19</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">&#8203;</div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:219.76pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12.5pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Executive Compensation.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;We refer to the &#8220;Summary Compensation Table&#8221; set forth below for information regarding the compensation earned during the fiscal year ended December&#160;31, 2023 by our Named Executive Officers. </font>
        </div>
        <div style="margin-top:15.2pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Summary Compensation Table</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The following table sets forth a summary for the fiscal&#160;years ended December&#160;31, 2023 and 2022, respectively, of the cash and non-cash compensation awarded, paid or accrued by us or Protalix Ltd. to our Named Executive Officers. There were no restricted stock awards, long-term incentive plan payouts or other compensation paid during fiscal&#160;years December&#160;31, 2023 and 2022 by us or Protalix Ltd. to the Named Executive Officers, except as set forth below. All of the Named Executive Officers are employees of our subsidiary, Protalix Ltd. All currency amounts are expressed in U.S. dollars. </font>
        </div>
        <table style="width:456pt;height:140.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:153.72pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Name and Principal Position </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Year </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Salary</font>
                <br >
                <font style="letter-spacing:-0.16pt;">($) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Bonus</font>
                <br >
                <font style="letter-spacing:-0.16pt;">($) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Stock</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Awards ($) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Option</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Awards</font>
                <br >
                <font style="letter-spacing:-0.16pt;">($)</font><font style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(1)</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">All Other</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Compensation</font>
                <br >
                <font style="letter-spacing:-0.16pt;">($)</font><font style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(2)</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Total</font>
                <br >
                <font style="letter-spacing:-0.16pt;">($) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:153.72pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Dror Bashan </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">2023</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">356,929</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">892,328</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,061,558</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">246,560</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.31pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">127,566</td>
            <td style="padding:0pt;padding-left:7.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">2,684,941</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:153.72pt;white-space:normal;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;font-style:italic;">
                <font style="letter-spacing:0.2pt;">President and Chief Executive Officer</font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">2022</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">359,972</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">817,576</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">177,564</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.31pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">113,184</td>
            <td style="padding:0pt;padding-left:7.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,468,296</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:153.72pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Eyal Rubin </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">2023</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">287,692</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">302,507</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">227,331</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">114,925</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.31pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">96,580</td>
            <td style="padding:0pt;padding-left:7.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,029,035</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:153.72pt;white-space:normal;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;font-style:italic;">
                <font style="letter-spacing:0.2pt;">Senior Vice President and Chief Financial Officer</font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">2022</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">312,515</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">397,678</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">168,667</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">75,889</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.31pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">103,532</td>
            <td style="padding:0pt;padding-left:7.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,058,281</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:153.72pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Yaron Naos </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">2023</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">216,504</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">212,367</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">129,081</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">133,469</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.31pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">84,948</td>
            <td style="padding:0pt;padding-left:7.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">776,369</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:153.72pt;text-align:left;">
              <div style="margin-left:10pt;font-style:italic;">
                <font style="letter-spacing:0.2pt;">Senior Vice President, Operations</font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">2022</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">239,201</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">81,176</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">123,310</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.31pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">89,578</td>
            <td style="padding:0pt;padding-left:7.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">533,265</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:13.7pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:9.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:9.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Amounts in this column represent the grant date fair value of the option awards as computed in accordance with ASC 718, not including any estimates of forfeitures related to service-based vesting conditions. See Note 9(c) &#8220;Stock based compensation,&#8221; of the Notes to Consolidated Financial Statements in our Annual Report on Form 10-K for the year ended December&#160;31, 2023 for a discussion of assumptions we made in determining the grant date fair value of our option awards for the fiscal year ended December&#160;31, 2022 and 2023. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:5.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(2)</font>
          <br >
        </div>
        <div style=" margin-top:5.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Includes employer contributions to pension and/or insurance plans and other miscellaneous payments. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">20</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">&#8203;</div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-weight:normal;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:46.5pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">Outstanding Equity Awards at Fiscal Year-End</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-weight:normal;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">The following table sets forth information with respect to the Named Executive Officers concerning outstanding equity awards as of December&#160;31, 2023. </font>
        </div>
        <table style="width:456pt;height:241pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:150.18pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Option Awards </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Stock Awards </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt; width:150.18pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Name </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number</font>
                <br >
                <font style="letter-spacing:-0.16pt;">of Securities</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Underlying</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Unexercised</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Options</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Exercisable </font>
                <br >
                <font style="letter-spacing:-0.16pt;">(#) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number</font>
                <br >
                <font style="letter-spacing:-0.16pt;">of Securities</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Underlying</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Unexercised</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Options</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Unexercisable </font>
                <br >
                <font style="letter-spacing:-0.16pt;">(#) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Option </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Exercise</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Price </font>
                <br >
                <font style="letter-spacing:-0.16pt;">($) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Option </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Expiration</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Date </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number</font>
                <br >
                <font style="letter-spacing:-0.16pt;">of shares</font>
                <br >
                <font style="letter-spacing:-0.16pt;">or&#160;units</font>
                <br >
                <font style="letter-spacing:-0.16pt;">of stock</font>
                <br >
                <font style="letter-spacing:-0.16pt;">that have</font>
                <br >
                <font style="letter-spacing:-0.16pt;">not vested </font>
                <br >
                <font style="letter-spacing:-0.16pt;">(#) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Market value</font>
                <br >
                <font style="letter-spacing:-0.16pt;">of shares</font>
                <br >
                <font style="letter-spacing:-0.16pt;">or&#160;units</font>
                <br >
                <font style="letter-spacing:-0.16pt;">of stock</font>
                <br >
                <font style="letter-spacing:-0.16pt;">that have</font>
                <br >
                <font style="letter-spacing:-0.16pt;">not vested </font>
                <br >
                <font style="letter-spacing:-0.16pt;">($) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;height:7.25pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:150.18pt;text-align:left;" rowspan="3">
              <div style="white-space:nowrap; line-height:12pt; padding-bottom:0pt;">
                <font style="letter-spacing:0.2pt;">Dror Bashan </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;" rowspan="3">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; line-height:12pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; line-height:12pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; line-height:12pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; line-height:12pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; line-height:12pt; min-width:24.75pt; text-align:right; white-space:nowrap;">608,986</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.945pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; line-height:12pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,083,996</td>
            <td style="padding:0pt;padding-left:1.945pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;height:15pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">160,000</td>
            <td style="padding:0pt;padding-left:4.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.82pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">4.69</td>
            <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">6/30/2029</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.945pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.945pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;height:15pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">234,375</td>
            <td style="padding:0pt;padding-left:4.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.82pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">515,625</td>
            <td style="padding:0pt;padding-left:6.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1.03</td>
            <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">9/7/2032</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.945pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.945pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;height:7pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:150.18pt;text-align:left;" rowspan="3">
              <div style="white-space:nowrap; line-height:12pt; padding-bottom:0pt;">
                <font style="letter-spacing:0.2pt;">Eyal Rubin </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;" rowspan="3">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; line-height:12pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; line-height:12pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; line-height:12pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; line-height:12pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:24.75pt; text-align:right; white-space:nowrap;">226,007</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.945pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:30.75pt; text-align:right; white-space:nowrap;">402,293</td>
            <td style="padding:0pt;padding-left:1.945pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;height:15pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">80,000</td>
            <td style="padding:0pt;padding-left:4.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.82pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">2.00</td>
            <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">9/22/2029</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.945pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.945pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;height:15pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">109,375</td>
            <td style="padding:0pt;padding-left:4.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.82pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">240,625</td>
            <td style="padding:0pt;padding-left:6.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1.03</td>
            <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">9/7/2032</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.945pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.945pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;height:7pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:150.18pt;text-align:left;" rowspan="5">
              <div style="white-space:nowrap; line-height:12pt; padding-bottom:0pt;">
                <font style="letter-spacing:0.2pt;">Yaron Naos </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;" rowspan="5">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; line-height:12pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; line-height:12pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; line-height:12pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; line-height:12pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:24.75pt; text-align:right; white-space:nowrap;">171,732</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.945pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:30.75pt; text-align:right; white-space:nowrap;">305,683</td>
            <td style="padding:0pt;padding-left:1.945pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;height:15pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">5,000</td>
            <td style="padding:0pt;padding-left:4.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.82pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">17.20</td>
            <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">3/23/2025</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.945pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.945pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;height:15pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">60,000</td>
            <td style="padding:0pt;padding-left:4.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.82pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">5.60</td>
            <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">9/13/2028</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.945pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.945pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;height:15pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">99,658</td>
            <td style="padding:0pt;padding-left:4.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.82pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">22,998</td>
            <td style="padding:0pt;padding-left:6.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">3.59</td>
            <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">8/11/2030</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.945pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.945pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;height:19pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">106,250</td>
            <td style="padding:0pt;padding-left:4.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.82pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">233,750</td>
            <td style="padding:0pt;padding-left:6.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1.03</td>
            <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">9/7/2032</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.945pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.945pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">Pay Versus Performance</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-weight:normal;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">As required by Section&#160;953(a) of the Dodd-Frank Wall Street Reform and Consumer Protection Act, and Item&#160;402(v) of Regulation&#160;S-K, we are providing the following information about the relationship between executive &#8220;compensation actually paid&#8221; and certain financial performance of our Company. </font>
        </div>
        <table style="width:456pt;height:98.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:65.76pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Year </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Summary</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Compensation</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Table Total for</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Mr.&#160;Bashan</font><font style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(1)</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Compensation</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Actually paid to</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Mr.&#160;Bashan</font><font style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(2)</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Average</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Summary</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Compensation</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Table Total for</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Non-CEO </font>
                <br >
                <font style="letter-spacing:-0.16pt;">NEOs</font><font style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(3)</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Average</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Compensation</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Actually Paid to</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Non-CEO </font>
                <br >
                <font style="letter-spacing:-0.16pt;">NEOs</font><font style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(4)</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Value of Initial</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Fixed $100</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Investment Based</font>
                <br >
                <font style="letter-spacing:-0.16pt;">On Total</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Stockholder</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Return</font><font style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(5)</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Net Income</font><font style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(6)</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:65.76pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">2023 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.155pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">2,684,941</td>
            <td style="padding:0pt;padding-left:2.155pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.835pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">3,186,324</td>
            <td style="padding:0pt;padding-left:3.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.005pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">902,702</td>
            <td style="padding:0pt;padding-left:6.005pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.42pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,094,613</td>
            <td style="padding:0pt;padding-left:4.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.015pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">129.93</td>
            <td style="padding:0pt;padding-left:15.015pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">8,312,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:65.76pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.155pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,468,296</td>
            <td style="padding:0pt;padding-left:2.155pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.835pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,899,221</td>
            <td style="padding:0pt;padding-left:3.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.005pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">795,773</td>
            <td style="padding:0pt;padding-left:6.005pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.42pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,056,338</td>
            <td style="padding:0pt;padding-left:4.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.015pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">37.74</td>
            <td style="padding:0pt;padding-left:15.015pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">(14,927,000<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:65.76pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.155pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,157,699</td>
            <td style="padding:0pt;padding-left:2.155pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.835pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">(627,211<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.005pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">671,056</td>
            <td style="padding:0pt;padding-left:6.005pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.42pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,961</td>
            <td style="padding:0pt;padding-left:4.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.015pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">22.87</td>
            <td style="padding:0pt;padding-left:15.015pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">(27,582,000<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.5pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:normal;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-weight:normal;font-size:10pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">The dollar amounts reported are the amounts reported in the &#8220;Total&#8221; column of the Summary Compensation Table for Mr.&#160;Bashan, our President and Chief Executive Officer. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:normal;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">(2)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-weight:normal;font-size:10pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">The dollar amounts reported represent the amount of &#8220;compensation actually paid&#8221; to Mr.&#160;Bashan, as computed in accordance with SEC regulations. The dollar amounts do not reflect the actual amount of compensation earned by or paid to Mr.&#160;Bashan during the applicable year. In accordance with SEC regulations, the following adjustments were made to Mr.&#160;Bashan&#8217;s total compensation to determine the compensation actually paid: </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-weight:normal;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-weight:normal;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">21</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">&#8203;</div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-weight:normal;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <table style="width:416pt;height:89.5pt;margin-left:20pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:169.68pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Year </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Summary</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Compensation</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Table Total for</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Mr.&#160;Bashan </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Less: Summary</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Compensation</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Table Reported</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Value of Equity</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Awards</font><font style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(a)</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Plus: Equity </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Award</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Adjustments</font><font style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(b)</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Equals:</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Compensation</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Actually paid </font>
                <br >
                <font style="letter-spacing:-0.16pt;">to Mr. Bashan </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:169.68pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">2023 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.155pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">2,684,941</td>
            <td style="padding:0pt;padding-left:2.155pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.36pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,308,118</td>
            <td style="padding:0pt;padding-left:3.36pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">1,809,501</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.16pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">3,186,324</td>
            <td style="padding:0pt;padding-left:1.16pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:169.68pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.155pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,468,296</td>
            <td style="padding:0pt;padding-left:2.155pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.36pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">995,140</td>
            <td style="padding:0pt;padding-left:3.36pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">1,426,065</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.16pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,899,221</td>
            <td style="padding:0pt;padding-left:1.16pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:169.68pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.155pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,157,699</td>
            <td style="padding:0pt;padding-left:2.155pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.36pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">667,595</td>
            <td style="padding:0pt;padding-left:3.36pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">(1,117,315<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.16pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">(627,211<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.16pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-left:20pt; margin-top:13.69pt; width:436pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-left:20pt; margin-top:9.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:normal;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">(a)</font>
          <br >
        </div>
        <div style=" margin-top:9.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;font-weight:normal;font-size:10pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Represents the aggregate grant-date fair value of equity awards as reported in the &#8220;Stock Awards&#8221; and &#8220;Option Awards&#8221; columns in the Summary Compensation Table for the applicable year. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:normal;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">(b)</font>
          <br >
        </div>
        <div style=" margin-top:5.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;font-weight:normal;font-size:10pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">The equity award adjustments for each applicable year were as set forth in the table below. The valuation assumptions used to calculate fair values did not materially differ from those disclosed at the time of grant. The amounts deducted or added in calculating the equity award adjustments are as follows: </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <table style="width:416pt;height:143.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:35.09pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Year </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Year End Fair</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Value of Unvested</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Equity Awards</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Granted in the</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Covered Year </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Year over Year</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Change in fair</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Value of</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Outstanding</font>
                <br >
                <font style="letter-spacing:-0.16pt;">and Unvested</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Equity Awards</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Granted in</font>
                <br >
                <font style="letter-spacing:-0.16pt;">prior Years </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Year End</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Fair Value</font>
                <br >
                <font style="letter-spacing:-0.16pt;">of Vested</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Equity</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Awards</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Granted in</font>
                <br >
                <font style="letter-spacing:-0.16pt;">the Covered</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Year </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Year over Year</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Change in Fair</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Value of Equity</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Awards Granted</font>
                <br >
                <font style="letter-spacing:-0.16pt;">in Prior Years</font>
                <br >
                <font style="letter-spacing:-0.16pt;">that Vested </font>
                <br >
                <font style="letter-spacing:-0.16pt;">in the Year </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Fair Value</font>
                <br >
                <font style="letter-spacing:-0.16pt;">at the End</font>
                <br >
                <font style="letter-spacing:-0.16pt;">of the Prior</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Year of</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Equity</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Awards that</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Failed to</font>
                <br >
                <font style="letter-spacing:-0.16pt;">meet</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Vesting</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Conditions</font>
                <br >
                <font style="letter-spacing:-0.16pt;">in the Year </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Value of</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Dividend</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Equivalents</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Accrued or</font>
                <br >
                <font style="letter-spacing:-0.16pt;">other Earnings</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Paid on Stock</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Awards not</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Otherwise</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Reflected in</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Fair Value </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Total Equity</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Award</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Adjustments </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:35.09pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">2023 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.165pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">934,501</td>
            <td style="padding:0pt;padding-left:11.165pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.92pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">210,735</td>
            <td style="padding:0pt;padding-left:3.92pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.614999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">505,750</td>
            <td style="padding:0pt;padding-left:0.614999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.27pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">158,515</td>
            <td style="padding:0pt;padding-left:6.27pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.83pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8199;&#8212;</td>
            <td style="padding:0pt;padding-left:9.83pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.535pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8199;&#8212;</td>
            <td style="padding:0pt;padding-left:14.535pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">1,809,501</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:35.09pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.165pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">717,652</td>
            <td style="padding:0pt;padding-left:11.165pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.92pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">110,664</td>
            <td style="padding:0pt;padding-left:3.92pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.614999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">566,768</td>
            <td style="padding:0pt;padding-left:0.614999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.27pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">30,981</td>
            <td style="padding:0pt;padding-left:6.27pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.83pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.83pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.535pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.535pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">1,426,065</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:35.09pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.165pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:11.165pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.92pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(981,931<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.92pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.614999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.614999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.27pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(135,384<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:6.27pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.83pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.83pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.535pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.535pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">(1,117,315<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:2.69pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:normal;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">(3)</font>
          <br >
        </div>
        <div style=" margin-top:2.69pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-weight:normal;font-size:10pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">The dollar amounts reported represent the average of the amounts reported for our Named Executive Officers as a group (excluding our CEO) in the &#8220;Total&#8221; column of the Summary Compensation Table in each applicable year. The Named Executive Officers included for purposes of calculating the average amounts are Mr.&#160;Rubin and Mr.&#160;Naos. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:5.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:normal;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">(4)</font>
          <br >
        </div>
        <div style=" margin-top:5.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-weight:normal;font-size:10pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">The dollar amounts reported represent the average amount of &#8220;compensation actually paid&#8221; to the Named Executive Officers identified in footnote 3, as computed in accordance with SEC regulations. The dollar amounts do not reflect the actual amount of compensation earned by or paid to the Named Executive Officers during the applicable year. In accordance with the SEC regulations, the following adjustments were made to average total compensation for the Named Executive Officers for each year to determine the compensation actually paid: </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <table style="width:416pt;height:98.4999999999999pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:158.24pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Year </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Average </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Reported</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Summary</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Compensation</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Table Total for</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Other NEOs </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Less: Summary</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Compensation </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Table Average</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Reported Value </font>
                <br >
                <font style="letter-spacing:-0.16pt;">of Equity Awards </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Plus: Average</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Equity Award</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Adjustments</font><font style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(a)</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Equals: Average</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Compensation</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Actually Paid to</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Other NEOs </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:158.24pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">2023 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.005pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">902,702</td>
            <td style="padding:0pt;padding-left:6.005pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.01pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">302,403</td>
            <td style="padding:0pt;padding-left:10.01pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.515pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">494,314</td>
            <td style="padding:0pt;padding-left:3.515pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.42pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,094,613</td>
            <td style="padding:0pt;padding-left:4.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:158.24pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.005pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">795,773</td>
            <td style="padding:0pt;padding-left:6.005pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.01pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">183,933</td>
            <td style="padding:0pt;padding-left:10.01pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.515pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">444,498</td>
            <td style="padding:0pt;padding-left:3.515pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.42pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,056,338</td>
            <td style="padding:0pt;padding-left:4.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:158.24pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.005pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">671,056</td>
            <td style="padding:0pt;padding-left:6.005pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.01pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">266,777</td>
            <td style="padding:0pt;padding-left:10.01pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.515pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(402,318<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.515pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.42pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,961</td>
            <td style="padding:0pt;padding-left:4.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-left:20pt; margin-top:13.7pt; width:436pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-left:20pt; margin-top:9.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:normal;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">(a)</font>
          <br >
        </div>
        <div style=" margin-top:9.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;font-weight:normal;font-size:10pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">The amounts deducted or added in calculating the total average equity award adjustments are as follows: </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-weight:normal;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-weight:normal;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">22</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">&#8203;</div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-weight:normal;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <table style="width:416pt;height:143.5pt;margin-left:20pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:56.53pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Year </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Average </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Year End</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Fair Value of</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Unvested </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Equity</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Awards </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Granted</font>
                <br >
                <font style="letter-spacing:-0.16pt;">in the Covered</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Year </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Year over </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Year</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Average</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Change in </font>
                <br >
                <font style="letter-spacing:-0.16pt;">fair Value of</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Outstanding </font>
                <br >
                <font style="letter-spacing:-0.16pt;">and Unvested </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Equity Awards</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Granted in </font>
                <br >
                <font style="letter-spacing:-0.16pt;">prior Years </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Average</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Year</font>
                <br >
                <font style="letter-spacing:-0.16pt;">End Fair</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Value of</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Vested</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Equity</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Awards</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Granted in</font>
                <br >
                <font style="letter-spacing:-0.16pt;">the Covered</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Year </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Year over</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Year Average</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Change in</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Fair Value </font>
                <br >
                <font style="letter-spacing:-0.16pt;">of Equity</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Awards</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Granted in</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Prior Years</font>
                <br >
                <font style="letter-spacing:-0.16pt;">that Vested </font>
                <br >
                <font style="letter-spacing:-0.16pt;">in the Year </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Fair Value at</font>
                <br >
                <font style="letter-spacing:-0.16pt;">the End of</font>
                <br >
                <font style="letter-spacing:-0.16pt;">the Prior</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Year of</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Equity</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Awards that</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Failed to</font>
                <br >
                <font style="letter-spacing:-0.16pt;">meet Vesting</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Conditions in</font>
                <br >
                <font style="letter-spacing:-0.16pt;">the Year </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Average </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Value of </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Dividend</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Equivalents</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Accrued or</font>
                <br >
                <font style="letter-spacing:-0.16pt;">other Earnings</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Paid on Stock</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Awards not</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Otherwise</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Reflected in</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Fair Value </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Total Average</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Equity Award</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Adjustments </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:56.53pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">2023 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.7pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">317,561</td>
            <td style="padding:0pt;padding-left:4.7pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.73pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">89,197</td>
            <td style="padding:0pt;padding-left:3.73pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.115pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">22,868</td>
            <td style="padding:0pt;padding-left:3.115pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.96pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">64,688</td>
            <td style="padding:0pt;padding-left:3.96pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.995pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8199;&#8212;</td>
            <td style="padding:0pt;padding-left:11.995pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.535pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8199;&#8212;</td>
            <td style="padding:0pt;padding-left:14.535pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.43pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">494,314</td>
            <td style="padding:0pt;padding-left:2.43pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:56.53pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.7pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">330,120</td>
            <td style="padding:0pt;padding-left:4.7pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.73pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">36,648</td>
            <td style="padding:0pt;padding-left:3.73pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.115pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">67,913</td>
            <td style="padding:0pt;padding-left:3.115pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.96pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">9,817</td>
            <td style="padding:0pt;padding-left:3.96pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.995pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:11.995pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.535pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.535pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.43pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">444,498</td>
            <td style="padding:0pt;padding-left:2.43pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:56.53pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.7pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.7pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.73pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(352,159<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.73pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.115pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.115pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.96pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(50,159<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.96pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.995pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:11.995pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.535pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.535pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.43pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(402,318<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.43pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:normal;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">(5)</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-weight:normal;font-size:10pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Cumulative TSR is the value of a $100 investment in our common stock calculated by dividing the difference between the per share price of our common stock at the end of each year shown and the beginning of the measurement period by the per share price of our common stock at the beginning of the measurement period. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:normal;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">(6)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-weight:normal;font-size:10pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">The dollar amounts reported represent the amount of net income reflected in our Consolidated Statements of Income included in our Annual Report on Form 10-K for the applicable fiscal year. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">Relationship Between Compensation Actually Paid, Company Total Shareholder Return (&#8220;TSR&#8221;) and Net Income (Loss)</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-weight:normal;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">Compensation actually paid to Mr.&#160;Bashan during the year ended December&#160;31, 2023 was approximately $3.2&#160;million, an increase of approximately $1.3&#160;million from approximately $1.9&#160;million for the year ended December&#160;31, 2022. Average compensation actually paid to our Non-CEO Named Executive Officers for both of the&#160;years ended December&#160;31, 2023 and 2022 was approximately $1.1&#160;million. For the year ended December&#160;31, 2023, our TSR was $129.93, an increase of 244%, compared to TSR of $37.74 for the year ended December&#160;31, 2022. Our net income for the year ended December&#160;31, 2023 was $8.3&#160;million compared to a loss of $14.9&#160;million over the same period in 2022. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-weight:normal;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">Compensation actually paid to Mr.&#160;Bashan and to our Non-CEO Named Executive Officers as a group is not directly correlated with our TSR or our net income (loss) over the three&#160;years presented in the above tables. Over the course of fiscal&#160;years 2021 and 2022, we focused primarily on the clinical and regulatory development of pegunigalsidase alfa. During fiscal year 2023, we shifted our focus to the regulatory approval process for pegunigalsidase alfa, supporting our commercial partner&#8217;s launch efforts post approval and redirecting our R&amp;D and clinical resources towards the stregnthening of our pipeline of product candidates. Accordingly, TSR and net income (loss), as performance measures, are not directly correlated to our executive compensation determinations. In the year ended December&#160;31, 2022, given the clinical and regulatory advancement of pegunigalsidase alfa and the improvement in our liquidity position, we elected to award to Mr.&#160;Bashan and to our Non-CEO Named Executive Officers increased compensation, in part as compensation for fiscal&#160;years 2020 and 2021, years for which we elected to defer the payment of cash bonuses to preserve liquidity. Particularly for Mr.&#160;Bashan, but also for the Non-CEO Named Executive Officers, the compensation paid in fiscal year 2022 focused more on equity grants to facilitate our continued efforts to maintain sufficient cash resources. As increases in the market price of our common stock correspond to increases in the fair market value of our equity grants, the calculation of compensation actually paid with respect to equity grants held by Mr.&#160;Bashan and to our Non-CEO Named Executive Officers increases in a like manner. In the year ended December&#160;31, 2023, given the approval of pegunigalsidase alfa for adult patients with Fabry disease by both the FDA and the EMA, the advancement in the clinical development of our PRX-115 drug candidate and strengthening of our Company&#8217;s liquidity and cash position, the Compensation Committee of our Board of Directors elected to award to Mr.&#160;Bashan and to our Non-CEO Named Executive Officers, as well as other officers and employees of our company, an annual cash bonus and a one-time special cash bonus for such positive achievements. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-weight:normal;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-weight:normal;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">23</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">&#8203;</div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">All information provided above under the &#8220;Pay Versus Performance&#8221; heading will not be deemed to be incorporated by reference into any of our filings under the Securities Act of 1933 (the &#8220;Securities Act&#8221;) or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing, except to the extent we specifically incorporate such information by reference.</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Potential Payments upon Termination or Change-in-Control/Corporate Transaction</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Each of our Named Executive Officers (while they remain employed by the Company) is entitled to be insured by Protalix Ltd. under a Manager&#8217;s Policy in lieu of severance upon termination. The intention of such Manager&#8217;s Policies is to provide our officers with severance protection of one month&#8217;s salary for each year of employment. The following payments would be payable in connection with a change of control of the Company: $1.0&#160;million to the President and Chief Executive Officer and $400,000 to each of the other Named Executive Officers, subject to certain terms and conditions. In addition to the foregoing, the vesting periods of outstanding options held by our Named Executive Officers are accelerated upon a change of control. Had we experienced a change of control on December&#160;31, 2023, the value of the acceleration of the vesting period of the options and shares held by Mr.&#160;Bashan would have been $1.5&#160;million; the value of the acceleration of the vesting period of the options and shares held by Mr.&#160;Rubin would have been $0.6&#160;million and the value of the acceleration of the vesting period of the options and shares held by Mr.&#160;Naos would have been $0.5&#160;million. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Employment Arrangements</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Dror Bashan.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Pursuant to Mr.&#160;Bashan&#8217;s employment agreement, his current monthly base salary is NIS&#160;109,250 (approximately $30,100) and Mr.&#160;Bashan is entitled to an annual discretionary bonus subject to the sole discretion of our Board of Directors, to be determined on the basis of agreed-upon annual objectives which shall include both measurable and strategic parameters. He is also entitled to a one-time bonus of $1.0&#160;million upon the occurrence of certain change of control transactions. The monthly salary is subject to cost of living adjustments from time to time as may be required by law. Mr.&#160;Bashan was granted an option award upon his employment and he is entitled to additional equity awards from time to time on a discretionary basis. Mr.&#160;Bashan&#8217;s employment agreement is terminable by the Company on 180&#160;days&#8217; written notice for any reason. Mr.&#160;Bashan may terminate the agreement on 90&#160;days&#8217; written notice for any reason during its term. We may terminate Mr.&#160;Bashan&#8217;s employment agreement for cause without notice. Mr.&#160;Bashan is entitled to be insured by the Company under a Manager&#8217;s Policy in lieu of severance, Company contributions towards vocational studies, annual recreational allowances, a company car, a company laptop and a company phone. Mr.&#160;Bashan is entitled to 25 working days of vacation. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Eyal Rubin.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Pursuant to Mr.&#160;Rubin&#8217;s employment agreement, his current monthly base salary is NIS 80,000 (approximately $22,100) and Mr.&#160;Rubin is entitled to an annual discretionary bonus subject to the sole discretion of our Board of Directors, to be determined on the basis of agreed-upon annual objectives which shall include both measurable and strategic parameters. He is also entitled to a one-time bonus of $400,000 upon the occurrence of certain change of control transactions. The monthly salary is subject to cost of living adjustments from time to time as may be required by law. Mr.&#160;Rubin was granted an option award upon his employment and he is entitled to additional equity awards from time to time on a discretionary basis. In addition, contingent upon certain conditions, Mr.&#160;Rubin is entitled to a grant of restricted stock&#160;units with an aggregate value of $100,000, on an annual basis. Additional equity awards may be granted from time to time on a discretionary basis. Mr.&#160;Rubin&#8217;s employment agreement is terminable by the Company on 180&#160;days&#8217; written notice for any reason. Mr.&#160;Rubin may terminate the agreement on 90&#160;days&#8217; written notice for any reason. We may terminate the Mr.&#160;Rubin&#8217;s employment agreement for cause without notice. Mr.&#160;Rubin is entitled to be insured by the Company under a Manager&#8217;s Policy in lieu of severance, Company contributions towards vocational studies, annual recreational allowances, a company car, a company laptop and a company phone. Mr.&#160;Rubin is entitled to 25 working days of vacation. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Yaron Naos.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Mr.&#160;Naos&#8217; current monthly base salary is NIS 65,550 (approximately $18,100) and he is entitled to an annual discretionary bonus for performance subject to the sole discretion of our Compensation Committee. The monthly salary is subject to cost of living adjustments from time to time as may be required by law. In addition, vesting of all of Mr.&#160;Naos&#8217; options and restricted shares will be accelerated in full upon a Corporate Transaction or a Change in Control, as those terms are defined in our Plan. Mr.&#160;Naos&#8217; </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">24</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">&#8203;</div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">employment is terminable by either party on 60&#160;days&#8217; written notice for any reason and we may terminate the agreement for cause without notice. Mr.&#160;Naos is entitled to be insured by the Company under a Manager&#8217;s Policy in lieu of severance, Company contributions towards vocational studies, annual recreational allowances, a company car, a company phone, a company laptop and a company phone. Mr.&#160;Naos is entitled to 29 working days of vacation. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Amended and Restated 2006 Stock Incentive Plan</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our Board of Directors and our stockholders initially approved our Plan on December&#160;14, 2006. Since its initial approval, our stockholders have approved a number of amendments to the plan, the last time being on June&#160;28, 2023. Of the 12,475,171 shares reserved for issuance under the Plan as of December&#160;31, 2023, there are outstanding options to purchase 6,965,901 shares of our common stock in the aggregate, subject to adjustment for a stock split or any future stock dividend or other similar change in our common stock or our capital structure. As of December&#160;31, 2023, options to acquire 633,409 shares of common stock remain available for grant under the Plan. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our Plan provides for the grant of stock options, restricted stock, restricted stock&#160;units, stock appreciation rights and dividend equivalent rights, collectively referred to as &#8220;awards.&#8221; Stock options granted under the Plan may be either incentive stock options under the provisions of Section&#160;422 of the IRC, or non-qualified stock options. Incentive stock options may be granted only to employees. Awards other than incentive stock options may be granted to employees, directors and consultants. Shares issued in connection with awards other than options or stock appreciation rights shall count as one and one-half (1.5) shares for each share issued for purposes of the number of shares authorized for issuance under the Plan. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Plan is also designed to comply with the provisions of the Israeli Income Tax Ordinance New Version, 1961 (including as amended pursuant to Amendment 132 thereto), or the Tax Ordinance, and is intended to enable us to grant awards to grantees who are Israeli residents as follows: (i)&#160;awards to employees pursuant to Section&#160;102 of the Tax Ordinance; and (ii)&#160;awards to non-employees pursuant to Section&#160;3(I) of the Tax Ordinance. For this purpose, &#8220;employee&#8221; refers only to employees, office holders and directors of the Company or a related entity excluding those who are considered &#8220;Controlling Stockholders&#8221; pursuant to, or otherwise excluded by, the Tax Ordinance. In accordance with the terms and conditions imposed by the Tax Ordinance, grantees who receive awards under the Plan may be afforded certain tax benefits in Israel as described below. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our Board of Directors or the Compensation Committee, referred to as the &#8220;plan administrator,&#8221; will administer our Plan, including selecting the grantees, determining the number of shares to be subject to each award, determining the exercise or purchase price of each award, and determining the vesting and exercise periods of each award. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The exercise price of stock options granted under the Plan must be equal to at least 100% of the fair market value of our common stock on the date of grant; however, in certain circumstances, grants may be made at a lower price to Israeli grantees who are residents of the State of Israel. If, however, incentive stock options are granted to an employee who owns stock possessing more than 10% of the voting power of all classes of our stock or the stock of any parent or subsidiary of the Company, the exercise price of any incentive stock option granted must equal at least 110% of the fair market value on the grant date and the maximum term of these incentive stock options must not exceed five&#160;years. The maximum term of all other awards must not exceed 10&#160;years (or five&#160;years in the case of an incentive stock option granted to any participant who owns stock representing more than 10% of the voting power of all classes of our stock or the stock of any parent or subsidiary of the Company). The plan administrator will determine the exercise or purchase price (if any) of all other awards granted under the Plan. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Under the Plan, incentive stock options and options to Israeli grantees may not be sold, pledged, assigned, hypothecated, transferred or disposed of in any manner other than by will or by the laws of descent or distribution and may be exercised during the lifetime of the participant only by the participant. Other awards shall be transferable by will or by the laws of descent or distribution and to the extent and in the manner authorized by the plan administrator by gift or pursuant to a domestic relations order to members </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">25</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">&#8203;</div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">of the participant&#8217;s immediate family. The Plan permits the designation of beneficiaries by holders of awards, including incentive stock options. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If the service of a participant in the Plan is terminated for any reason other than cause, the participant may exercise awards that were vested as of the termination date for a period ending upon the earlier of 12&#160;months from the date of termination (or such shorter or longer period set forth in the award agreement) or the expiration date of the awards unless otherwise determined by the plan administrator. If the service of a participant in the Plan is terminated for cause, the participant may exercise awards that were vested as of the termination date for a period ending upon the earlier of 14&#160;days from the date of termination (or such shorter or longer period set forth in the award agreement) or the expiration date of the awards unless otherwise determined by the plan administrator. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In the event of a corporate transaction, all awards will terminate unless assumed by the successor corporation. Unless otherwise provided in a participant&#8217;s award agreement, in the event of a corporate transaction and with respect to the portion of each award that is assumed or replaced, then such portion will automatically become fully vested and exercisable immediately upon termination of a participant&#8217;s service if the participant is terminated by the successor company or us without cause within 12&#160;months after the corporate transaction. With respect to the portion of each award that is not assumed or replaced, such portion will automatically become fully vested and exercisable immediately prior to the effective date of the corporate transaction so long as the participant&#8217;s service has not been terminated prior to such date. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In the event of a change in control, except as otherwise provided in a participant&#8217;s award agreement, following a change in control (other than a change in control that also is a corporate transaction) and upon the termination of a participant&#8217;s service without cause within 12&#160;months after a change in control, each award of such participant that is outstanding at such time will automatically become fully vested and exercisable immediately upon the participant&#8217;s termination. In addition, the stock options and shares of restricted stock issued to each of our Named Executive Officers are subject to accelerated vesting immediately upon a corporate transaction or a change in control of the Company, as defined in our Plan. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Under our Plan, a corporate transaction is generally defined as: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">a merger or consolidation in which we are not the surviving entity, except for the principal purpose of changing the Company&#8217;s state of incorporation; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the sale, transfer or other disposition of all or substantially all of our assets; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the complete liquidation or dissolution of the Company; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any reverse merger in which we are the surviving entity but our shares of common stock outstanding immediately prior to such merger are converted or exchanged by virtue of the merger into other property, whether in the form of securities, cash or otherwise, or in which securities possessing more than forty&#160;percent (40%) of the total combined voting power of our outstanding securities are transferred to a person or persons different from those who held such securities immediately prior to such merger; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">an acquisition in a single or series of related transactions by any person or related group of persons of beneficial ownership of securities possessing more than fifty&#160;percent (50%) of the total combined voting power of our outstanding securities but excluding any such transaction or series of related transactions that the plan administrator determines not to be a corporate transaction (provided however that the plan administrator shall have no discretion in connection with a corporate transaction for the purchase of all or substantially all of our shares unless the principal purpose of such transaction is changing our state of incorporation). </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Under our Plan, a change of control is defined as: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the direct or indirect acquisition by any person or related group of persons of beneficial ownership of securities possessing more than fifty&#160;percent (50%) of the total combined voting power of our outstanding securities pursuant to a tender or exchange offer made directly to our stockholders and which a majority of the members of our Board of Directors (who have generally been on our board for at least 12&#160;months) who are not affiliates or associates of the offeror do not recommend stockholders accept the offer; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">26</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">&#8203;</div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:24pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">a change in the composition of our Board of Directors over a period of 12&#160;months or less, such that a majority of the members of our Board of Directors ceases, by reason of one or more contested elections for board membership, to be comprised of individuals who were previously directors of the Company. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Unless terminated sooner, the Plan will automatically terminate on December&#160;31, 2028. Our Board of Directors has the authority to amend, suspend or terminate our Plan. No amendment, suspension or termination of the Plan shall adversely affect any rights under awards already granted to a participant. To the extent necessary to comply with applicable provisions of federal securities laws, state corporate and securities laws, the IRC, the rules of any applicable stock exchange or national market system, and the rules of any non-U.S. jurisdiction applicable to awards granted to residents therein (including the Tax Ordinance), we shall obtain stockholder approval of any such amendment to the Plan in such a manner and to such a degree as required. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Impact of Israeli Tax Law</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The awards granted to employees pursuant to Section&#160;102 of the Tax Ordinance under the Plan may be designated by us as approved options under the capital gains alternative, or as approved options under the ordinary income tax alternative. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">To qualify for these benefits, certain requirements must be met, including registration of the options in the name of a trustee. Each option, and any shares of common stock acquired upon the exercise of the option, must be held by the trustee for a period commencing on the date of grant and deposit into trust with the trustee and ending 24&#160;months thereafter. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Under the terms of the capital gains alternative, we may not deduct expenses pertaining to the options for tax purposes. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Under the Plan, we may also grant to employees options pursuant to Section&#160;102(c) of the Tax Ordinance that are not required to be held in trust by a trustee. This alternative, while facilitating immediate exercise of vested options and sale of the underlying shares, will subject the optionee to the marginal income tax rate of up to 50% as well as payments to the National Insurance Institute and health tax on the date of the sale of the shares or options. Under the Plan, we may also grant to non-employees options pursuant to Section&#160;3(I) of the Tax Ordinance. Under that section, the income tax on the benefit arising to the optionee upon the exercise of options and the issuance of common stock is generally due at the time of exercise of the options. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">These options shall be further subject to the terms of the tax ruling that has been obtained by Protalix Ltd. from the Israeli tax authorities in connection with the merger. Under the tax ruling, the options issued by us in connection with the assumption of Section&#160;102 options previously issued by Protalix Ltd. under the capital gains alternative shall be issued to a trustee, shall be designated under the capital gains alternative and the issuance date of the original options shall be deemed the issuance date for the assumed options for the calculation of the respective holding period. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">All related party transactions are reviewed and approved by the Audit and Finance Committee, as required by the Audit and Finance Committee Charter. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">There were no transactions during the last two fiscal&#160;years, or any currently proposed transaction, in which we were or are to be a participant and in which the amount involved exceeded or exceeds the lesser of $120,000 or one&#160;percent of the average of our total assets at year end for the last two completed fiscal&#160;years. &#8199; </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">27</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">&#8203;</div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:112pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">AUDIT AND FINANCE COMMITTEE REPORT</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">The information contained in this report shall not be deemed to be &#8220;soliciting material&#8221; or to be &#8220;filed&#8221; with the SEC, nor shall such information be incorporated by reference into any future filings with the SEC, or subject to the liabilities of Section&#160;18 of the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;), except to the extent that we specifically incorporate it by reference into a document filed under the Securities Act of 1933 or the Exchange Act.</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Audit and Finance Committee of our Board of Directors operates under a written charter adopted by our Board of Directors, and currently consists of Shmuel &#8220;Muli&#8221; Ben Zvi, Ph.D., Chairman of the Committee, Amos Bar Shalev and Aharon Schwartz, Ph.D. As described more fully in its charter, the Audit and Finance Committee provides oversight of the quality and integrity of our consolidated financial statements, internal controls and financial reporting process, and our process to manage business and financial risks and compliance with legal, ethical and regulatory requirements. In addition, the Audit and Finance Committee interacts directly with and evaluates the qualifications, independence and performance of the independent auditors, Kesselman &amp; Kesselman, and is responsible for the appointment, compensation, retention and oversight of the work of the auditors. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Management is responsible for the preparation, presentation and integrity of the consolidated financial statements, and evaluation of and assessment of the effectiveness of our internal control over financial reporting. The independent auditors are responsible for performing an independent audit of the consolidated financial statements in accordance with the standards of the Public Company Accounting Oversight Board (the &#8220;PCAOB&#8221;). The Audit and Finance Committee&#8217;s responsibility is to monitor and oversee these processes. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Audit and Finance Committee has reviewed and discussed the audited consolidated financial statements with our Board of Directors and management. The Audit and Finance Committee has discussed with Kesselman &amp; Kesselman, Certified Public Accountant (lsr.), a member of PricewaterhouseCoopers International Limited (&#8220;Kesselman &amp; Kesselman&#8221;) the matters required to be discussed by the applicable requirements of the PCAOB and the U.S. Securities and Exchange Committee (&#8220;SEC&#8221;). The Audit and Finance Committee has received the written disclosures and the letter from Kesselman &amp; Kesselman required by applicable requirements of the PCAOB regarding the independent accountant&#8217;s communications with the Audit and Finance Committee concerning independence, and has discussed with Kesselman &amp; Kesselman that firm&#8217;s independence from our Company. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Based on the review and discussions of the audited consolidated financial statements and discussions with management and Kesselman &amp; Kesselman, the Audit and Finance Committee recommended to Board of Directors that the audited consolidated financial statements be included in our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2023 for filing with the SEC. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Respectfully submitted on April&#160;29, 2024, </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Shmuel &#8220;Muli&#8221; Ben Zvi, Ph.D., Chairman </font> <br ><font style="letter-spacing:0.2pt;">Amos Bar Shalev </font> <br ><font style="letter-spacing:0.2pt;">Aharon Schwartz, Ph.D.</font></div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">28</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">&#8203;</div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:176pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">PROPOSAL 2: ADVISORY VOTE TO APPROVE EXECUTIVE COMPENSATION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As required by Section&#160;14A of the Exchange Act, we are providing our stockholders with the opportunity to vote to approve, on a non-binding, advisory basis, the compensation of our Named Executive Officers as disclosed in this proxy statement in accordance with the compensation disclosure rules of the SEC. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We believe that the executive compensation program for the Named Executive Officers, as described in the &#8220;Management&#8221; section of this proxy statement, is based on a pay-for-performance culture and seeks to align the interests of our Named Executive Officers with the interests of our stockholders. We believe that our compensation programs are designed to reward our Named Executive Officers for the achievement of short-term and long-term strategic and operational goals and the achievement of increased total stockholder return, while at the same time creating a culture that focuses executives on prudent risk management and appropriately rewards them for performance. Our executive compensation program is also designed to be competitive with our peer companies, and seeks to enable us to attract and retain the best possible executive talent. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We also believe that the extensive disclosure of compensation information provided in this proxy statement provides our stockholders the information they need to make an informed decision as they weigh the pay of the Named Executive Officers in relation to our performance. This &#8220;Say-on-Pay&#8221; proposal gives you the stockholder the opportunity to endorse or not endorse the compensation we paid to the Named Executive Officers through the resolution set forth below. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;RESOLVED, that the compensation paid to the Named Executive Officers of Protalix BioTherapeutics, Inc., as disclosed pursuant to Item&#160;402 of Regulation&#160;S-K, including the compensation tables and narrative discussion included in this proxy statement, is hereby APPROVED.&#8221; </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Because your vote is advisory, it will not be binding upon our Company, our Board of Directors or the Compensation Committee. The vote on this resolution is not intended to address any specific element of compensation, but rather relates to the overall compensation of our Named Executive Officers, as described in this proxy statement in accordance with the compensation disclosure rules of the SEC. Our Company, our Board of Directors, and the Compensation Committee will consider the outcome of the vote when evaluating future executive compensation arrangements for our Named Executive Officers. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This proposal is provided as required pursuant to Rule&#160;14a-21(a) promulgated under the Exchange Act. </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our Board of Directors recommends that stockholders vote &#8220;FOR&#8221; the approval of the executive compensation as disclosed in this proxy statement and as described in this &#8220;Proposal 2: Advisory Vote to Approve Executive Compensation.&#8221; </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">29</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">&#8203;</div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">PROPOSAL 3: AMENDMENTS TO THE PROTALIX BIOTHERAPEUTICS, INC.</font>
          <br >
          <font style="letter-spacing:-0.2pt;">2006 STOCK INCENTIVE PLAN, AS AMENDED, TO INCREASE THE NUMBER OF</font>
          <br >
          <font style="letter-spacing:-0.2pt;">AUTHORIZED SHARES OF COMMON STOCK RESERVED FOR ISSUANCE UNDER THE PLAN</font>
          <br >
          <font style="letter-spacing:-0.2pt;">AND TO AMEND CERTAIN OTHER TERMS OF THE PLAN</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">General</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are asking our stockholders to approve an amendment to our amended 2006 Stock Incentive Plan, or the Existing Plan and, as amended, the Plan, so that we can continue to use the Plan in order to attract and retain key talent, encourage stock ownership by our employees, non-employee directors and consultants, better align with governance best practices. Our Board of Directors unanimously approved the proposed amendment to the Plan, subject to approval of our stockholders at the meeting. Approval of the Plan requires the affirmative vote of a majority of the outstanding shares of our common stock that are present in person or by proxy at the meeting and entitled to vote on this matter. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Primary Changes</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As part of the proposed amendments to the Existing Plan, we propose to: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Increase the number of shares of common stock reserved for issuance under the Existing Plan by 5,000,000 shares to 17,475,171 shares; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Increase the annual per person limits on the number of shares covered by awards of stock options and stock appreciation rights by 5,000,000 shares to 17,475,171 shares; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Increase the per person limits on the number of shares covered by awards of restricted stock and restricted stock&#160;units intended to be &#8220;performance based compensation&#8221; by 5,000,000 shares to 17,475,171 shares. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:-0.2pt;">Background on Code Section&#160;162(m) Approval</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are also asking our stockholders to approve this amendment to the material terms of the Existing Plan so that we may grant awards under the Plan that are designed to qualify for the exception from the limits on corporate income tax deductions pursuant to Code Section&#160;162(m). To the extent we grant such awards and they qualify for the exception, we may deduct for federal income tax purposes compensation in excess of $1.0&#160;million that may be paid to certain executive officers in any single year. Compensation includes cash compensation and income arising from the exercise of nonstatutory stock options, as a result of the grant, vesting or settlement of other types of equity awards, and from disqualifying dispositions of incentive stock options. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Under Code Section&#160;162(m), no deduction is allowed in any taxable year of our Company for compensation in excess of $1.0&#160;million paid to our &#8220;covered employees.&#8221; A &#8220;covered employee&#8221; is our chief executive officer and our three other most highly compensated officers, other than our chief financial officer. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">An exception to the $1.0&#160;million limit under Code Section&#160;162(m) applies to compensation that is paid to a covered employee pursuant to a stock incentive plan approved by stockholders and that specifies, among other things, the maximum number of shares with respect to which options and stock appreciation rights may be granted to eligible participants under such plan during a specified period. Compensation paid pursuant to options granted under such a plan and with an exercise price equal to the fair market value of common stock on the date of grant is deemed to be inherently performance-based, since such awards provide value to participants only if the stock price appreciates. To the extent required by Section&#160;162(m) of the Code or the regulations thereunder, in applying the foregoing limitation, if any option or stock appreciation right is canceled, the canceled award shall continue to count against the maximum number of shares with respect to which an award may be granted to a participant. The Plan provides that the maximum number of shares with respect to which options and stock appreciation rights may be granted to a participant during a calendar year is 12,475,171 shares. The foregoing limitation shall be adjusted proportionately by the plan administrator in the event of a stock split, reverse stock split, stock dividend, combination or reclassification of shares or other similar change in our shares of common stock or our capital structure. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">30</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">&#8203;</div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">For awards of restricted stock and restricted stock&#160;units that are intended to be performance-based compensation under Section&#160;162(m) of the Code, the maximum number of shares of common stock subject to such awards that may be granted to a participant during a calendar year is 12,475,171 shares. The foregoing limitation shall be adjusted proportionately by the plan administrator in the event of a stock split, reverse stock split, stock dividend, combination or reclassification of shares or other similar change in our shares or our capital structure. In order for restricted stock and restricted stock&#160;units to qualify as performance-based compensation, the plan administrator must establish a performance goal with respect to such award in writing not later than 90&#160;days after the commencement of the services to which it relates (or, if earlier, the date after which 25% of the period of service to which the performance goal relates has elapsed) and while the outcome is substantially uncertain. In addition, the performance goal must be stated in terms of an objective formula or standard. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The Plan includes the following performance criteria that may be considered by the plan administrator when granting performance-based awards: (i)&#160;increase in share price, (ii)&#160;earnings per share; (iii)&#160;total stockholder return; (iv)&#160;operating margin; (v)&#160;gross margin; (vi)&#160;return on equity; (vii)&#160;return on assets; (viii)&#160;return on investment; (ix)&#160;operating income; (x)&#160;net operating income; (xi)&#160;pre-tax profit; (xii)&#160;cash flow; (xiii)&#160;revenue: (xiv)&#160;expenses; (xv)&#160;earnings before interest, taxes and depreciation; (xvi)&#160;economic value added; and (xvii)&#160;market share. The performance criteria may be applicable to our Company, any parent or subsidiary of our Company, and/or any individual business&#160;units of our Company or any parent or subsidiary of our Company. In addition, the performance criteria will be calculated in accordance with generally accepted accounting principles, excluding the effect (whether positive or negative) of any change in accounting standards and any extraordinary, unusual or nonrecurring item occurring after the establishment of the performance criteria applicable to the award. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Stockholder approval of the Plan pursuant to this proposal will constitute stockholder approval of the material terms of the Plan, including the per person limitations on stock awards and the performance criteria described above, for Code Section&#160;162(m) purposes. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">We believe strongly that approval of this amendment to the Existing Plan is essential to our success. Our employees are our most valuable asset. Stock options and the other awards permitted under the Plan are vital to our ability to attract and retain outstanding and highly skilled employees, especially in the competitive labor markets in which we operate. These awards also are crucial to our ability to motivate employees to achieve our goals. Our Board of Directors after reviewing the allocation of awards under the Plan has determined that it is in the best interest of our Company to increase the equity compensation granted to our current and future employees. The proposed terms of the Plan are designed to allow us to continue to attract, retain and motivate people whose skills and performance are critical to our success. We will continue to monitor the environment in which we operate and make changes to our equity compensation program to help us meet our goals, including achieving long-term stockholder value. </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our Board of Directors recommends that stockholders vote &#8220;FOR&#8221; the adoption of the amendments to the Protalix BioTherapeutics, Inc. Amended and Restated 2006 Stock Incentive Plan described in this Proposal&#160;3: Amendments to the Protalix BioTherapeutics, Inc. Amended and Restated 2006 Stock Incentive Plan to Increase the Number of Authorized Shares of Common Stock Reserved for Issuance under the Plan and to Amend Certain other Terms of the Plan.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A general description of the principal terms of the Plan is set forth below. This description is qualified in its entirety by the terms of the Plan, a copy of which is attached hereto as </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Appendix&#160;A</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">At December&#160;31, 2023, there were outstanding under the Existing Plan options to purchase common stock issued covering 6,965,601shares of our common stock with a weighted average exercise price of $2.13 per share and a weighted average remaining contractual life of 7.97&#160;years. The outstanding options represent approximately 8.7% of our outstanding shares on an &#8220;as exercised&#8221; basis. As of December&#160;31, 2023, we had 633,409 shares of common stock available for future issuance under the Existing Plan. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As of April&#160;24, 2024, the fair market value of a share of our common stock was $1.21. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">31</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">&#8203;</div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Equity Compensation Plan&#160;Information</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following table provides information as of December&#160;31, 2023 with respect to the shares of our common stock that may be issued under our existing equity compensation plan. </font>
        </div>
        <table style="width:456pt;height:127pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:164.89pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">A </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">B </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">C </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt; width:164.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Plan&#160;Category </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number of Securities</font>
                <br >
                <font style="letter-spacing:-0.16pt;">to be Issued</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Upon Exercise of</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Outstanding Options </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Weighted Average</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Exercise Price of</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Outstanding Options </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number of Securities Remaining</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Available for Future Issuance</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Under Equity Compensation Plans</font>
                <br >
                <font style="letter-spacing:-0.16pt;">(Excluding Securities Reflected in</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Column A) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:164.89pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Equity Compensation Plans Approved </font>
                <br >
                <font style="letter-spacing:0.2pt;">by Stockholders </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.115pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">6,965,601</td>
            <td style="padding:0pt;padding-left:15.115pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:23.465pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">2.13</td>
            <td style="padding:0pt;padding-left:23.465pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:41.06pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">633,409</td>
            <td style="padding:0pt;padding-left:41.06pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:164.89pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Equity Compensation Plans Not Approved by Stockholders </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.115pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:15.115pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:23.465pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:23.465pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:41.06pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:41.06pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.833pt 0pt; width:164.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.115pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.833pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">6,965,601</td>
            <td style="padding:0pt;padding-left:15.115pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:23.465pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 0.833pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">2.13</td>
            <td style="padding:0pt;padding-left:23.465pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:41.06pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">633,409</td>
            <td style="padding:0pt;padding-left:41.06pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:11.8pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">General Description</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Purpose</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The purposes of the Plan are to attract and retain the best available personnel, to provide additional incentives to our officers, directors, employees and consultants through ownership of our common stock, and to promote the success of our business. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Shares Reserved for Issuance under the Plan</font><font style="font-weight:bold;letter-spacing:-0.2pt;">.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;We currently have 12,475,171 shares of common stock reserved for issuance under the Existing Plan. If approved by our stockholders, the total number of shares of common stock reserved for issuance under the Plan will be increased by 5,000,000 shares for a total of 17,475,171 shares. Shares issued in connection with awards other than options or stock appreciation rights shall count as one and one-half (1.5) shares for each share issued. The number of shares of common stock available under the Plan will be subject to adjustment in the event of a stock split, reverse stock split, stock dividend, combination or reclassification of shares or other similar change in our shares or our capital structure. Any shares of common stock covered by an award (or portion of an award) which is forfeited, canceled or expires (whether voluntarily or involuntarily) are deemed not to have been issued for purposes of determining the maximum aggregate number of shares of common stock which may be issued under the Plan. Shares that actually have been issued under the Plan pursuant to an award will not be returned to the Plan and will not be available for future issuance under the Plan, except that if unvested shares of common stock are forfeited, or repurchased by us at the lower of their original purchase price or their fair market value (as defined in the Plan) at the time of repurchase, such shares of common stock shall become available for future grant under the Plan. Any shares covered by an award which are surrendered (i)&#160;in payment of the award exercise or purchase price (including pursuant to the &#8220;net exercise&#8221; of an option pursuant to Section&#160;7(b)(v) of the Plan) or (ii)&#160;in satisfaction of tax withholding obligations incident to the exercise of an award will not be returned to the Plan and will not be available for future issuance under the Plan. Shares that are covered by the portion of a SAR that is exercised (whether or not shares are actually issued) will be considered issued. Shares that are counted as one and one-half (1.5) shares upon issuance will be counted as one and one-half (1.5) shares upon return. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">During any calendar year, the maximum number of shares with respect to which options and stock appreciation rights may be granted to a participant is currently 12,475,171 shares. If approved by our stockholders, the maximum number of shares with respect to which options and stock appreciation rights may be granted to a participant in any calendar year will be 17,475,171 shares. The maximum number of shares of restricted stock and restricted stock&#160;units that are intended to be performance-based compensation under Section&#160;162(m) of the Code that may be awarded to a participant in any calendar year is 17,475,171 shares. The foregoing limitations shall be adjusted proportionately by the plan administrator in the event of a stock split, reverse stock split, stock dividend, combination or reclassification of shares or other similar change in our shares or our capital structure, and its determination shall be final, binding and conclusive. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Administration</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Our Board of Directors or the Compensation Committee, referred to as the &#8220;plan administrator,&#8221; administers the Plan, including selecting the grantees, determining the number of shares to be subject to each award, determining the exercise or purchase price of each award, and determining the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">32</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">&#8203;</div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">vesting and exercise periods of each award. The Plan is currently being administered by the Compensation Committee. With respect to grants to officers and directors, the Compensation Committee shall be constituted in such a manner as to satisfy applicable laws, including Rule&#160;16b-3 promulgated under the Exchange Act. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Terms and Conditions of Awards.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The Amendment provides for the grant of stock options, restricted stock, restricted stock&#160;units, stock appreciation rights and dividend equivalent rights, collectively referred to as &#8220;awards.&#8221; Stock options granted under the Plan may be either incentive stock options under the provisions of Section&#160;422 of the Internal Revenue Code, or non-qualified stock options. Incentive stock options may be granted only to our employees or to employees of our related entities. Awards other than incentive stock options may be granted to our employees, directors and consultants or to employees, consultants and directors of our related entities. Because the Plan provides for broad discretion in selecting which eligible persons will participate and in granting awards, the total number of persons who will actually participate in the Amended Plan and the benefits that will be provided to the participants cannot be determined at this time. As of December&#160;31, 2023, approximately 200 employees (three of whom are current named executive officers of the Company) and six non-employee directors were eligible for awards under the Plan. In addition, we engage certain consultants that also may be eligible for awards under the Plan. To the extent that the aggregate fair market value of the shares subject to options designated as incentive stock options which become exercisable for the first time by a participant during any calendar year exceeds $100,000, such excess options shall be treated as nonqualified stock options. Each award granted under the Plan shall be designated in an award agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Plan is also designed to comply with the provisions of the Israeli Income Tax Ordinance New Version, 1961 (including as amended pursuant to Amendment 132 thereto), or the tax ordinance, and is intended to enable us to grant awards to grantees who are Israeli residents as follows: (i)&#160;awards to employees pursuant to Section&#160;102 of the tax ordinance; and (ii)&#160;awards to non-employees pursuant to Section&#160;3(I) of the tax ordinance. For this purpose, &#8220;employee&#8221; refers only to employees, office holders and directors of our Company or a related entity excluding those who are considered &#8220;Controlling Stockholders&#8221; pursuant to, or otherwise excluded by, the tax ordinance. In accordance with the terms and conditions imposed by the tax ordinance, grantees who receive awards under the Amendment may be afforded certain tax benefits in Israel as described below. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The exercise price of stock options granted under the Plan must be equal to at least 100% of the fair market value of our common stock on the date of grant. If, however, incentive stock options are granted to an employee who owns stock possessing more than 10% of the voting power of all classes of our stock or the stock of any parent or subsidiary of our Company, the exercise price of any incentive stock option granted must equal at least 110% of the fair market value on the grant date and the maximum term of these incentive stock options must not exceed five&#160;years. The maximum term of all other awards must not exceed 10&#160;years (or 5&#160;years in the case of an incentive stock option granted to any participant who owns stock representing more than 10% of the voting power of all classes of our stock or the stock of any parent or subsidiary of our Company). The plan administrator will determine the exercise or purchase price (if any) of all other awards granted under the Plan. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Under the Plan, incentive stock options and options to Israeli grantees may not be sold, pledged, assigned, hypothecated, transferred or disposed of in any manner other than by will or by the laws of descent or distribution and may be exercised during the lifetime of the participant only by the participant. Other awards shall be transferable by will or by the laws of descent or distribution and, during the lifetime of the participant, to the extent and in the manner authorized by the plan administrator by gift or pursuant to a domestic relations order to members of the participant&#8217;s immediate family. The Plan permits the designation of beneficiaries by holders of awards, including incentive stock options. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If the service of a participant in the Plan is terminated for any reason other than cause, the participant may exercise awards that were vested as of the termination date for a period ending upon the earlier of 12&#160;months from the date of termination (or such shorter or longer period set forth in the award agreement) or the expiration date of the awards unless otherwise determined by the plan administrator. If the service of a participant in the Plan is terminated for cause, the participant may exercise awards that were vested as of the termination date for a period ending upon the earlier of 14&#160;days from the date of termination (or such shorter or longer period set forth in the award agreement) or the expiration date of the awards unless otherwise determined by the plan administrator. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">33</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">&#8203;</div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Performance Criteria.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Amendment, Suspension and Termination.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The Board may at any time amend, suspend, or terminate the Plan; provided, however, that no such amendment shall be made without the approval of the Company&#8217;s stockholders if such amendment would require stockholder approval under any other applicable law or regulation. Any amendment, suspension or termination of the Plan may not adversely affect the rights of any participant under an outstanding award (unless such participant&#8217;s consent is obtained). Notwithstanding the foregoing, the reduction or increase of the exercise price of any stock option or the base appreciation amount of a SAR and the canceling of any stock option or SAR at a time when its exercise price or base appreciation amount exceeds the fair market value of the underlying shares in exchange for another award shall be subject to stockholder approval unless such exchange occurs in connection with a corporate transaction. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Corporate Transaction and Change in Control</font><font style="font-weight:bold;letter-spacing:-0.2pt;">.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;In the event of a corporate transaction, all outstanding awards will terminate unless assumed by the successor corporation. Unless otherwise provided in a participant&#8217;s award agreement, in the event of a corporate transaction and with respect to the portion of each award that is assumed or replaced, then such portion will automatically become fully vested and exercisable immediately upon termination of a participant&#8217;s service if the participant is terminated by the successor company or us without cause within 12&#160;months after the corporate transaction. With respect to the portion of each award that is not assumed or replaced, such portion of the award will automatically become fully vested and exercisable immediately prior to the effective date of the corporate transaction so long as the participant&#8217;s service has not been terminated prior to such date. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In the event of a change in control, except as otherwise provided in a participant&#8217;s award agreement, following a change in control (other than a change in control that also is a corporate transaction) and upon the termination of a participant&#8217;s service without cause within 12&#160;months after a change in control, each award of such participant that is outstanding at such time will automatically become fully vested and exercisable immediately upon the participant&#8217;s termination. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Under the Plan, a corporate transaction is generally defined as: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">a merger or consolidation in which we are not the surviving entity, except for the principal purpose of changing our Company&#8217;s state of incorporation; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the sale, transfer or other disposition of all or substantially all of our assets; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the complete liquidation or dissolution of our Company; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any reverse merger in which we are the surviving entity but our shares of common stock outstanding immediately prior to such merger are converted or exchanged by virtue of the merger into other property, whether in the form of securities, cash or otherwise, or in which securities possessing more than forty&#160;percent (40%) of the total combined voting power of our outstanding securities are transferred to a person or persons different from those who held such securities immediately prior to such merger; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">acquisition in a single or series of related transactions by any person or related group of persons (other than by us or by an employee benefit plan sponsored by us) of beneficial ownership of securities possessing more than fifty&#160;percent (50%) of the total combined voting power of our outstanding securities but excluding any such transaction or series of related transactions that the plan administrator determines not to be a corporate transaction (provided however that the plan administrator shall have no discretion in connection with a corporate transaction for the purchase of all or substantially all of our shares unless the principal purpose of such transaction is changing our Company&#8217;s state of incorporation). </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Under the Plan, a change of control is defined as: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the direct or indirect acquisition by any person or related group of persons of beneficial ownership of securities possessing more than fifty&#160;percent (50%) of the total combined voting power of our outstanding securities pursuant to a tender or exchange offer made directly to our stockholders and which a majority of the members of our Board of Directors (who have generally been on our </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">34</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">&#8203;</div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:30pt; width:426pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Board of Directors for at least 12&#160;months) who are not affiliates or associates of the offeror do not recommend stockholders accept the offer; or </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">a change in the composition of our Board of Directors over a period of 12&#160;months or less, such that a majority of the members of our Board of Directors ceases, by reason of one or more contested elections for board membership, to be comprised of individuals who were previously directors of our Company. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Amendment, Suspension or Termination of the Plan</font><font style="font-weight:bold;letter-spacing:-0.2pt;">.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Unless terminated sooner, the Plan will automatically terminate on December&#160;31, 2028. Our Board of Directors has the authority to amend, suspend or terminate the Plan. No amendment, suspension or termination of the Plan shall adversely affect any rights under awards already granted to a participant. To the extent necessary to comply with applicable provisions of federal securities laws, state corporate and securities laws, the Internal Revenue Code, the rules of any applicable stock exchange or national market system, and the rules of any non-U.S. jurisdiction applicable to awards granted to residents therein (including the tax ordinance), we shall obtain stockholder approval of any such amendment to the Plan in such a manner and to such a degree as required. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Amended Plan&#160;Benefits</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The grant of awards under the Plan, including grants to our executive officers, is subject to the discretion of the plan administrator. Except as set forth below, the allocation of the new shares is not determinable at this time. </font>
        </div>
        <table style="width:456pt;height:58pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="7">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">New Plan&#160;Benefits </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, amended </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:144pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Name and Position </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:144pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Dollar Value ($) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:144pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number of Units </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 2.5pt 0pt; width:144pt;">
              <font style="letter-spacing:0.2pt;">Eyal Rubin, Sr. VP &amp; CFO </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:144pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 2.5pt 0pt; width:144pt;white-space:normal;">
              <font style="letter-spacing:0.2pt;">Annual Grant of Restricted Stock for $100,000</font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Certain Federal Tax Consequences</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following summary of the U.S. federal income tax consequences of the Plan transactions is based upon federal income tax laws in effect on the date of this Proxy Statement. This summary does not purport to be complete, and does not discuss state, local or non-U.S. tax consequences. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Nonqualified Stock Options</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The grant of a nonqualified stock option under the Plan will not result in any U.S. federal income tax consequences to us or the participant, if a U.S. taxpayer. Upon exercise of a nonqualified stock option, the participant is subject to income taxes at the rate applicable to ordinary compensation income on the difference between the option exercise price and the fair market value of the shares at the time of exercise. This income is subject to withholding for U.S. federal income and employment tax purposes. We are entitled to an income tax deduction in the amount of the income recognized by the participant, subject to possible limitations imposed by Section&#160;162(m) of the Code and so long as we withhold the appropriate taxes with respect to such income (if required) and the participant&#8217;s total compensation is deemed reasonable in amount. Any gain or loss on the participant&#8217;s subsequent disposition of the shares will receive long or short-term capital gain or loss treatment, depending on whether the shares are held for more than one year following exercise. We do not receive a tax deduction for any such gain. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A nonqualified stock option can be considered deferred compensation and be subject to Section&#160;409A of the Code. A nonqualified stock option that does not meet the requirements of Code Section&#160;409A can result in the acceleration of income recognition, an additional 20% tax obligation, plus penalties and interest. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Incentive Stock Options</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The grant of an incentive stock option under the Plan will not result in any U.S. federal income tax consequences to us or the participant, if a U.S. taxpayer. A participant recognizes no federal taxable income upon exercising an incentive stock option (subject to the alternative minimum tax rules discussed below), and we receive no deduction at the time of exercise. In the event of a disposition of stock acquired upon exercise of an incentive stock option, the tax consequences depend upon how long the participant has held the shares. If the participant does not dispose of the shares within two&#160;years after the incentive stock option was granted, nor within one year after the incentive stock option was exercised, the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">35</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">&#8203;</div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">participant will recognize a long-term capital gain (or loss) equal to the difference between the sale price of the shares and the exercise price. We are not entitled to any deduction under these circumstances. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If the participant is a U.S. taxpayer and fails to satisfy either of the foregoing holding periods (referred to as a &#8220;disqualifying disposition&#8221;), he or she must recognize ordinary income in the year of the disposition. The amount of ordinary income generally is the lesser of (i)&#160;the difference between the amount realized on the disposition and the exercise price or (ii)&#160;the difference between the fair market value of the stock at the time of exercise and the exercise price. Any gain in excess of the amount taxed as ordinary income will be treated as a long or short-term capital gain, depending on whether the stock was held for more than one year. We are entitled, in the year of the disqualifying disposition, to a deduction equal to the amount of ordinary income recognized by the participant, subject to possible limitations imposed by Section&#160;162(m) of the Code and so long as the participant&#8217;s total compensation is deemed reasonable in amount. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The &#8220;spread&#8221; under an incentive stock option&#8201;&#8212;&#8201;i.e., the difference between the fair market value of the shares at exercise and the exercise price&#8201;&#8212;&#8201;is classified as an item of adjustment in the year of exercise for purposes of the alternative minimum tax. If a participant&#8217;s alternative minimum tax liability exceeds such participant&#8217;s regular income tax liability, the participant will owe the larger amount of taxes. In order to avoid the application of alternative minimum tax with respect to incentive stock options, the participant must sell the shares within the calendar year in which the incentive stock options are exercised. However, such a sale of shares within the year of exercise will constitute a disqualifying disposition, as described above. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Stock Appreciation Rights</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Recipients of stock appreciation rights, or SARs, if U.S. taxpayers, generally should not recognize income until the SAR is exercised (assuming there is no ceiling on the value of the right). Upon exercise, the recipient will normally recognize taxable ordinary income for U.S. federal income tax purposes equal to the amount of cash and fair market value of the shares, if any, received upon such exercise. Recipients who are employees will be subject to withholding for federal income and employment tax purposes with respect to income recognized upon exercise of a SAR. Recipients will recognize gain upon the disposition of any shares received on exercise of a SAR equal to the excess of (i)&#160;the amount realized on such disposition over (ii)&#160;the ordinary income recognized with respect to such shares under the principles set forth above. That gain will be taxable as long or short-term capital gain depending on whether the shares were held for more than one year. We will be entitled to a tax deduction to the extent and in the year that ordinary income is recognized by the recipient, subject to possible limitations imposed by Section&#160;162(m) of the Code and so long as we withhold the appropriate taxes with respect to such income (if required) and the recipient&#8217;s total compensation is deemed reasonable in amount. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">A SAR can be considered non-qualified deferred compensation and be subject to Section&#160;409A of the Code. A SAR that does not meet the requirements of Code Section&#160;409A can result in the acceleration of income recognition, an additional 20% tax obligation, plus penalties and interest. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Restricted Stock</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The grant of restricted stock will subject the recipient to ordinary compensation income on the difference between the amount paid for such stock and the fair market value of the shares on the date that the restrictions lapse. This income is subject to withholding for federal income and employment tax purposes. We are entitled to an income tax deduction in the amount of the ordinary income recognized by the recipient, subject to possible limitations imposed by Section&#160;162(m) of the Code and so long as we withhold the appropriate taxes with respect to such income (if required) and the participant&#8217;s total compensation is deemed reasonable in amount. Any gain or loss on the recipient&#8217;s subsequent disposition of the shares will receive long or short-term capital gain or loss treatment depending on how long the stock has been held since the restrictions lapsed. We do not receive a tax deduction for any such gain. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Recipients of restricted stock may make an election under Section&#160;83(b) of the Code, or a Section&#160;83(b) Election, to recognize as ordinary compensation income in the year that such restricted stock is granted, the amount equal to the spread between the amount paid for such stock and the fair market value on the date of the issuance of the stock. If such an election is made, the recipient recognizes no further amounts of compensation income upon the lapse of any restrictions and any gain or loss on subsequent disposition will be long or short-term capital gain to the recipient. The Section&#160;83(b) Election must be made within 30&#160;days from the time the restricted stock is issued. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Restricted Stock Units</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Recipients of restricted stock&#160;units generally should not recognize income until such&#160;units are converted into cash or shares. Upon conversion, the recipient will normally recognize </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">36</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">&#8203;</div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:8pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">taxable ordinary income for federal income tax purposes equal to the amount of cash and fair market value of the shares, if any, received upon such conversion. Recipients who are employees will be subject to withholding for federal income and employment tax purposes with respect to income recognized upon conversion of the restricted stock&#160;units. Participants will recognize gain upon the disposition of any shares received upon conversion of the restricted stock&#160;units equal to the excess of (i)&#160;the amount realized on such disposition over (ii)&#160;the ordinary income recognized with respect to such shares under the principles set forth above. That gain will be taxable as long or short-term capital gain depending on whether the shares were held for more than one year. We will be entitled to a tax deduction to the extent and in the year that ordinary income is recognized by the recipient, subject to possible limitations imposed by Section&#160;162(m) of the Code and so long as we withhold the appropriate taxes with respect to such income (if required) and the recipient&#8217;s total compensation is deemed reasonable in amount. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Restricted stock&#160;units also can be considered non-qualified deferred compensation and be subject to Section&#160;409A of the Code. A grant of restricted stock&#160;units that is non-qualified deferred compensation but does not meet the requirements of Code Section&#160;409A will result in an additional 20% tax obligation, plus penalties and interest to such recipient. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Dividends and Dividend Equivalents</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Recipients of stock-based awards that earn dividends or dividend equivalents will recognize taxable ordinary income on any dividend payments received with respect to unvested and/or unexercised shares subject to such awards, which income is subject to withholding for federal income and employment tax purposes. We are entitled to an income tax deduction in the amount of the income recognized by a participant, subject to possible limitations imposed by Section&#160;162(m) of the Code and so long as we withhold the appropriate taxes with respect to such income (if required) and the individual&#8217;s total compensation is deemed reasonable in amount. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Impact of Israeli Tax Law</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The awards granted to employees pursuant to Section&#160;102 of the tax ordinance under the Plan may be designated by us as approved options under the capital gains alternative, or as approved options under the ordinary income tax alternative. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">To qualify for these benefits, certain requirements must be met, including registration of the options in the name of a trustee. Each option, and any shares of common stock acquired upon the exercise of the option, must be held by the trustee for a period commencing on the date of grant and deposit into trust with the trustee and ending 24&#160;months thereafter. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Under the terms of the capital gains alternative, we may not deduct expenses pertaining to the options for tax purposes. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Under the Plan, we may also grant to employees options pursuant to Section&#160;102(c) of the tax ordinance that are not required to be held in trust by a trustee. This alternative, while facilitating immediate exercise of vested options and sale of the underlying shares, will subject the optionee to the marginal income tax rate of up to 50% as well as payments to the National Insurance Institute and health tax on the date of the sale of the shares or options. Under the 2006 Stock Incentive Plan, we may also grant to non-employees options pursuant to Section&#160;3(I) of the tax ordinance. Under that section, the income tax on the benefit arising to the optionee upon the exercise of options and the issuance of common stock is generally due at the time of exercise of the options. </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">These options shall be further subject to the terms of the tax ruling that has been obtained by Protalix Ltd. from the Israeli tax authorities in connection with our merger in 2006. Under the tax ruling, the options issued by us in connection with the assumption of Section&#160;102 options previously issued by Protalix Ltd. under the capital gains alternative shall be issued to a trustee, shall be designated under the capital gains alternative and the issuance date of the original options shall be deemed the issuance date for the assumed options for the calculation of the respective holding period. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">37</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">&#8203;</div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">PROPOSAL 4: RATIFICATION OF APPOINTMENT OF </font>
          <br >
          <font style="letter-spacing:-0.2pt;">INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our Board of Directors, upon the recommendation of its Audit and Finance Committee, has ratified the selection of Kesselman &amp; Kesselman to serve as our independent registered public accounting firm for the fiscal year ending December&#160;31, 2024. The Audit and Finance Committee of our Board of Directors is solely responsible for selecting our independent public accountants. Although stockholder approval is not required to appoint Kesselman &amp; Kesselman as our independent public accountant firm, we believe that submitting the appointment of Kesselman &amp; Kesselman to our stockholders for ratification is a matter of good corporate governance. If our stockholders do not ratify the appointment, then the appointment may be reconsidered by the Audit and Finance Committee. Even if the appointment is ratified, the Audit and Finance Committee may engage a different independent registered public accounting firm at any time during the year if it determines that such a change would be in the best interest of our Company and our stockholders. The proxy will be voted as specified, and if no specification is made, the proxy will be cast &#8220;FOR&#8221; this proposal. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">During our fiscal year ended December&#160;31, 2023, there were no disagreements with Kesselman &amp; Kesselman on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedures, which if not resolve to their satisfaction would have caused them to make reference to the subject matter of the disagreements in connection with their opinion. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Audit and Finance Committee will consider whether the provision of any other services by Kesselman &amp; Kesselman is compatible with maintaining the independence of Kesselman &amp; Kesselman. The Audit and Finance Committee has concluded that Kesselman &amp; Kesselman is independent. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We expect representatives of Kesselman &amp; Kesselman will be present at the meeting. They will have the opportunity to make a statement if they desire to do so and are expected to be available to answer stockholders&#8217; questions. </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our Board of Directors recommends that stockholders vote &#8220;FOR&#8221; the ratification of the appointment of Kesselman &amp; Kesselman for the fiscal year ending December&#160;31, 2024.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table sets forth fees billed to us by our independent registered public accounting firm during the fiscal&#160;years ended December&#160;31, 2023 and 2022 for: (i)&#160;services rendered for the audit of our annual financial statements and the review of our quarterly financial statements; (ii)&#160;services by our independent registered public accounting firm that are reasonably related to the performance of the audit or review of our financial statements and that are not reported as Audit Fees; (iii)&#160;services rendered in connection with tax compliance, tax advice and tax planning; and (iv)&#160;all other fees for services rendered. </font>
        </div>
        <table style="width:416pt;height:82pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:316.59pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Year Ended December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:316.59pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2023 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:316.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Audit Fees </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">220,750 </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">254,750</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:316.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Audit Related Fees </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:316.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Tax Fees </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">39,440 </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">71,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:316.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">All Other Fees </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Policy on Audit and Finance Committee Pre-Approval of Audit and Permissible Non-Audit Services of Independent Auditors</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our Audit and Finance Committee has the sole authority to approve the scope of the audit and any audit-related services, as well as all audit fees and terms. The Audit and Finance Committee must pre-approve any audit and non-audit services provided by our independent registered public accounting firm. The Audit and Finance Committee will not approve the engagement of the independent registered public accounting firm to perform any services that the independent registered public accounting firm would be prohibited from providing under applicable laws, rules and regulations, including those of self-regulating organizations. The Audit and Finance Committee will approve permitted non-audit services by our independent registered public accounting firm only if it determines that using a different firm to perform </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">38</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">&#8203;</div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:4pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">such services will be more effective or economical. The Audit and Finance Committee annually reviews and pre-approves the statutory audit fees that can be provided by the independent registered public accounting firm. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">SOLICITATION OF PROXIES</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have engaged Alliance Advisors LLC to assist us in soliciting proxies for the meeting. We will pay Alliance Advisors a base fee of approximately $10,000, plus reasonable out-of-pocket expenses, plus an additional fee based upon the number of contacts with stockholders made and work performed. We estimate the total amount payable to Alliance Advisors will be approximately $100,000. Our officers, directors and employees may solicit proxies in person or by telephone, fax or email. We will pay these officers, employees and directors no additional compensation for these services. We will ask banks, brokers and other institutions, nominees and fiduciaries to forward these proxy materials to their principals and to obtain authority to execute proxies. We will then reimburse them for their expenses. We will pay all of the costs of soliciting these proxies. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If you need assistance in voting by telephone or over the Internet or completing your proxy card or have questions regarding the meeting, please contact our proxy advisor: </font>
        </div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Alliance Advisors, LLC</font>
          <br >
          <font style="letter-spacing:0.2pt;">200 Broadacres Drive, 3rd Floor</font>
          <br >
          <font style="letter-spacing:0.2pt;">Bloomfield, NJ 07003</font>
          <br >
          <font style="letter-spacing:0.2pt;">+1 (855) 200-7892 (toll free in the United States) </font>
          <br >
          <font style="letter-spacing:0.2pt;">PLX@AllianceAdvisors.com </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">STOCKHOLDER PROPOSALS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">All stockholder proposals intended to be presented at our 2025 Annual Meeting of Stockholders must be submitted in writing to Eyal Rubin, Corporate Secretary, Protalix BioTherapeutics, Inc., 2 University Plaza, Suite 100, Hackensack, NJ 07601, and received by us no later than January&#160;23, 2025, and must comply in all other respects with applicable rules and regulations of the SEC relating to such inclusion. Such notice must include, with respect to each matter the stockholder proposes to bring before the meeting: (i)&#160;a brief description of the business desired to be brought before the meeting and the reasons for conducting such business at the meeting; (ii)&#160;the name and record address of the stockholder proposing such business; (iii)&#160;the class and number of shares of our Company which are beneficially owned by the stockholder; and (iv)&#160;any material interest of the stockholder in such business. In addition, the notice must include certain information relating to any derivative or hedging transactions by the stockholder delivering such notice and its Stockholder Associated Persons, as defined in our By-Laws, and other arrangements with other parties regarding our securities, as presented in detail in our By-Laws. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Any such proposal submitted with respect to our 2025 Annual Meeting of Stockholders which is submitted outside the requirements of Rule&#160;14a-8 promulgated under the Exchange Act will be considered timely if we receive written notice of that proposal not less than 45&#160;days nor more than 75&#160;days prior to the date in 2025 on which we first mailed this proxy statement in 2024; however, if the date of the meeting is changed by more than 30&#160;days from the date of the prior year&#8217;s meeting, the notice will be considered untimely if it is not received at least 90&#160;days prior to the newly announced date that we will mail our proxy statement. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">ANNUAL REPORT TO STOCKHOLDERS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our FY2023 Annual Report, which provides additional information about us, will be distributed to all stockholders entitled to vote along with the proxy materials. Additional copies of our FY2023 Annual Report are available on the Internet at http://www.sec.gov and http://www.protalix.com and are also available in paper form without charge upon written request to Investor Relations, Protalix BioTherapeutics, Inc., 2&#160;University Plaza, Suite 100, Hackensack, NJ 07601. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">39</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">&#8203;</div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:130pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">HOUSEHOLDING OF PROXY MATERIALS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The SEC has adopted rules that permit companies and intermediaries (e.g., brokers) to satisfy the delivery requirements for proxy statements and annual reports with respect to two or more stockholders sharing the same address by delivering a single proxy statement addressed to those stockholders. This process, which is commonly referred to as &#8220;householding,&#8221; potentially means extra convenience for stockholders and cost savings for companies. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This year, a number of brokers with account holders who are stockholders of our Company will be &#8220;householding&#8221; our proxy materials. A single proxy statement may be delivered to multiple stockholders sharing an address unless contrary instructions have been received from the affected stockholders. Once a stockholder has received notice from its broker that it will be &#8220;householding&#8221; communications to such stockholder&#8217;s address, &#8220;householding&#8221; will continue until such stockholder is notified otherwise or until such stockholder notifies its broker or us that it no longer wishes to participate in &#8220;householding.&#8221; If, at any time, a stockholder no longer wishes to participate in &#8220;householding&#8221; and would prefer to receive a separate proxy statement and annual report in the future such stockholder may (1)&#160;notify its broker or (2)&#160;direct its written request to: Eyal Rubin, Corporate Secretary, Protalix BioTherapeutics, Inc., 2 University Plaza, Suite 100, Hackensack, NJ 07601, +1 (201) 696-9345. Stockholders who currently receive multiple copies of the proxy statement at their address and would like to request &#8220;householding&#8221; of their communications should contact their broker. In addition, we will promptly deliver, upon written or oral request to the address or telephone number above, a separate copy of the annual report and proxy statement to such stockholders at a shared address to which a single copy of the documents was delivered. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">OTHER MATTERS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our Board of Directors knows of no other business to be acted upon at the meeting. However, if any other business properly comes before the meeting, it is the intention of the persons named in the enclosed proxy to vote on such matters in accordance with their best judgment. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The prompt return of your proxy is appreciated and will be helpful in obtaining the necessary vote. Therefore, whether or not you expect to attend the meeting please sign the proxy and return it in the enclosed envelope or vote by internet or telephone. </font>
        </div>
        <div style="text-indent:240pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">BY ORDER OF THE BOARD OF DIRECTORS, </font>
        </div>
        <div style="position:relative;margin-left:240pt; margin-top:10pt; width:216pt;">
          <img src="sg_eyalrubin-bw.jpg" alt="[MISSING IMAGE: sg_eyalrubin-bw.jpg]" height="39" width="123" >
        </div>
        <div style="margin-left:240pt; margin-top:5pt; width:216pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Eyal Rubin </font> <br ><font style="letter-spacing:0.2pt;">Sr. Vice President and Chief Financial Officer and</font><br ><font style="letter-spacing:0.2pt;">Corporate Secretary </font></div>
        <div style="margin-left:240pt; margin-top:8pt; width:216pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Carmiel, Israel </font>
          <br >
          <font style="letter-spacing:0.2pt;">April&#160;29, 2024</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">40</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">&#8203;</div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; text-align:right; width:436pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Appendix&#160;A</font>&#8203;</div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">PROTALIX BIOTHERAPEUTICS, INC. </font>
          <br >
          <font style="letter-spacing:-0.2pt;">AMENDED AND RESTATED 2006 STOCK INCENTIVE PLAN, AS AMENDED </font>
          <br >
          <font style="letter-spacing:-0.2pt;">(</font><font style=" text-decoration:underline #0081C4 solid;color:#0081C4;letter-spacing:-0.2pt;">June 27, 2024</font><font style=" text-decoration:line-through;color:#FC0014;letter-spacing:-0.2pt;">June&#160;28, 2023</font><font style="letter-spacing:-0.2pt;">)</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">1.&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Purposes of the Plan</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The purposes of this Plan are to attract and retain the best available personnel, to provide additional incentives to Employees, Directors and Consultants and to promote the success of the Company&#8217;s business. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">2.&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Definitions</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The following definitions shall apply as used herein and in the individual Award Agreements except as defined otherwise in an individual Award Agreement. In the event a term is separately defined in an individual Award Agreement, such definition shall supercede the definition contained in this Section&#160;2. </font>
        </div>
        <div style="margin-left:40pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">3(I) Option</font><font style="letter-spacing:0.2pt;">&#8221; means Award granted under Section&#160;3(I). </font>
        </div>
        <div style="margin-left:40pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">102 Option</font><font style="letter-spacing:0.2pt;">&#8221; means Award granted under Section&#160;102. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Administrator</font><font style="letter-spacing:0.2pt;">&#8221; means the Board or any of the Committees appointed to administer the Plan. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(d)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Affiliate</font><font style="letter-spacing:0.2pt;">&#8221; and &#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Associate</font><font style="letter-spacing:0.2pt;">&#8221; shall have the respective meanings ascribed to such terms in Rule&#160;12b-2 promulgated under the Exchange Act. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(e)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Applicable Laws</font><font style="letter-spacing:0.2pt;">&#8221; means the legal requirements relating to the Plan and the Awards under applicable provisions of federal securities laws, state corporate and securities laws, the Code, the rules of any applicable stock exchange or national market system, and the rules of any non-U.S. jurisdiction applicable to Awards granted to residents therein. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(f)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Assumed</font><font style="letter-spacing:0.2pt;">&#8221; means that pursuant to a Corporate Transaction either (i)&#160;the Award is expressly affirmed by the Company or (ii)&#160;the contractual obligations represented by the Award are expressly assumed (and not simply by operation of law) by the successor entity or its Parent in connection with the Corporate Transaction with appropriate adjustments to the number and type of securities of the successor entity or its Parent subject to the Award and the exercise or purchase price thereof which at least preserves the compensation element of the Award existing at the time of the Corporate Transaction as determined in accordance with the instruments evidencing the agreement to assume the Award. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(g)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Award</font><font style="letter-spacing:0.2pt;">&#8221; means the grant of an Option, SAR, Dividend Equivalent Right, Restricted Stock, Restricted Stock Unit or other right or benefit under the Plan. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(h)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Award Agreement</font><font style="letter-spacing:0.2pt;">&#8221; means the written agreement evidencing the grant of an Award executed by the Company and the Grantee, including any amendments thereto. </font>
        </div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:7.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(i)</font>
          <br >
        </div>
        <div style=" margin-top:7.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Board</font><font style="letter-spacing:0.2pt;">&#8221; means the Board of Directors of the Company. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(j)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Cause</font><font style="letter-spacing:0.2pt;">&#8221; means, with respect to the termination by the Company or a Related Entity of the Grantee&#8217;s Continuous Service, that such termination is for &#8220;Cause&#8221; as such term (or word of like import) is expressly defined in a then-effective written agreement between the Grantee and the Company or such Related Entity, or in the absence of such then-effective written agreement and definition, is based on, in the determination of the Administrator, the Grantee&#8217;s: (i)&#160;performance of any act or failure to perform any act in bad faith which is materially detrimental to the Company or a Related Entity as reasonably determined in good faith by a unanimous decision of members of the Board entitled to vote thereon; (ii)&#160;dishonesty, intentional misconduct or material breach of any agreement with the Company or a Related Entity; (iii)&#160;commission of a crime involving dishonesty, breach of trust, or physical or emotional harm to any person; (iv)&#160;embezzlement of funds of the Company or a Related Entity; (v)&#160;ownership, direct or indirect (i.e., by means of a holding company or family member), of an interest in a person or entity (other than a minority interest in a publicly traded company) in competition with the products or services of the Company or a Related Entity, including those products or services </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-1</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">&#8203;</div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">contemplated in a plan adopted by the Board; (vi)&#160;any breach of the Grantee&#8217;s fiduciary duties or duties of care to the Company or a Related Entity (except for conduct taken in good faith); (vii)&#160;any material failure to carry out a reasonable and legitimate directive of the Board; or (viii)&#160;any material breach of an Employee&#8217;s undertakings of confidentiality and non competition. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(k)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Change in Control</font><font style="letter-spacing:0.2pt;">&#8221; means a change in ownership or control of the Company effected through either of the following transactions: </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(i)&nbsp;&nbsp;&nbsp;the direct or indirect acquisition by any person or related group of persons (other than an acquisition from or by the Company or by a Company-sponsored employee benefit plan or by a person that directly or indirectly controls, is controlled by, or is under common control with, the Company) of beneficial ownership (within the meaning of Rule&#160;13d-3 of the Exchange Act) of securities possessing more than fifty&#160;percent (50%) of the total combined voting power of the Company&#8217;s outstanding securities pursuant to a tender or exchange offer made directly to the Company&#8217;s stockholders which a majority of the Continuing Directors who are not Affiliates or Associates of the offeror do not recommend such stockholders accept, or </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(ii)&nbsp;&nbsp;&nbsp;a change in the composition of the Board over a period of twelve (12) months or less such that a majority of the Board members (rounded up to the next whole number) ceases, by reason of one or more contested elections for Board membership, to be comprised of individuals who are Continuing Directors. </font>
        </div>
        <div style="margin-left:40pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(l)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Code</font><font style="letter-spacing:0.2pt;">&#8221; means the Internal Revenue Code of 1986, as amended. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(m)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Committee</font><font style="letter-spacing:0.2pt;">&#8221; means any committee composed of members of the Board appointed by the Board to administer the Plan. </font>
        </div>
        <div style="margin-left:40pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(n)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Common Stock</font><font style="letter-spacing:0.2pt;">&#8221; means the common stock of the Company. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(o)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Company</font><font style="letter-spacing:0.2pt;">&#8221; means Protalix BioTherapeutics, Inc., a Delaware corporation, or any successor entity that adopts the Plan in connection with a Corporate Transaction. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(p)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Consultant</font><font style="letter-spacing:0.2pt;">&#8221; means any person (other than an Employee or a Director, solely with respect to rendering services in such person&#8217;s capacity as a Director) who is engaged by the Company or any Related Entity to render consulting or advisory services to the Company or such Related Entity. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(q)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Continuing Directors</font><font style="letter-spacing:0.2pt;">&#8221; means members of the Board who either (i)&#160;have been Board members continuously for a period of at least twelve (12) months or (ii)&#160;have been Board members for less than twelve (12) months and were elected or nominated for election as Board members by at least a majority of the Board members described in clause (i)&#160;who were still in office at the time such election or nomination was approved by the Board. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(r)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Continuous Service</font><font style="letter-spacing:0.2pt;">&#8221; means that the provision of services to the Company or a Related Entity in any capacity of Employee, Director or Consultant is not interrupted or terminated. In jurisdictions requiring notice in advance of an effective termination as an Employee, Director or Consultant, Continuous Service shall be deemed terminated upon the actual cessation of providing services to the Company or a Related Entity notwithstanding any required notice period that must be fulfilled before a termination as an Employee, Director or Consultant can be effective under Applicable Laws. A Grantee&#8217;s Continuous Service shall be deemed to have terminated either upon an actual termination of Continuous Service or upon the entity for which the Grantee provides services ceasing to be a Related Entity. Continuous Service shall not be considered interrupted in the case of (i)&#160;any approved leave of absence, (ii)&#160;transfers among the Company, any Related Entity, or any successor, in any capacity of Employee, Director or Consultant, or (iii)&#160;any change in status as long as the individual remains in the service of the Company or a Related Entity in any capacity of Employee, Director or Consultant (except as otherwise provided in the Award Agreement). An approved leave of absence shall include sick leave, military leave, or any other authorized personal leave. For purposes of each Incentive Stock Option granted under the Plan, if such leave exceeds three (3)&#160;months, and reemployment upon expiration of such leave is not guaranteed by statute or contract, then the Incentive Stock Option </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-2</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">&#8203;</div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">shall be treated as a Non-Qualified Stock Option on the day three (3)&#160;months and one (1)&#160;day following the expiration of such three (3)&#160;month period. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(s)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Corporate Transaction</font><font style="letter-spacing:0.2pt;">&#8221; means any of the following transactions, provided, however, that the Administrator shall determine under parts (iv)&#160;and (v)&#160;whether multiple transactions are related, and its determination shall be final, binding and conclusive: </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(i)&nbsp;&nbsp;&nbsp;a merger or consolidation in which the Company is not the surviving entity, except for a transaction the principal purpose of which is to change the state in which the Company is incorporated; </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(ii)&nbsp;&nbsp;&nbsp;the sale, transfer or other disposition of all or substantially all of the assets of the Company; </font>
        </div>
        <div style="margin-left:60pt; margin-top:8pt; width:396pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(iii)&nbsp;&nbsp;&nbsp;the complete liquidation or dissolution of the Company; </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(iv)&nbsp;&nbsp;&nbsp;any reverse merger or series of related transactions culminating in a reverse merger (including, but not limited to, a tender offer followed by a reverse merger) in which the Company is the surviving entity but (A)&#160;the shares of Common Stock outstanding immediately prior to such merger are converted or exchanged by virtue of the merger into other property, whether in the form of securities, cash or otherwise, or (B)&#160;in which securities possessing more than forty&#160;percent (40%) of the total combined voting power of the Company&#8217;s outstanding securities are transferred to a person or persons different from those who held such securities immediately prior to such merger or the initial transaction culminating in such merger; or </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(v)&nbsp;&nbsp;&nbsp;acquisition in a single or series of related transactions by any person or related group of persons (other than the Company or by a Company-sponsored employee benefit plan) of beneficial ownership (within the meaning of Rule&#160;13d-3 of the Exchange Act) of securities possessing more than fifty&#160;percent (50%) of the total combined voting power of the Company&#8217;s outstanding securities but excluding any such transaction or series of related transactions that the Administrator determines shall not be a Corporate Transaction (provided however that the Administrator shall have no discretion in connection with a Corporate Transaction for the purchase of all or substantially all of the shares of the Company unless the principal purpose of such transaction is to change the state in which the Company is incorporated). </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(t)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Covered Employee</font><font style="letter-spacing:0.2pt;">&#8221; means an Employee who is a &#8220;covered employee&#8221; under Section&#160;162(m)(3) of the Code. </font>
        </div>
        <div style="text-indent:40pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(u)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Director</font><font style="letter-spacing:0.2pt;">&#8221; means a member of the Board or the board of directors of any Related Entity. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(v)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Disability</font><font style="letter-spacing:0.2pt;">&#8221; means as defined under the long-term disability policy of the Company or the Related Entity to which the Grantee provides services regardless of whether the Grantee is covered by such policy. If the Company or the Related Entity to which the Grantee provides service does not have a long-term disability plan in place, &#8220;Disability&#8221; means that a Grantee is unable to carry out the responsibilities and functions of the position held by the Grantee by reason of any medically determinable physical or mental impairment for a period of not less than ninety (90) consecutive days. A Grantee will not be considered to have incurred a Disability unless he or she furnishes proof of such impairment sufficient to satisfy the Administrator in its discretion. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(w)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Dividend Equivalent Right</font><font style="letter-spacing:0.2pt;">&#8221; means a right entitling the Grantee to compensation measured by dividends paid with respect to Common Stock. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(x)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Employee</font><font style="letter-spacing:0.2pt;">&#8221; means any person, including an Officer or Director, who is in the employ of the Company or any Related Entity, subject to the control and direction of the Company or any Related Entity as to both the work to be performed and the manner and method of performance. The payment of a director&#8217;s fee by the Company or a Related Entity shall not be sufficient to constitute &#8220;employment&#8221; by the Company. </font>
        </div>
        <div style="margin-left:40pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(y)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Exchange Act</font><font style="letter-spacing:0.2pt;">&#8221; means the Securities Exchange Act of 1934, as amended. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-3</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">&#8203;</div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; text-indent:20pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(z)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Fair Market Value</font><font style="letter-spacing:0.2pt;">&#8221; means, as of any date, the value of Common Stock determined as follows: </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(i)&nbsp;&nbsp;&nbsp;If the Common Stock is listed on one or more established stock exchanges or national market systems, including without limitation the American Stock Exchange, its Fair Market Value shall be the closing sales price for such stock (or the closing bid, if no sales were reported) as quoted on the principal exchange or system on which the Common Stock is listed (as determined by the Administrator) on the date of determination (or, if no closing sales price or closing bid was reported on that date, as applicable, on the last trading date such closing sales price or closing bid was reported), as reported in The Wall Street Journal or such other source as the Administrator deems reliable; </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(ii)&nbsp;&nbsp;&nbsp;If the Common Stock is regularly quoted on an automated quotation system (including the OTC Bulletin Board) or by a recognized securities dealer, its Fair Market Value shall be the closing sales price for such stock as quoted on such system or by such securities dealer on the date of determination, but if selling prices are not reported, the Fair Market Value of a share of Common Stock shall be the mean between the high bid and low asked prices for the Common Stock on the date of determination (or, if no such prices were reported on that date, on the last date such prices were reported), as reported in The Wall Street Journal or such other source as the Administrator deems reliable; or </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(iii)&nbsp;&nbsp;&nbsp;In the absence of an established market for the Common Stock of the type described in (i)&#160;and (ii), above, the Fair Market Value thereof shall be determined by the Administrator in good faith. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(aa)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Grantee</font><font style="letter-spacing:0.2pt;">&#8221; means an Employee, Director or Consultant who receives an Award under the Plan. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(bb)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Incentive Stock Option</font><font style="letter-spacing:0.2pt;">&#8221; means an Option intended to qualify as an incentive stock option within the meaning of Section&#160;422 of the Code. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(cc)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Israeli Employee</font><font style="letter-spacing:0.2pt;">&#8221; means Employees, office holders of the Company or a Related Company (&#8220;Nosei Misra&#8221;&#8201;&#8212;&#8201;as such term is defined in the Israeli Companies Law 1999) and Directors (excluding those who are considered a &#8220;Controlling Shareholder&#8221; pursuant to Section&#160;32(9) of the Tax Ordinance or otherwise excluded by the Tax Ordinance). </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(dd)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Israeli Grantee</font><font style="letter-spacing:0.2pt;">&#8221; means Grantees who are residents of the State of Israel or those who are deemed to be residents of the State of Israel for the payment of tax (whether such grantee is entitled to the tax benefits under Section&#160;102 or not). </font>
        </div>
        <div style="margin-left:40pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(ee)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">ITA</font><font style="letter-spacing:0.2pt;">&#8221; means Israeli Tax Authorities. </font>
        </div>
        <div style="text-indent:40pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(ff)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Non-Employee</font><font style="letter-spacing:0.2pt;">&#8221; means Consultants or any other person who is not an Israeli Employee. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(gg)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Non-Qualified Stock Option</font><font style="letter-spacing:0.2pt;">&#8221; means an Option not intended to qualify as an Incentive Stock Option. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(hh)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Non-Trustee 102 Option</font><font style="letter-spacing:0.2pt;">&#8221; shall mean a 102 Option granted pursuant to Section&#160;102(c) of the Tax Ordinance and not held in trust by the Trustee. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(ii)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Officer</font><font style="letter-spacing:0.2pt;">&#8221; means a person who is an officer of the Company or a Related Entity within the meaning of Section&#160;16 of the Exchange Act and the rules and regulations promulgated thereunder. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(jj)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Option</font><font style="letter-spacing:0.2pt;">&#8221; means an option to purchase Shares pursuant to an Award Agreement granted under the Plan. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(kk)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Parent</font><font style="letter-spacing:0.2pt;">&#8221; means a &#8220;parent corporation&#8221;, whether now or hereafter existing, as defined in Section&#160;424(e) of the Code. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(ll)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Performance-Based Compensation</font><font style="letter-spacing:0.2pt;">&#8221; means compensation qualifying as &#8220;performance-based compensation&#8221; under Section&#160;162(m) of the Code. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-4</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">&#8203;</div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:40pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(mm)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Plan</font><font style="letter-spacing:0.2pt;">&#8221; means this Amended and Restated 2006 Stock Incentive Plan. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(nn)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Related Entity</font><font style="letter-spacing:0.2pt;">&#8221; means any Parent or Subsidiary of the Company. With respect to Israeli Grantees of 102 Options, the definition shall further include any entity permitted under Section&#160;102 (a)&#160;of the Tax Ordinance. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(oo)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Replaced</font><font style="letter-spacing:0.2pt;">&#8221; means that pursuant to a Corporate Transaction the Award is replaced with a comparable stock award or a cash incentive program of the Company, the successor entity (if applicable) or Parent of either of them which preserves the compensation element of such Award existing at the time of the Corporate Transaction and provides for subsequent payout in accordance with the same (or a more favorable) vesting schedule applicable to such Award. The determination of Award comparability shall be made by the Administrator and its determination shall be final, binding and conclusive. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(pp)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Restricted Stock</font><font style="letter-spacing:0.2pt;">&#8221; means Shares issued under the Plan to the Grantee for such consideration, if any, and subject to such restrictions on transfer, rights of first refusal, repurchase provisions, forfeiture provisions, and other terms and conditions as established by the Administrator. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(qq)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Restricted Stock Units</font><font style="letter-spacing:0.2pt;">&#8221; means an Award which may be earned in whole or in part upon the passage of time or the attainment of performance criteria established by the Administrator and which may be settled for cash, Shares or other securities or a combination of cash, Shares or other securities as established by the Administrator. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(rr)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Rule&#160;16b-3</font><font style="letter-spacing:0.2pt;">&#8221; means Rule&#160;16b-3 promulgated under the Exchange Act or any successor thereto. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(ss)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">SAR</font><font style="letter-spacing:0.2pt;">&#8221; means a stock appreciation right entitling the Grantee to Shares or cash compensation, as established by the Administrator, measured by appreciation in the value of Common Stock. </font>
        </div>
        <div style="text-indent:40pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(tt)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;3(I)</font><font style="letter-spacing:0.2pt;">&#8221; means section 3(I) of the Tax Ordinance as may be amended from time to time. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(uu)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;102</font><font style="letter-spacing:0.2pt;">&#8221; means section 102 of the Tax Ordinance as may be amended from time to time. </font>
        </div>
        <div style="margin-left:40pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(vv)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Share</font><font style="letter-spacing:0.2pt;">&#8221; means a share of the Common Stock. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(ww)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Subsidiary</font><font style="letter-spacing:0.2pt;">&#8221; means a &#8220;subsidiary corporation&#8221;, whether now or hereafter existing, as defined in Section&#160;424(f) of the Code. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(xx)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Tax Ordinance</font><font style="letter-spacing:0.2pt;">&#8221; means the Israeli Income Tax Ordinance [New Version], 1961 (including as amended pursuant to Amendment 132 thereto) and to the extent not specifically indicated hereunder also the rules, regulations and orders or procedures promulgated thereunder from time to time, as amended or replaced from time to time. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(yy)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Trustee</font><font style="letter-spacing:0.2pt;">&#8221; means any individual appointed by the Company to serve as trustee and approved by the ITA, in accordance with the provisions of Section&#160;102(a) of the Tax Ordinance and the regulations promulgated thereunder. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(zz)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Trustee 102 Option</font><font style="letter-spacing:0.2pt;">&#8221; means a 102 Option granted pursuant to Section&#160;102(b) of the Tax Ordinance and held in trust by the Trustee for the benefit of an Israeli Grantee. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">3.&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Stock Subject to the Plan</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;Subject to the provisions of Section below, the maximum aggregate number of Shares which may be issued pursuant to all Awards (including Incentive Stock Options) under the Plan is </font><font style=" text-decoration:underline #0081C4 solid;font-weight:bold;color:#0081C4;letter-spacing:-0.2pt;">17,475,171</font><font style=" text-decoration:line-through;font-weight:bold;color:#FC0014;letter-spacing:-0.2pt;">12,475,171</font><font style="letter-spacing:0.2pt;"> Shares. Notwithstanding the foregoing, any Shares issued from and after November&#160;10, 2014 in connection with Awards other than Options and SARs shall be counted against the limit set forth herein as one and one-half (1.5) Shares for every one (1)&#160;Share issued in connection with such Award (and shall be counted as one and one-half (1.5) Shares for every one (1)&#160;Share returned or deemed not have been issued from the Plan pursuant to Section&#160;3(b) below in connection with Awards other than Options and SARs). The Shares to be issued pursuant to Awards may be authorized, but unissued, or reacquired Common Stock. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-5</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">&#8203;</div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; text-indent:20pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;Any Shares covered by an Award (or portion of an Award) which is forfeited, canceled or expires (whether voluntarily or involuntarily) shall be deemed not to have been issued for purposes of determining the maximum aggregate number of Shares which may be issued under the Plan. Shares that actually have been issued under the Plan pursuant to an Award shall not be returned to the Plan and shall not become available for future issuance under the Plan, except that if unvested Shares are forfeited, or repurchased by the Company at the lower of their original purchase price or their Fair Market Value at the time of repurchase, such Shares shall become available for future grant under the Plan. Notwithstanding anything to the contrary contained herein: (i)&#160;Shares tendered or withheld in payment of an Option exercise price shall not be returned to the Plan and shall not become available for future issuance under the Plan; (ii)&#160;Shares withheld by the Company to satisfy any tax withholding obligation shall not be returned to the Plan and shall not become available for future issuance under the Plan; and (iii)&#160;all Shares covered by the portion of an SAR that is exercised (whether or not Shares are actually issued to the Grantee upon exercise of the SAR) shall be considered issued pursuant to the Plan. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">4.&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Administration of the Plan</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:40pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Plan&#160;Administrator</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(i)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Administration with Respect to Directors and Officers</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;With respect to grants of Awards to Directors or Employees who are also Officers or Directors of the Company, the Plan shall be administered by (A)&#160;the Board or (B)&#160;a Committee designated by the Board, which Committee shall be constituted in such a manner as to satisfy the Applicable Laws and to permit such grants and related transactions under the Plan to be exempt from Section&#160;16(b) of the Exchange Act in accordance with Rule&#160;16b-3. Once appointed, such Committee shall continue to serve in its designated capacity until otherwise directed by the Board. </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(ii)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Administration With Respect to Consultants and Other Employees</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;With respect to grants of Awards to Employees or Consultants who are neither Directors nor Officers of the Company, the Plan shall be administered by (A)&#160;the Board or (B)&#160;a Committee designated by the Board, which Committee shall be constituted in such a manner as to satisfy the Applicable Laws. Once appointed, such Committee shall continue to serve in its designated capacity until otherwise directed by the Board. The Board may authorize one or more Officers to grant such Awards and may limit such authority as the Board determines from time to time. </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(iii)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Administration With Respect to Covered Employees</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Notwithstanding the foregoing, grants of Awards to any Covered Employee intended to qualify as Performance-Based Compensation shall be made only by a Committee (or subcommittee of a Committee) which is comprised solely of two or more Directors eligible to serve on a committee making Awards qualifying as Performance-Based Compensation. In the case of such Awards granted to Covered Employees, references to the &#8220;Administrator&#8221; or to a &#8220;Committee&#8221; shall be deemed to be references to such Committee or subcommittee. </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(iv)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Administration With Respect to Israeli Grantees</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;With respect to grants of Awards to Israeli Grantees, the Plan shall be administered by (A)&#160;the Board or (B)&#160;a Committee or one or more Officers designated by the Board, which Committee or Officers shall be constituted or appointed in such a manner as to satisfy the ITA and the Applicable Laws applicable to Awards for Israeli Grantees. Once appointed, such Committee or Officer shall continue to serve in its/his/</font>&#8203;<font style="letter-spacing:0.2pt;">her designated capacity until otherwise directed by the Board. </font></div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(v)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Administration Errors</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;In the event an Award is granted in a manner inconsistent with the provisions of this subsection (a), such Award shall be presumptively valid as of its grant date to the extent permitted by the Applicable Laws. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Powers of the Administrator</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Subject to Applicable Laws and the provisions of the Plan (including any other powers given to the Administrator hereunder), and except as otherwise provided by the Board, the Administrator shall have the authority, in its discretion: </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(i)&nbsp;&nbsp;&nbsp;to select the Employees, Directors and Consultants to whom Awards may be granted from time to time hereunder; </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-6</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">&#8203;</div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:60pt; width:396pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(ii)&nbsp;&nbsp;&nbsp;to determine whether and to what extent Awards are granted hereunder; </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(iii)&nbsp;&nbsp;&nbsp;to determine the number of Shares or the amount of other consideration to be covered by each Award granted hereunder; </font>
        </div>
        <div style="margin-left:60pt; margin-top:8pt; width:396pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(iv)&nbsp;&nbsp;&nbsp;to approve forms of Award Agreements for use under the Plan; </font>
        </div>
        <div style="margin-left:60pt; margin-top:8pt; width:396pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(v)&nbsp;&nbsp;&nbsp;to determine the terms and conditions of any Award granted hereunder; </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(vi)&nbsp;&nbsp;&nbsp;to amend the terms of any outstanding Award granted under the Plan, provided that (A)&#160;any amendment that would adversely affect the Grantee&#8217;s rights under an outstanding Award shall not be made without the Grantee&#8217;s written consent, provided, however, that an amendment or modification that may cause an Incentive Stock Option to become a Non-Qualified Stock Option shall not be treated as adversely affecting the rights of the Grantee, (B)&#160;the reduction of the exercise price of any Option awarded under the Plan and the base appreciation amount of any SAR awarded under the Plan shall be subject to stockholder approval and (C)&#160;canceling an Option or SAR at a time when its exercise price or base appreciation amount (as applicable) exceeds the Fair Market Value of the underlying Shares, in exchange for another Option, SAR, Restricted Stock, or other Award or for cash shall be subject to stockholder approval, unless the cancellation and exchange occurs in connection with a Corporate Transaction. Notwithstanding the foregoing, canceling an Option or SAR in exchange for another Option, SAR, Restricted Stock, or other Award or for cash with an exercise price, purchase price or base appreciation amount (as applicable) that is equal to or greater than the exercise price or base appreciation amount (as applicable) of the original Option or SAR shall not be subject to stockholder approval; </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(vii)&nbsp;&nbsp;&nbsp;to construe and interpret the terms of the Plan and Awards, including without limitation, any notice of award or Award Agreement, granted pursuant to the Plan; </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(viii)&nbsp;&nbsp;&nbsp;to grant Awards to Employees, Directors and Consultants employed outside the United States on such terms and conditions different from those specified in the Plan as may, in the judgment of the Administrator, be necessary or desirable to further the purpose of the Plan; and </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(ix)&nbsp;&nbsp;&nbsp;to designate Awards as 102 Options (whether through a trustee or not) or 3(I) Options subject to the limitations under the ITA or any other Applicable Law and to determine the type and route of the Trustee 102 Options. </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(x)&nbsp;&nbsp;&nbsp;to take such other action, not inconsistent with the terms of the Plan, as the Administrator deems appropriate. </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The express grant in the Plan of any specific power to the Administrator shall not be construed as limiting any power or authority of the Administrator; provided that the Administrator may not exercise any right or power reserved to the Board. Any decision made, or action taken, by the Administrator or in connection with the administration of this Plan shall be final, conclusive and binding on all persons having an interest in the Plan. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Indemnification</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;In addition to such other rights of indemnification as they may have as members of the Board or as Officers or Employees of the Company or a Related Entity, members of the Board and any Officers or Employees of the Company or a Related Entity to whom authority to act for the Board, the Administrator or the Company is delegated shall be defended and indemnified by the Company to the extent permitted by law on an after-tax basis against all reasonable expenses, including attorneys&#8217; fees, actually and necessarily incurred in connection with the defense of any claim, investigation, action, suit or proceeding, or in connection with any appeal therein, to which they or any of them may be a party by reason of any action taken or failure to act under or in connection with the Plan, or any Award granted hereunder, and against all amounts paid by them in settlement thereof (provided such settlement is approved by the Company) or paid by them in satisfaction of a judgment in any such claim, investigation, action, suit or proceeding, except in relation to matters as to which it shall be adjudged in such claim, investigation, action, suit or proceeding that such person is liable for gross negligence, bad faith or intentional misconduct; </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">however</font><font style="letter-spacing:0.2pt;">, that within </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-7</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">&#8203;</div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">thirty (30)&#160;days after the institution of such claim, investigation, action, suit or proceeding, such person shall offer to the Company, in writing, the opportunity at the Company&#8217;s expense to defend the same. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">5.&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Eligibility</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Awards other than Incentive Stock Options may be granted to Employees, Directors and Consultants. Incentive Stock Options may be granted only to Employees of the Company or a Parent or a Subsidiary of the Company. An Employee, Director or Consultant who has been granted an Award may, if otherwise eligible, be granted additional Awards. Awards may be granted to such Employees, Directors or Consultants who are residing in non-U.S. jurisdictions as the Administrator may determine from time to time, provided however that Awards to Israeli Grantees under Section&#160;102 or Section&#160;3(I) of the Tax Ordinance shall be subject to Section&#160;20 below. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company does not warrant that the Plan will be recognized by the income tax authorities in any jurisdiction or that future changes will not be made to the provisions of applicable laws or rules or regulations which are promulgated from time to time thereunder, or that any exemption or benefit currently available, whether by the ITA pursuant to Section&#160;102 or otherwise, will not be abolished. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">6.&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Terms and Conditions of Awards</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Types of Awards</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The Administrator is authorized under the Plan to award any type of arrangement to an Employee, Director or Consultant that is not inconsistent with the provisions of the Plan and that by its terms involves or might involve the issuance of (i)&#160;Shares, (ii)&#160;cash or (iii)&#160;an Option, a SAR, or similar right with a fixed or variable price related to the Fair Market Value of the Shares and with an exercise or conversion privilege related to the passage of time, the occurrence of one or more events, or the satisfaction of performance criteria or other conditions. Such awards include, without limitation, Options, SARs, sales or bonuses of Restricted Stock, Restricted Stock Units or Dividend Equivalent Rights, and an Award may consist of one such security or benefit, or two (2)&#160;or more of them in any combination or alternative. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Designation of Award</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Each Award shall be designated in the Award Agreement. In the case of an Option, the Option shall be designated as either an Incentive Stock Option or a Non-Qualified Stock Option and with respect to Israeli Grantees may be further designated as 102 Options or 3(I)&#160;Options under the Tax Ordinance subject to the qualifications described in Section&#160;20 below. However, notwithstanding such designation, an Option will qualify as an Incentive Stock Option under the Code only to the extent the $100,000 limitation of Section&#160;422(d) of the Code is not exceeded. The $100,000 limitation of Section&#160;422(d) of the Code is calculated based on the aggregate Fair Market Value of the Shares subject to Options designated as Incentive Stock Options which become exercisable for the first time by a Grantee during any calendar year (under all plans of the Company or any Parent or Subsidiary of the Company). For purposes of this calculation, Incentive Stock Options shall be taken into account in the order in which they were granted, and the Fair Market Value of the Shares shall be determined as of the grant date of the relevant Option. In the event that the Code or the regulations promulgated thereunder are amended after the date the Plan becomes effective to provide for a different limit on the Fair Market Value of Shares permitted to be subject to Incentive Stock Options, then such different limit will be automatically incorporated herein and will apply to any Options granted after the effective date of such amendment. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Conditions of Award</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Subject to the terms of the Plan, the Administrator shall determine the provisions, terms, and conditions of each Award including, but not limited to, the Award vesting schedule, repurchase provisions, rights of first refusal, forfeiture provisions, form of payment (cash, Shares, or other consideration) upon settlement of the Award, payment contingencies, and satisfaction of any performance criteria. The performance criteria established by the Administrator may be based on any one of, or combination of, the following: (i)&#160;increase in share price, (ii)&#160;earnings per share, (iii)&#160;total stockholder return, (iv)&#160;operating margin, (v)&#160;gross margin, (vi)&#160;return on equity, (vii)&#160;return on assets, (viii)&#160;return on investment, (ix)&#160;operating income, (x)&#160;net operating income, (xi)&#160;pre-tax profit, (xii)&#160;cash flow, (xiii)&#160;revenue, (xiv)&#160;expenses, (xv)&#160;earnings before interest, taxes and depreciation, (xvi)&#160;economic value added and (xvii)&#160;market share. The performance criteria may be applicable to the Company, Related Entities and/or any individual business&#160;units of the Company or any Related Entity. Partial achievement of the specified criteria may result in a payment or vesting corresponding to the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-8</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">&#8203;</div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">degree of achievement as specified in the Award Agreement. In addition, the performance criteria shall be calculated in accordance with generally accepted accounting principles, but excluding the effect (whether positive or negative) of any change in accounting standards and any extraordinary, unusual or nonrecurring item, as determined by the Administrator, occurring after the establishment of the performance criteria applicable to the Award intended to be performance-based compensation. Each such adjustment, if any, shall be made solely for the purpose of providing a consistent basis from period to period for the calculation of performance criteria in order to prevent the dilution or enlargement of the Grantee&#8217;s rights with respect to an Award intended to be performance-based compensation. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(d)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Acquisitions and Other Transactions</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The Administrator may issue Awards under the Plan in settlement, assumption or substitution for, outstanding awards or obligations to grant future awards in connection with the Company or a Related Entity acquiring another entity, an interest in another entity or an additional interest in a Related Entity whether by merger, stock purchase, asset purchase or other form of transaction. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(e)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Deferral of Award Payment</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The Administrator may establish one or more programs under the Plan to permit selected Grantees the opportunity to elect to defer receipt of consideration upon exercise of an Award, satisfaction of performance criteria, or other event that absent the election would entitle the Grantee to payment or receipt of Shares or other consideration under an Award. The Administrator may establish the election procedures, the timing of such elections, the mechanisms for payments of, and accrual of interest or other earnings, if any, on amounts, Shares or other consideration so deferred, and such other terms, conditions, rules and procedures that the Administrator deems advisable for the administration of any such deferral program. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(f)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Separate Programs</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The Administrator may establish one or more separate programs under the Plan for the purpose of issuing particular forms of Awards to one or more classes of Grantees on such terms and conditions as determined by the Administrator from time to time. </font>
        </div>
        <div style="margin-left:40pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(g)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Individual Limitations on Awards</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(i)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Individual Limit for Options and SARs</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The maximum number of Shares with respect to which Options and SARs may be granted to any Grantee in any calendar year shall be </font><font style=" text-decoration:underline #0081C4 solid;font-weight:bold;color:#0081C4;letter-spacing:-0.2pt;">17,475,171</font><font style=" text-decoration:line-through;font-weight:bold;color:#FC0014;letter-spacing:-0.2pt;">12,475,171</font><font style="letter-spacing:0.2pt;"> Shares. Shares which shall not count against the limit set forth in the previous sentence. The foregoing limitations shall be adjusted proportionately in connection with any change in the Company&#8217;s capitalization pursuant to Section below. To the extent required by Section&#160;162(m) of the Code or the regulations thereunder, in applying the foregoing limitations with respect to a Grantee, if any Option or SAR is canceled, the canceled Option or SAR shall continue to count against the maximum number of Shares with respect to which Options and SARs may be granted to the Grantee. For this purpose, the repricing of an Option (or in the case of a SAR, the base amount on which the stock appreciation is calculated is reduced to reflect a reduction in the Fair Market Value of the Common Stock) shall be treated as the cancellation of the existing Option or SAR and the grant of a new Option or SAR. </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(ii)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Individual Limit for Restricted Stock and Restricted Stock Units</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;For awards of Restricted Stock and Restricted Stock Units that are intended to be Performance-Based Compensation, the maximum number of Shares with respect to which such Awards may be granted to any Grantee in any calendar year shall be </font><font style=" text-decoration:underline #0081C4 solid;font-weight:bold;color:#0081C4;letter-spacing:-0.2pt;">17,475,171</font><font style=" text-decoration:line-through;font-weight:bold;color:#FC0014;letter-spacing:-0.2pt;">12,475,171</font><font style="letter-spacing:0.2pt;"> Shares. The foregoing limitation shall be adjusted proportionately in connection with any change in the Company&#8217;s capitalization pursuant to Section&#160;10 below. </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(iii)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Deferral</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;If the vesting or receipt of Shares under an Award is deferred to a later date, any amount (whether denominated in Shares or cash) paid in addition to the original number of Shares subject to such Award will not be treated as an increase in the number of Shares subject to the Award if the additional amount is based either on a reasonable rate of interest or on one or more predetermined actual investments such that the amount payable by the Company at the later date will be based on the actual rate of return of a specific investment (including any decrease as well as any increase in the value of an investment). </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-9</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">&#8203;</div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; text-indent:20pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(h)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Early Exercise</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The Award Agreement may, but need not, include a provision whereby the Grantee may elect at any time while an Employee, Director or Consultant to exercise any part or all of the Award prior to full vesting of the Award. Any unvested Shares received pursuant to such exercise may be subject to a repurchase right in favor of the Company or a Related Entity or to any other restriction the Administrator determines to be appropriate. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(i)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Term of Award</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The term of each Award shall be the term stated in the Award Agreement, provided, however, that the term of an Award shall be no more than ten (10) years from the date of grant thereof. However, in the case of an Incentive Stock Option granted to a Grantee who, at the time the Option is granted, owns stock representing more than ten&#160;percent (10%) of the voting power of all classes of stock of the Company or any Parent or Subsidiary of the Company, the term of the Incentive Stock Option shall be five (5)&#160;years from the date of grant thereof or such shorter term as may be provided in the Award Agreement. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(j)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Transferability of Awards</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Incentive Stock Options or Options to Israeli Grantees may not be sold, pledged, assigned, hypothecated, transferred, or disposed of in any manner other than by will or by the laws of descent or distribution and may be exercised, during the lifetime of the Grantee, only by the Grantee. Other Awards shall be transferable (i)&#160;by will and by the laws of descent and distribution and (ii)&#160;during the lifetime of the Grantee, to the extent and in the manner authorized by the Administrator but only to the extent such transfers are made to family members, to family trusts, to family controlled entities, to charitable organizations, and pursuant to domestic relations orders or agreements, in all cases without payment for such transfers to the Grantee. Notwithstanding the foregoing, the Grantee may designate one or more beneficiaries of the Grantee&#8217;s Award in the event of the Grantee&#8217;s death on a beneficiary designation form provided by the Administrator. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(k)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Time of Granting Awards</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The date of grant of an Award shall for all purposes be the date on which the Administrator makes the determination to grant such Award, or such other date as is determined by the Administrator. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">7.&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Award Exercise or Purchase Price, Consideration and Taxes</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Exercise or Purchase Price</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The exercise or purchase price, if any, for an Award shall be as follows: </font>
        </div>
        <div style="margin-left:60pt; margin-top:8pt; width:396pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(i)&nbsp;&nbsp;&nbsp;In the case of an Incentive Stock Option: </font>
        </div>
        <div style="margin-left:60pt; text-indent:20pt; margin-top:8pt; width:396pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(A)&nbsp;&nbsp;&nbsp;granted to an Employee who, at the time of the grant of such Incentive Stock Option owns stock representing more than ten&#160;percent (10%) of the voting power of all classes of stock of the Company or any Parent or Subsidiary of the Company, the per Share exercise price shall be not less than one hundred ten&#160;percent (110%) of the Fair Market Value per Share on the date of grant; or </font>
        </div>
        <div style="margin-left:60pt; text-indent:20pt; margin-top:8pt; width:396pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(B)&nbsp;&nbsp;&nbsp;granted to any Employee other than an Employee described in the preceding paragraph, the per Share exercise price shall be not less than one hundred&#160;percent (100%) of the Fair Market Value per Share on the date of grant. </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(ii)&nbsp;&nbsp;&nbsp;In the case of a Non-Qualified Stock Option, the per Share exercise price shall be not less than one hundred&#160;percent (100%) of the Fair Market Value per Share on the date of grant. </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(iii)&nbsp;&nbsp;&nbsp;In the case of Awards intended to qualify as Performance-Based Compensation, the exercise or purchase price, if any, shall be not less than one hundred&#160;percent (100%) of the Fair Market Value per Share on the date of grant. </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(iv)&nbsp;&nbsp;&nbsp;In the case of SARs (other than with respect to Israeli Grantees), the base appreciation amount shall not be less than one hundred&#160;percent (100%) of the Fair Market Value per Share on the date of grant. </font>
        </div>
        <div style="margin-left:60pt; margin-top:8pt; width:396pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(v)&nbsp;&nbsp;&nbsp;In the case of other Awards, such price as is determined by the Administrator. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-10</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">&#8203;</div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:40pt; text-indent:20pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(vi)&nbsp;&nbsp;&nbsp;Notwithstanding the foregoing provisions of this Section&#160;7(a), in the case of an Award issued pursuant to Section&#160;6(d) above, the exercise or purchase price for the Award shall be determined in accordance with the provisions of the relevant instrument evidencing the agreement to issue such Award. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Consideration</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Subject to Applicable Laws, the consideration to be paid for the Shares to be issued upon exercise or purchase of an Award including the method of payment, shall be determined by the Administrator. In addition to any other types of consideration the Administrator may determine, the Administrator is authorized to accept as consideration for Shares issued under the Plan the following: </font>
        </div>
        <div style=" float:left; margin-left:60pt; line-height:12pt; margin-top:7.01pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(i)</font>
          <br >
        </div>
        <div style=" margin-top:7.01pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:80pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">cash; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:60pt; line-height:12pt; margin-top:7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(ii)</font>
          <br >
        </div>
        <div style=" margin-top:7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:80pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">check; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(iii)&nbsp;&nbsp;&nbsp;surrender of Shares or delivery of a properly executed form of attestation of ownership of Shares as the Administrator may require which have a Fair Market Value on the date of surrender or attestation equal to the aggregate exercise price of the Shares as to which said Award shall be exercised; </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(iv)&nbsp;&nbsp;&nbsp;with respect to Options, payment through a broker-dealer sale and remittance procedure pursuant to which the Grantee (A)&#160;shall provide written instructions to a Company designated brokerage firm to effect the immediate sale of some or all of the purchased Shares and remit to the Company sufficient funds to cover the aggregate exercise price payable for the purchased Shares and (B)&#160;shall provide written directives to the Company to deliver the certificates for the purchased Shares directly to such brokerage firm in order to complete the sale transaction; or </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(v)&nbsp;&nbsp;&nbsp;with respect to Options, payment through a &#8220;net exercise&#8221; such that, without the payment of any funds, the Grantee may exercise the Option and receive the net number of Shares equal to (i)&#160;the number of Shares as to which the Option is being exercised, multiplied by (ii)&#160;a fraction, the numerator of which is the Fair Market Value per Share (on such date as is determined by the Administrator) less the Exercise Price per Share, and the denominator of which is such Fair Market Value per Share (the number of net Shares to be received shall be rounded down to the nearest whole number of Shares); </font>
        </div>
        <div style="margin-left:60pt; margin-top:8pt; width:396pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(vi)&nbsp;&nbsp;&nbsp;any combination of the foregoing methods of payment. </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Administrator may at any time or from time to time, by adoption of or by amendment to the standard forms of Award Agreement described in Section&#160;4(b)(iv), or by other means, grant Awards which do not permit all of the foregoing forms of consideration to be used in payment for the Shares or which otherwise restrict one or more forms of consideration. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Taxes</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;No Shares shall be delivered under the Plan to any Grantee or other person until such Grantee or other person has made arrangements acceptable to the Administrator for the satisfaction of any non-U.S., federal, state, or local income and employment tax withholding obligations, including, without limitation, obligations incident to the receipt of Shares. Upon exercise or vesting of an Award the Company shall withhold or collect from the Grantee an amount sufficient to satisfy such tax obligations, including, but not limited to, by surrender of the whole number of Shares covered by the Award sufficient to satisfy the minimum applicable tax withholding obligations incident to the exercise or vesting of an Award (reduced to the lowest whole number of Shares if such number of Shares withheld would result in withholding a fractional Share with any remaining tax withholding settled in cash). </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">8.&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Exercise of Award</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:40pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Procedure for Exercise; Rights as a Stockholder</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(i)&nbsp;&nbsp;&nbsp;Any Award granted hereunder shall be exercisable at such times and under such conditions as determined by the Administrator under the terms of the Plan and specified in the Award Agreement provided however that the standard vesting schedule for Israeli Grantees shall be as set forth in Section&#160;20. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-11</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">&#8203;</div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:40pt; text-indent:20pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(ii)&nbsp;&nbsp;&nbsp;An Award shall be deemed to be exercised when written notice of such exercise has been given to the Company in accordance with the terms of the Award by the person entitled to exercise the Award and full payment for the Shares with respect to which the Award is exercised has been made, including, to the extent selected, use of the broker-dealer sale and remittance procedure to pay the purchase price as provided in Section&#160;7(b). </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Exercise of Award Following Termination of Continuous Service</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;In the event of termination of a Grantee&#8217;s Continuous Service for any reason other than Cause, Disability or death, such Grantee may, but only within twelve (12) months from the date of such termination (or such longer or shorter period as specified in the Award Agreement but in no event later than the expiration date of the term of such Award as set forth in the Award Agreement), exercise the portion of the Grantee&#8217;s Award that was vested at the date of such termination or such other portion of the Grantee&#8217;s Award as may be determined by the Administrator. To the extent that the Grantee&#8217;s Award was unvested at the date of termination, or if Grantee does not exercise the vested portion of the Grantee&#8217;s Award within the time specified herein, the Award shall terminate. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Exercise of Award Following Termination of Continuous Service for Cause</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;In the event of termination of a Grantee&#8217;s Continuous Service for Cause, such Grantee may, but only within fourteen (14) days from the date of such termination (or such longer or shorter period as specified in the Award Agreement but in no event later than the expiration date of the term of such Award as set forth in the Award Agreement), exercise the portion of the Grantee&#8217;s Award that was vested at the date of such termination or such other portion of the Grantee&#8217;s Award as may be determined by the Administrator. To the extent that the Grantee&#8217;s Award was unvested at the date of termination, or if Grantee does not exercise the vested portion of the Grantee&#8217;s Award within the time specified herein, the Award shall terminate. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(d)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Disability of Grantee</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;In the event of termination of a Grantee&#8217;s Continuous Service as a result of his or her Disability, such Grantee may, but only within twelve (12) months from the date of such termination (or such longer or shorter period as specified in the Award Agreement but in no event later than the expiration date of the term of such Award as set forth in the Award Agreement), exercise the portion of the Grantee&#8217;s Award that was vested at the date of such termination or such other portion of the Grantee&#8217;s Award as may be determined by the Administrator. To the extent that the Grantee&#8217;s Award was unvested at the date of termination, or if Grantee does not exercise the vested portion of the Grantee&#8217;s Award within the time specified herein, the Award shall terminate. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(e)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Death of Grantee</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;In the event of a termination of the Grantee&#8217;s Continuous Service as a result of his or her death, or in the event of the death of the Grantee during the post-termination exercise periods following the Grantee&#8217;s termination of Continuous Service specified in this Section&#160;8, above, the Grantee&#8217;s estate or a person who acquired the right to exercise the Award by bequest or inheritance may exercise the portion of the Grantee&#8217;s Award that was vested as of the date of termination or such other portion of the Grantee&#8217;s Award as may be determined by the Administrator, within twelve (12) months from the date of death (or such longer or shorter period as specified in the Award Agreement but in no event later than the expiration of the term of such Award as set forth in the Award Agreement). To the extent that, at the time of death, the Grantee&#8217;s Award was unvested, or if the Grantee&#8217;s estate or a person who acquired the right to exercise the Award by bequest or inheritance does not exercise the vested portion of the Grantee&#8217;s Award within the time specified herein, the Award shall terminate. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(f)&nbsp;&nbsp;&nbsp;The holder of an Option shall have none of the rights of a stockholder with respect to the Shares subject to the Option until such shares are transferred to the holder (or the Trustee, if applicable) upon the exercise of the Option. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">9.&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Conditions Upon Issuance of Shares</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;If at any time the Administrator determines that the delivery of Shares pursuant to the exercise, vesting or any other provision of an Award is or may be unlawful under Applicable Laws, the vesting or right to exercise an Award or to otherwise receive Shares pursuant to the terms of an Award shall be suspended until the Administrator determines that such delivery is lawful and shall be further </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-12</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">&#8203;</div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">subject to the approval of counsel for the Company with respect to such compliance. The Company shall have no obligation to effect any registration or qualification of the Shares under federal or state laws or other Applicable Laws. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;As a condition to the exercise of an Award, the Company may require the person exercising such Award make such representations and warranties which, in the opinion of the Company, are required to ensure that such exercise, or a subsequent sale or disposition of any Shares obtained upon such exercise, does not contravene any Applicable Law, including inter alia, representations and warranties at the time of any such exercise that the Shares are being purchased only for investment and without any present intention to sell or distribute such Shares if, in the opinion of counsel for the Company, such a representation is required by any Applicable Laws. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;Unless otherwise set forth in an Award Agreement, Shares issued to a Grantee or the Trustee, as applicable, shall be subject to such restrictions as required by the appropriate securities&#8217; law and in the event that the Company&#8217;s shares shall be registered for trading in any public market, Grantee&#8217;s rights to sell the Shares may be subject to certain limitations (including a lock-up period), as will be requested by the Company or its underwriters, and the Grantee by executing an Award Agreement unconditionally agrees and accepts any such limitations and undertakes to further execute any agreement as may be requested by the Company or its underwriters from time to time. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">10.&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Adjustments Upon Changes in Capitalization</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Subject to any required action by the stockholders of the Company, the number of Shares covered by each outstanding Award, and the number of Shares which have been authorized for issuance under the Plan but as to which no Awards have yet been granted or which have been returned to the Plan, the exercise or purchase price of each such outstanding Award, the maximum number of Shares with respect to which Awards may be granted to any Grantee in any calendar year, as well as any other terms that the Administrator determines require adjustment shall be proportionately adjusted for (i)&#160;any increase or decrease in the number of issued Shares resulting from a stock split, reverse stock split, stock dividend, combination or reclassification of the Shares, or similar transaction affecting the Shares, (ii)&#160;any other increase or decrease in the number of issued Shares effected without receipt of consideration by the Company, or (iii)&#160;any other transaction with respect to Common Stock including a corporate merger, consolidation, acquisition of property or stock, separation (including a spin-off or other distribution of stock or property), reorganization, liquidation (whether partial or complete) or any similar transaction; provided, however that conversion of any convertible securities of the Company shall not be deemed to have been &#8220;effected without receipt of consideration.&#8221; In the event of any distribution of cash or other assets to stockholders other than a normal cash dividend, the Administrator shall also make such adjustments as provided in this Section&#160;10 or substitute, exchange or grant Awards to effect such adjustments (collectively &#8220;adjustments&#8221;). Any such adjustments to outstanding Awards will be effected in a manner that precludes the enlargement of rights and benefits under such Awards. In connection with the foregoing adjustments, the Administrator may, in its discretion, prohibit the exercise of Awards or other issuance of Shares, cash or other consideration pursuant to Awards during certain periods of time. Except as the Administrator determines, no issuance by the Company of shares of any class, or securities convertible into shares of any class, shall affect, and no adjustment by reason hereof shall be made with respect to, the number or price of Shares subject to an Award. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">11.&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Corporate Transactions and Changes in Control</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Termination of Award to Extent Not Assumed in Corporate Transaction</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Effective upon the consummation of a Corporate Transaction, all outstanding Awards under the Plan shall terminate. However, all such Awards shall not terminate to the extent they are Assumed in connection with the Corporate Transaction. </font>
        </div>
        <div style="margin-left:40pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Acceleration of Award Upon Corporate Transaction or Change in Control</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(i)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Corporate Transaction</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Except as provided otherwise in an individual Award Agreement, in the event of a Corporate Transaction and: </font>
        </div>
        <div style="margin-left:60pt; text-indent:20pt; margin-top:8pt; width:396pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(A)&nbsp;&nbsp;&nbsp;for the portion of each Award that is Assumed or Replaced, then such Award (if Assumed), the replacement Award (if Replaced), or the cash incentive program (if Replaced) automatically shall become fully vested, exercisable and payable and be released from any </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-13</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">&#8203;</div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:60pt; width:396pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">repurchase or forfeiture rights (other than repurchase rights exercisable at Fair Market Value) for all of the Shares (or other consideration) at the time represented by such Assumed or Replaced portion of the Award, immediately upon termination of the Grantee&#8217;s Continuous Service if such Continuous Service is terminated by the successor company or the Company without Cause within twelve (12) months after the Corporate Transaction; and </font>
        </div>
        <div style="margin-left:60pt; text-indent:20pt; margin-top:8pt; width:396pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(B)&nbsp;&nbsp;&nbsp;for the portion of each Award that is neither Assumed nor Replaced, such portion of the Award shall automatically become fully vested and exercisable and be released from any repurchase or forfeiture rights (other than repurchase rights exercisable at Fair Market Value) for all of the Shares (or other consideration) at the time represented by such portion of the Award, immediately prior to the specified effective date of such Corporate Transaction, provided that the Grantee&#8217;s Continuous Service has not terminated prior to such date. </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(ii)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Change in Control</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Except as provided otherwise in an individual Award Agreement, following a Change in Control (other than a Change in Control which also is a Corporate Transaction) and upon the termination of the Continuous Service of a Grantee if such Continuous Service is terminated by the Company or Related Entity without Cause within twelve (12) months after a Change in Control, each Award of such Grantee which is at the time outstanding under the Plan automatically shall become fully vested and exercisable and be released from any repurchase or forfeiture rights (other than repurchase rights exercisable at Fair Market Value), immediately upon the termination of such Continuous Service. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Effect of Acceleration on Incentive Stock Options</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Any Incentive Stock Option accelerated under this Section in connection with a Corporate Transaction or Change in Control shall remain exercisable as an Incentive Stock Option under the Code only to the extent the $100,000 dollar limitation of Section&#160;422(d) of the Code is not exceeded. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">12.&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Effective Date and Term of Plan</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The Plan shall become effective upon the earlier to occur of its adoption by the Board or its approval by the stockholders of the Company. It shall continue in effect until December&#160;31, 2028 unless sooner terminated. Subject to Section&#160;17, below, and Applicable Laws, Awards may be granted under the Plan upon its becoming effective. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">13.&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Amendment, Suspension or Termination of the Plan</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;The Board may at any time amend, suspend or terminate the Plan; </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">however</font><font style="letter-spacing:0.2pt;">, that no such amendment shall be made without the approval of the Company&#8217;s stockholders to the extent such approval is required by Applicable Laws, or if such amendment would lessen the stockholder approval requirements of Section&#160;4(b)(vi) or this Section&#160;13(a). </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;No Award may be granted during any suspension of the Plan or after termination of the Plan. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;No suspension or termination of the Plan (including termination of the Plan under Section&#160;11, above) shall adversely affect any rights under Awards already granted to a Grantee. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">14.&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Reservation of Shares</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;The Company, during the term of the Plan, will at all times reserve and keep available such number of Shares as shall be sufficient to satisfy the requirements of the Plan. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;The inability of the Company to obtain authority from any regulatory body having jurisdiction, which authority is deemed by the Company&#8217;s counsel to be necessary to the lawful issuance and sale of any Shares hereunder, shall relieve the Company of any liability in respect of the failure to issue or sell such Shares as to which such requisite authority shall not have been obtained. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">15.&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">No Effect on Terms of Employment/Consulting Relationship</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The Plan shall not confer upon any Grantee any right with respect to the Grantee&#8217;s Continuous Service, nor shall it interfere in any way with his or her right or the right of the Company or any Related Entity to terminate the Grantee&#8217;s Continuous Service at any time, with or without cause, including but not limited to, Cause, and with or without notice. The ability of the Company or any Related Entity to terminate the employment of a Grantee who is employed </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-14</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">&#8203;</div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:8pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">at will is in no way affected by its determination that the Grantee&#8217;s Continuous Service has been terminated for Cause for the purposes of this Plan. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">16.&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">No Effect on Retirement and Other Benefit Plans</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Except as specifically provided in a retirement or other benefit plan of the Company or a Related Entity, Awards shall not be deemed compensation for purposes of computing benefits or contributions under any retirement plan of the Company or a Related Entity, and shall not affect any benefits under any other benefit plan of any kind or any benefit plan subsequently instituted under which the availability or amount of benefits is related to level of compensation. The Plan is not a &#8220;Pension Plan&#8221; or &#8220;Welfare Plan&#8221; under the Employee Retirement Income Security Act of 1974, as amended. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">17.&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Stockholder Approval</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The grant of Incentive Stock Options under the Plan shall be subject to approval by the stockholders of the Company within twelve (12) months before or after the date the Plan is adopted excluding Incentive Stock Options issued in substitution for outstanding Incentive Stock Options pursuant to Section&#160;424(a) of the Code. Such stockholder approval shall be obtained in the degree and manner required under Applicable Laws. The Administrator may grant Incentive Stock Options under the Plan prior to approval by the stockholders, but until such approval is obtained, no such Incentive Stock Option shall be exercisable. In the event that stockholder approval is not obtained within the twelve (12) month period provided above, all Incentive Stock Options previously granted under the Plan shall be exercisable as Non-Qualified Stock Options. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">18.&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Unfunded Obligation</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Grantees shall have the status of general unsecured creditors of the Company. Any amounts payable to Grantees pursuant to the Plan shall be unfunded and unsecured obligations for all purposes, including, without limitation, Title I of the Employee Retirement Income Security Act of 1974, as amended. Neither the Company nor any Related Entity shall be required to segregate any monies from its general funds, or to create any trusts, or establish any special accounts with respect to such obligations. The Company shall retain at all times beneficial ownership of any investments, including trust investments, which the Company may make to fulfill its payment obligations hereunder. Any investments or the creation or maintenance of any trust or any Grantee account shall not create or constitute a trust or fiduciary relationship between the Administrator, the Company or any Related Entity and a Grantee, or otherwise create any vested or beneficial interest in any Grantee or the Grantee&#8217;s creditors in any assets of the Company or a Related Entity. The Grantees shall have no claim against the Company or any Related Entity for any changes in the value of any assets that may be invested or reinvested by the Company with respect to the Plan. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">19.&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Construction</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Captions and titles contained herein are for convenience only and shall not affect the meaning or interpretation of any provision of the Plan. Except when otherwise indicated by the context, the singular shall include the plural and the plural shall include the singular. Use of the term &#8220;or&#8221; is not intended to be exclusive, unless the context clearly requires otherwise. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">20.&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Israeli Grantees</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;This Section shall apply only to Israeli Grantees and is intended to enable the Company to grant Awards under the Plan pursuant and subject to Section&#160;102 and Section&#160;3(I) of the Tax Ordinance. Accordingly, the Plan is designated to comply with the Tax Ordinance and the rules, regulations and orders or procedures promulgated thereunder from time to time, as amended or replaced from time to time and shall be submitted to the ITA as required thereunder. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In any case of contradiction, whether explicit or implied, between the provisions of this Section and the Plan, the provisions set out in this Section shall prevail unless the Administrator decides otherwise to ensure compliance with the Tax Ordinance and other Applicable Laws. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Eligibility</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;102 Options may be granted only to Israeli Employees. Non-Employees may only be granted 3(I) Options. The grant of an Award hereunder shall neither entitle the Grantee to participate nor disqualify the Israeli Grantee from participating in, any other grant of Awards pursuant to the Plan or any other option or stock plan of the Company or any Related Company. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-15</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">&#8203;</div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:40pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Grant of Awards in Trust</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:60pt; line-height:12pt; margin-top:7.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(i)</font>
          <br >
        </div>
        <div style=" margin-top:7.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:80pt;">
          <!--blacklining:none;-->
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Grants Made Under Section&#160;102</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:60pt; text-indent:20pt; margin-top:8pt; width:396pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company may designate 102 Options as Trustee 102 Options or Non-Trustee 102&#160;Options. The designation of Non-Trustee 102 Options and Trustee 102 Options shall be subject to the terms and conditions set forth in Section&#160;102 of the Tax Ordinance and the regulations promulgated thereunder. </font>
        </div>
        <div style=" float:left; margin-left:60pt; line-height:12pt; margin-top:7.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(ii)</font>
          <br >
        </div>
        <div style=" margin-top:7.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:80pt;">
          <!--blacklining:none;-->
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Grant of Trustee 102 Options</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:60pt; text-indent:20pt; margin-top:8pt; width:396pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(1)&nbsp;&nbsp;&nbsp;The grant of the Trustee 102 Options shall be made under the Plan and shall be conditional upon the approval of the Plan by the ITA. Trustee 102 Options may be granted at any time after the passage of thirty (30) days following the delivery by the Company to the ITA of a notice pertaining to the appointment of the Trustee and the adoption of the Plan, unless otherwise determined by the ITA. Options which shall be granted pursuant to Section&#160;102 and/or any Shares issued upon exercise of such Options and/or other shares received subsequently following any realization of rights, shall be issued to the Trustee. Each Israeli Grantee in respect of whom a Trustee 102 Option is granted and held in trust by the Trustee shall be referred to as a &#8220;beneficial optionee&#8221; hereunder. </font>
        </div>
        <div style="margin-left:60pt; text-indent:20pt; margin-top:8pt; width:396pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(2)&nbsp;&nbsp;&nbsp;Trustee 102 Option(s) may either be classified as Capital Gain Option(s) or Ordinary Income Option(s): </font>
        </div>
        <div style="margin-left:80pt; text-indent:20pt; margin-top:8pt; width:376pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(A)&nbsp;&nbsp;&nbsp;Trustee 102 Option(s) elected and designated by the Company to qualify under the capital gain tax treatment in accordance with the provisions of Section&#160;102(b)(2) shall be referred to herein as &#8220;Capital Gain Option(s)&#8221; or &#8220;CGO&#8221;. </font>
        </div>
        <div style="margin-left:80pt; text-indent:20pt; margin-top:8pt; width:376pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(B)&nbsp;&nbsp;&nbsp;Trustee 102 Option(s) elected and designated by the Company to qualify under the ordinary income tax treatment in accordance with the provisions of Section&#160;102(b)(1) shall be referred to herein as &#8220;Ordinary Income Option(s)&#8221; or &#8220;OIO&#8221;. </font>
        </div>
        <div style="margin-left:60pt; text-indent:20pt; margin-top:8pt; width:396pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(3)&nbsp;&nbsp;&nbsp;The Company&#8217;s election of the type of Trustee 102 Options as CGO or OIO granted to Employees (the &#8220;Election&#8221;) shall be appropriately filed with the ITA 30&#160;days before the date of grant of a Trustee 102 Option, unless otherwise determined by the ITA. Such Election shall become effective beginning the first date of grant of a Trustee 102 Option under this Plan and shall remain in effect until the end of the year following the year during which the Company first granted Trustee 102 Options. The Election shall obligate the Company to grant only the type of Trustee 102 Option it has elected, and shall apply to all Israeli Grantees who were granted Trustee 102 Options during the period indicated herein or therein, all in accordance with the provisions of Section&#160;102(g) of the Tax Ordinance. Notwithstanding, such Election shall not prevent the Company from granting Non-Trustee 102 Options simultaneously. </font>
        </div>
        <div style="margin-left:60pt; text-indent:20pt; margin-top:8pt; width:396pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(4)&nbsp;&nbsp;&nbsp;All Trustee 102 Options must be held in trust by and issued on the name of the Trustee, as described below. </font>
        </div>
        <div style="margin-left:60pt; text-indent:20pt; margin-top:8pt; width:396pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(5)&nbsp;&nbsp;&nbsp;With respect to Trustee 102 Options, the provisions of the Plan and/or an Award Agreement shall be subject to the provisions of Section&#160;102 and the ITA&#8217;s permit, and the said provisions and permit shall be deemed an integral part of this Section and of the Award Agreement for the respective Grantees thereof. Any provision of Section&#160;102 and/or the said permit which is necessary in order to receive and/or to keep any tax benefit pursuant to Section&#160;102, which is not expressly specified in the Plan or the Award Agreement, shall be considered binding upon the Company and the Israeli Grantee. </font>
        </div>
        <div style=" float:left; margin-left:60pt; line-height:12pt; margin-top:7.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(iii)</font>
          <br >
        </div>
        <div style=" margin-top:7.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:80pt;">
          <!--blacklining:none;-->
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Issuance to Trustee</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:60pt; text-indent:20pt; margin-top:8pt; width:396pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(1)&nbsp;&nbsp;&nbsp;All Trustee 102 Options granted under the Plan and/or any Shares allocated or issued upon exercise of such Trustee 102 Options and/or other and all rights deriving from or in connection therewith, including, without limitation, in accordance with Section&#160;10 above </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-16</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">&#8203;</div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:60pt; width:396pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">or any bonus shares or stock dividends issued in connection therewith shall be granted by the Company to the Trustee, and the Trustee shall hold each such Trustee 102 Option and the Shares issued upon exercise thereof in trust for such period of time as required by Section&#160;102 or any regulations, rules or orders or procedures promulgated thereunder (the &#8220;Holding Period&#8221;), for the benefit of the Grantees in respect of whom such Trustee 102 Option was granted. All certificates representing Shares issued to the Trustee under the Plan shall be deposited with the Trustee, and shall be held by the Trustee until such time that such Shares are released from the Trust as herein provided. </font>
        </div>
        <div style="margin-left:60pt; text-indent:20pt; margin-top:8pt; width:396pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(2)&nbsp;&nbsp;&nbsp;In event the requirements for Trustee 102 Options are not met for any reason whatsoever, then the Trustee 102 Options may be treated as Non-Trustee 102 Options, all in accordance with the provisions of Section&#160;102 and regulations promulgated thereunder. </font>
        </div>
        <div style="margin-left:60pt; text-indent:20pt; margin-top:8pt; width:396pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(3)&nbsp;&nbsp;&nbsp;With respect to any Trustee 102 Option, subject to the provisions of Section&#160;102 and any rules or regulations or orders or procedures promulgated thereunder, an Israeli Grantee shall not be entitled to sell or release from Trust the Trustee 102 Option, the Shares received upon the exercise of such Option and/or any right deriving from or in connection therewith, including, without limitation, in accordance with Section&#160;10 above or any bonus shares or stock dividends issued in connection therewith, until the later of: (i)&#160;the lapse of the Holding Period required under Section&#160;102, and (ii)&#160;the vesting of such Options set forth in the respective Award Agreement (such later date being hereinafter referred to as the &#8220;Release Date&#8221;). Notwithstanding the foregoing, if such sale or release occurs during the Holding period, the provisions of Section&#160;102 and the rules or regulations promulgated thereunder shall apply and any expenses and/or tax consequences therefrom shall be borne by the Israeli Grantee. </font>
        </div>
        <div style="margin-left:60pt; text-indent:20pt; margin-top:8pt; width:396pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(4)&nbsp;&nbsp;&nbsp;Subject to the terms hereof, at any time after the Release Date with respect to any Trustee 102 Options or Shares the following shall apply: </font>
        </div>
        <div style="margin-left:80pt; text-indent:20pt; margin-top:8pt; width:376pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(A)&nbsp;&nbsp;&nbsp;Trustee 102 Options granted, and/or Shares or rights issued to the Trustee shall continue to be held by the Trustee, on behalf of the beneficial optionee. From and after the Release Date, upon the written request of any beneficial optionee, the Trustee shall release from the Trust the Trustee 102 Options granted, and/or the Shares or rights issued, on behalf of such beneficial optionee, by executing and delivering to the Company such instrument(s) as the Company may require, giving due notice of such release to such beneficial optionee, provided, however, that the Trustee shall not so release any such Trustee 102 Options and/or Shares and/or rights to such beneficial optionee unless the latter, prior to, or concurrently with, such release, provides the Trustee with evidence, satisfactory in form and substance to the Trustee, that all taxes, if any, required to be paid upon such release have, in fact, been paid. </font>
        </div>
        <div style="margin-left:80pt; text-indent:20pt; margin-top:8pt; width:376pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(B)&nbsp;&nbsp;&nbsp;Alternatively, from and after the Release Date, upon the written instructions of the beneficial optionee to sell any Shares and rights issued upon exercise of Trustee&#160;102 Options, the Trustee shall use its best efforts to effect such sale and shall transfer such Shares to the purchaser thereof concurrently with the receipt, or after having made suitable arrangements to secure the payment, of the purchase price in such transactions. The Trustee shall withhold from such proceeds any and all taxes required to be paid in respect of such sale, shall remit the amount so withheld to the appropriate tax authorities and shall pay the balance thereof directly to the beneficial optionee, reporting to such beneficial optionee and to the Company the amount so withheld and paid to said authorities. </font>
        </div>
        <div style="margin-left:80pt; text-indent:20pt; margin-top:8pt; width:376pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(C)&nbsp;&nbsp;&nbsp;Notwithstanding the foregoing, in the event the underwriters of securities of the Company impose restrictions on the transferability of the Shares during a lock-up period, the beneficial optionee shall not be entitled to release from Trust the Trustee 102 Options granted and/or the Shares issued and/or to instruct the Trustee to effect a sale of same, for as long as the restrictions are in effect. In the event the Trustee 102 Options granted and/or the Shares issued have been released from trust the restrictions imposed </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-17</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">&#8203;</div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:80pt; width:376pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">on the transferability of same shall nevertheless apply to said optionee&#8217;s Trustee 102 Options and/or Shares in the same manner. Consequently, the Israeli Grantee shall sign any documents required in order to effect the restrictions, for as long as the restrictions are in effect. </font>
        </div>
        <div style="margin-left:80pt; text-indent:20pt; margin-top:8pt; width:376pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(D)&nbsp;&nbsp;&nbsp;Upon receipt of the Award, the Israeli Grantee will sign an undertaking to release the Trustee from any liability in respect of any action or decision duly taken and bona fide executed in relation with the Plan, or any Option or Share or rights granted to same thereunder. The Trustee may establish additional terms and conditions in connection with Awards held in trust by the Trustee. </font>
        </div>
        <div style="margin-left:60pt; margin-top:8pt; width:396pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(iv)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Grant of Non-Trustee 102 Options</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:60pt; text-indent:20pt; margin-top:8pt; width:396pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(1)&nbsp;&nbsp;&nbsp;Awards granted pursuant to this subsection are intended to constitute Non-Trustee 102 Options and shall be subject to the general terms and conditions of the Plan and Section&#160;20, except for provisions of the Plan applying to Trustee 102 Awards or Options under a different tax law or regulation. </font>
        </div>
        <div style="margin-left:60pt; text-indent:20pt; margin-top:8pt; width:396pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(2)&nbsp;&nbsp;&nbsp;With respect to Non-Trustee 102 Options, if the Grantee ceases to be employed by or of service to the Company or a Related Company, the Grantee may be required to extend to the Company a security or guarantee for the payment of tax due at the time of sale of Shares or other rights, all in accordance with the provisions of Section&#160;102 and the rules, regulation or orders promulgated thereunder. </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(v)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Grants Made Under Section&#160;3(I)</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Awards granted pursuant to this subsection are intended to constitute 3(I) Options and shall be subject to the general terms and conditions of the Plan and Section&#160;20 thereof, except for said provisions of the Plan applying to Awards under a different tax law or regulation. The Administrator may choose to deposit the Awards granted pursuant to Section&#160;3(I) of the Tax Ordinance with a trustee. In such event, said trustee shall hold such Option in trust, until exercised by the Grantee, pursuant to the Company&#8217;s instructions from time to time. If determined by the Administrator, the trustee shall be responsible for withholding any taxes to which a Grantee become liable upon the exercise of Options. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Award Agreement</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Without derogating from the powers of the Administrator under the Plan, the Administrator shall adopt the form of Award Agreement for Israeli Grantees in form acceptable by the ITA and in compliance with the Tax Ordinance. The Award Agreement shall further indicate the type of Options (102, 3(I), Trustee, Non-Trustee etc.) granted thereunder. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(d)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Vesting</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Without derogating from the terms of any Award Agreement or the discretionary authority of the Administrator, the standard vesting for Options to Israeli Grantees shall be as follows: </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(i)&nbsp;&nbsp;&nbsp;Twenty five&#160;percent (25%) of the Options granted under each Award Agreement shall vest on the end of the first year of Continuous Service following the vesting commencement date determined by the Administrator and if not specified the date of the grant of an Option (the &#8220;First Anniversary&#8221;); and </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(ii)&nbsp;&nbsp;&nbsp;The remaining 75% of the Options shall vest on a quarterly basis over a period of three&#160;years commencing as of the First Anniversary in twelve (12) equal portions subject to Continuous Service of the Grantee. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(e)&nbsp;&nbsp;&nbsp;With respect to all Shares (in contrast to unexercised Options) allocated or issued upon the exercise of Options by the Israeli Grantee, the Grantee shall be entitled to receive dividends in accordance with the quantity of such Shares, subject however to any applicable taxation on distribution of dividends. Subject to the Tax Ordinance and any restrictions imposed by the Trustee or the ITA, during the period in which Shares are held by the Trustee on behalf of the Israeli Grantee, the cash dividends paid with respect thereto shall be paid directly to the Grantee after deduction of withholding tax applicable thereto. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(f)&nbsp;&nbsp;&nbsp;Without derogating from anything in the Plan, to the extent permitted by Applicable Laws, any tax consequences, attributable to the Israeli Grantee, arising from the grant or exercise of any </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-18</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">&#8203;</div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:452pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Option, from the payment for Shares covered thereby or from any other event or act (of the Company, a Related Company, the Trustee or the Grantee), hereunder, shall be borne solely by the Grantee. The Company and/or or a Related Company and/or the Trustee shall withhold taxes according to the requirements under the Applicable Laws, rules, and regulations, including withholding taxes at source. Furthermore, to the extent permitted by Applicable Law, the Grantee shall agree to indemnify the Company and/or a Related Company and/or the Trustee and hold them harmless against and from any and all liability for any such tax or interest or penalty thereon, including without limitation, liabilities relating to the necessity to withhold, or to have withheld, any such tax from any payment made to the Grantee. The Administrator and/or the Trustee shall not be required to release any Share certificate to a Grantee until all required payments have been fully made. </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Plan, to the extent applicable to Israeli Grantees, shall be governed by and construed and enforced in accordance with the laws of the State of Israel applicable to contracts made and to be performed therein, without giving effect to the principles of conflict of laws. The competent courts of Tel-Aviv, Israel shall have sole jurisdiction in any matters pertaining to Israeli Grantees.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-19</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.31pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#FFFFFF;font-family:Times New Roman, Times, serif ;font-size:1pt;">
      <div style="position:relative;padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">&#8203;</div>
      <div style="margin-top:-8pt;margin-left:0pt;width:595.31pt;">
        <div style="position:relative;z-index:-1;text-align:center; width:595.31pt;">
          <img src="px_24protalixproxy01-bw.jpg" alt="[MISSING IMAGE: px_24protalixproxy01-bw.jpg]" height="1024" width="792" >
        </div>
        <div style="margin-top:5pt; width:595.31pt; line-height:1pt;">
          <font style="letter-spacing:0.02pt;">PROTALIX BIOTHERAPEUTICS, INC.The Lotte New York Palace Hotel The Garrison Room455 Madison Avenue New York, NY 10022THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORSThe undersigned hereby appoints Dror Bashan and Eyal Rubin as proxies, each with full power of substitution, to represent and vote as designated on the reverse side, all the shares of Common Stock of Protalix BioTherapeutics, Inc. held of record by the undersigned on April 29, 2024, at the Annual Meeting of Stockholders to be held on June 27, 2024, or any adjournment or postponement thereof.UNLESS A CONTRARY DIRECTION IS INDICATED, THIS PROXY WILL BE VOTED FOR THE PROPOSALS, AS MORE SPECIFICALLY DESCRIBED IN THE PROXY STATEMENT. IF SPECIFIC INSTRUCTIONS ARE INDICATED, THIS PROXY WILL BE VOTED IN ACCORDANCE THEREWITH.(Continued and to be marked, dated and signed on the other side)PLEASE DETACH ALONG PERFORATED LINE AND MAIL IN THE ENVELOPE PROVIDED.Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting of Stockholders to be held on June 27, 2024.The Notice of Meeting, Proxy Statement, and our 2023 Form 10-K Report and Proxy Card are available at: http://www.web.viewproxy.com/Protalix/</font>&#8203;<font style="letter-spacing:0.02pt;">2024</font><font style="color:#000000;letter-spacing:0.02pt;"> </font></div>
      </div>
      <hr >
    </div>
    <div style=" width:595.31pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#FFFFFF;font-family:Times New Roman, Times, serif ;font-size:1pt;">
      <div style="position:relative;padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">&#8203;</div>
      <div style="margin-top:-8pt;margin-left:0pt;width:595.31pt;">
        <div style="position:relative;z-index:-1;margin-top:8pt; text-align:center; width:595.31pt;">
          <img src="px_24protalixproxy02-bwlr.jpg" alt="[MISSING IMAGE: px_24protalixproxy02-bwlr.jpg]" height="1014" width="783" >
        </div>
        <div style=" float:left; line-height:3pt; margin-top:-1pt; margin-bottom:0pt; text-align:left;white-space:nowrap;">
          <font style="letter-spacing:0.02pt;">Please mark your votes in blue or black ink as shown here &#9746;THE BOARD OF DIRECTORS RECOMMENDS A VOTE &#8220;FOR&#8221; THE ELECTION OF ALL DIRECTOR NOMINEES, A VOTE &#8220;FOR&#8221; PROPOSALS 2, 3 AND 4.PLEASE SIGN, DATE AND RETURN PROMPTLY IN THE ENCLOSED ENVELOPE.1.To elect seven members to the Board of Directors to serve for the ensuing year or until their respective successors have been duly elected2.To approve, on a non-binding advisory basis, the compensation of the Company&#8217;s named executive officers as disclosed in the proxy statement that accompanies this notice;2.&#9744;FORall nominees&#9744;WITHHOLD AUTHORITYfrom all nominees&#9744;FOR ALL EXCEPT(see instructions below)&#8226;Eliot Richard Forster, Ph.D.&#8226;Dror Bashan&#8226;Amos Bar Shalev&#8226;Shmuel &#8220;Muli&#8221; Ben Zvi, Ph.D.&#8226;Pol F. Boudes, M.D.&#8226;Gwen A. Melincoff&#8226;Aharon Schwartz, Ph.D.&#9744; FOR &#9744; AGAINST &#9744; ABSTAIN3.To adopt amendments to the Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended, to increase the number of shares of common stock available under the plan from 12,475,171 shares to 17,475,171 shares and to amend certain other terms of said plan;&#9744; FOR &#9744; AGAINST &#9744; ABSTAININSTRUCTION: To withhold authority to vote for any individual nominee(s), mark, &#8220;For All Except&#8221; and fill in the circle next to each nominee you </font>
        </div>
        <div style=" margin-left:0pt; margin-top:-1pt; margin-bottom:0pt; line-height:3pt; text-align:left;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.02pt;">wish to withhold, as shown here: &gt;4.To ratify the appointment of Kesselman &amp; Kesselman, Certified Public Accountant (lsr.), a member of PricewaterhouseCoopers International Limited, as our independent registered public accounting firm for the fiscal year ending December 31, 2024&#9744; FOR &#9744; AGAINST &#9744; ABSTAINDate: Signature Address Change/Comments: (If you noted any Address Changes and/or Comments above, please mark box.) &#9744; CONTROL NUMBERI plan to attend the meeting &#9744;Signature (if held jointly)NOTE: Please sign exactly as your name or names appear on this Proxy. When shares are held jointly, each holder should sign. When signing as executor, administrator, attorney, trustee or guardian, please give full title as such. If the signer is a corporation, please sign full corporate name by duly authorized officer, giving full title as such. If signer is a partnership, please sign in partnership name by authorized person. PLEASE DETACH ALONG PERFORATED LINE AND MAIL IN THE ENVELOPE PROVIDED.CONTROL NUMBERSCAN TOVIEW MATERIALS &amp; VOTEPROXY VOTING INSTRUCTIONSPlease have your 11-digit control number ready when voting by Internet or TelephoneMAILVote Your Shares by Mail:Mark, sign, and date your proxy card, then detach it, and return it in the postage-paid envelope provided.TELEPHONEVote Your Shares by Phone: Call 1 (866) 402-3905Use any touch-tone telephone to vote your Shares. Have your proxy card available whenyou call. Follow the voting instructions to vote your shares.INTERNETVote Your Shares on the Internet:Go to www.FCRVote.com/PLXHave your proxy card available when you access the above website. Follow the prompts to vote your shares.</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <hr >
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>lg_protalix-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 lg_protalix-4c.jpg
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M%!04%!04%!04%/_  !$( $X _P,!$0 "$0$#$0'_Q "X   " @,! 0
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MCLEKQNTQ+'98R8EK@MAJ,PCDE(XDDGB2225$\2>)U"G0T K'I/(.3YR0:@]
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MP(S3#I?4KJ]$J6V4@H3NX KI7PKJT!>+Y?[-C-M=O%_G-6^VL4ZDA]6U-3R
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MH"!>$K_\DL=6$JV#&I *Z';7KO>/+0'GU$(6NS8=L0I>W*K:3M!-!L>X\-$
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MKP!J (<DWW)L4[\9]DUGMCMYL,-,!G(K?%HJ6([\9LH?9;^V6E(.[\TGE7<
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,0X[MNW9[ZTX: __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>px_24protalixproxy01-bw.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 px_24protalixproxy01-bw.jpg
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M_\0 K  !  (# 0$! 0            8'! 4( P(!"0$! 0$
M      $"$   !@$# P("!0D""08) 1D  0(#! 4&$1('(1,(,2)!%%%A,A47
M<9'10E(CE!96@3-B)'2TU'4W5SBA<K)#LQBQ@E-S-"4UM38)TI-4A%4FP9)C
M@T2%E>&BT\3%)TEEU4:&*!$! 0$! 0$               $102$Q_]H # ,!
M  (1 Q$ /P#OX
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MAEQV-%E1YL9F;#=0_$D-I>8?;,E(6VX1*2I)ET,C(]2,&7J
M
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M[1Z SBMO,O\ V[\;_P"3PO\ WFL%CM7*/_AFY_R&5_V*@9<?_P#R>O\ [/Y
M_P#/57_1E@U4O\]S/\(*8OA_,4;I_P#24P$BX. ?]B>!?ZDA?]D0%<J__P P
M7_Z<_P#W "\?%.TUF?GE,^_D_,-5<Z2J(PYU01U4$RCZ$?IM4A+I:?K%J!QW
M-=4U9D51.H;J,F9463#D6;%<UVN,O)-*DF9&1EJ1^I'J7P!E#F^&\"K,#O\
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MDO1*2(B(@&4
M
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M80;#".<JV\L+Z!)<4U.7M>GI)9D9LOHE.-'HE6IH62S]IZ::$1F7$=QR5/\
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M"+X@BT\:N49'CE1D+;)QT6T*-/3'4HEJ;*4TETD&HM",T[M-01M
M
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M@/9"$MI2A"22A)$E*4EH1$70B(B ?H
M
M                                                 *IY8\A,"X:L
MJZJR]NP7)LV%R8QP8Z'D;$+V'N-3B-#U^! N*]_[]/"?_D;O^":_T@#%GM<W
MX6]GF-\=H1.^_P#*JQNZK%&PDHY1767GTDZK?JE>UE?3:?73J!BR00  $ Y$
MYAP_C"SQRHR<Y12\H?7%J_E6>\GN-K9;/N'N3M+5]'T_$%Q/P0 ?AF1$9F>A
M%U,S 1O%^0,/S1JVDXQ:LV4&DDJ@V$YD]8J7VVTNK)+IZ(6E*5D9K09I^L!Z
M8AG&+9[!EVF(V+=K60Y;E>Y-8)795(92A2R;69$2TD2R]Z=4G\#,!(0 !6#G
M/?'['*ZN&Y;TF-EQ&AMMQYI*83CKL=,I#:7=^NY2%D2=4EJKVEUTU+C99]R[
MBG'%YBN/9"B6J?F$HX-2<5I+K9.DXRU^]4:T[2W/H]"/X@)Z"    -5DU\SB
M]!8Y%(B29T:L87*?BP&R>E+;:+<KMH-2=QD6IZ:_D 1_C#E3$>7<=5DN(/.K
MAM/KB28\E!-2&7FR)6U:"4HBW)4E23(S(R/Z=2(-5A'..&\B9E>89B;4Z;(Q
MXW$V5L3"2K$J;<[1)0_W#-1K42NW[?<25*+H6H+BR@0 1CD'.Z3C3$;#-<B2
M^JGK>S\PF(@G7O\ &'D,)VI-22/W.%KU] &=B>2UV98U5974$ZFKN(S<V(3Z
M20Z33R=R=R2-1$>GU@-R YZR+S,XAQC(+7&K)FX.QIYDBOEFU#;4V;T5U32]
MAF^1FG<D]#T!<3OBWG?C?F!<N-AUBM5G!03LFMF-''E$R9DGN)2>I*1J9),T
M*/:9EKIJ6HQ90(@?*O+>*\.TD._RU$M<&=+3 8*"TE]SO*;6Z6I*6CIHV?Q!
M4[2HE))1>AEJ7]H(_0    'XI1)2:C]"+4_[ $ XHYBQ+F2LL+7$43$1:R04
M204YE+"C<4@EEM)*UZEH8+CYK.9<1MN4K3B&*B865U#'S4I:V4E$[?;:<]KA
M+,S/1Y/Z@&+"!&/.G0JR'(L;*0U$@16U/293ZTM---(+<I:UJ,B2DB+4S,!J
M\1R_'\[H6,FQ:7\_1RG'VHTPD+;2X<9Y;"S23A)/;O;41'IU]2Z -X @5ER[
MBE7RC5<1242SRNYBJG1%H:2<0FDH?</>YO(R/2.O]3Z 5/00
M
M
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MEZ*0N+9J2?\ :1@<=:@R
M
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M]DDI-2_34U:GH0JJN(_&')\2YJN;?(6$*XU@-VZ,624E#OMM3[!()DE&;?\
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MR9 @L_R134ZJ^7*)YIM3;O8G-I2EC4E&6K[9>U.GY@3CH$$
M
M
M
M
M
M
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MNI /J#G^#6=^]BM=DE9+R6/N)ZH8F,N2TFV6JR-I*C5JG]8M.GQ 2,
M
M
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M"#(
M
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MPR>)QIPS+6.G[)I^(&K&!
M
M
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MKKZ$8#W
M
M
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MJ)TGHQ[=5M.DE&XR)23,MI=#U3KHK08N$$
M
M
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MBW+X&>>9UOEM3%?C4UG2K56NRF5QW)49F/&93))"R(]CO;-39G^KI\0.--P
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M[D+^1^'K"NAN[+O*U?<L)*3]_9>+64O3UT[1*;U^"EI BIJ7Q:YY_#5O!2Y
M@P,6L(Z79>-.P]Z4.OJ3(6VMWMFLU)<_6(_AT!=;_P 7+!CD7AS*^"<R(V[3
M'CE5$AASJ\W"F&X2%%KZK8?)Q)?L[4?4!53<.4N5<@\DX5PUEL7;3<-RK299
MGN4HGE-S"6A"R46AI[Q-MH+XM&K3H E7.58K#O)U.899?W.'X=DU>TQ#RNC(
M][#K,=#*V5J)#AZ;FMRTI2:M%I/TU GQ)."X&#Y!GF;YQBEQEV2S(=3(K)V5
MWY1ONZ<A2&R0E"B2A_>1,IVI4GHA.JMNJ2 KU\0B;3XT9DHB(C.;<&X?TF5;
M']?[ *K?&JJPM_!3(FJR.N4]&NCEO-M)-2R88DQE.+T+KHA/N5]"2,_@!U]\
MO<TX;FOC)C.&8RY*FWM8Q3MY TB*\EFO^29[!]]Y2";_ 'CI$EK:H]WU>@&,
MWFJHE4.;</\ )-O96M'A*\:KZJ3DM(1JEU[Z&'3/:>BMNY,A)Z::J3OVD9D!
M$NX7C<?9?SNQD.-9-F>;VV-0G4*RJU*.=.IAYEQOY=:G&VGRT-]1MITU4LC/
M3:1J KL8&0
M
M
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M3VH(BU,!D@
M
M
M     JC*/(7 \.Y/K>*KY,R-<V91S9LC;:^[D*EFI+27'#=):=RD[=>WH1F6
MIZ:F1<;7E;F'&N'X51.R6+-E-7,PJ^*5>VTXI+IIW:K[KK>B=/HU/Z@,6$"
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MCH2!/A6D&-9UKZ)5?,:1(B265$MMUEU)+0M"BZ&E1&1D8(R
M
M
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M1+-.O4D[M=I'\ 92@
M
M
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ML^H&6]
M
M
M                   81T]2JV3?*@QSO$L'#39&T@Y1137W#9)W3>2#5[MN
MNFO4!F@
M
M
M
M
M
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M$IGL69;.5/JHYJ3-C1"+<:U$F2XM.U/51FE>WJ:DEH>A?$YROR+;=\>I'-6
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M:5H-:O@9*/4]"6+L!
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MGYIHKDR;R=ZQ-]"'3_>K:8FRR?4G7J9;G6E:_'4C KHF]Y7X_P ;SVGX_N;
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MAIQME;;AM)0E?]ZA2%;$K^T2^OH2NEP0
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M:5N,M,F@B1TTT:(_[06UB\X<(U?-]-5TUI;2*EJKE*F-N16T.*6I39MZ'O\
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M\3^C0BT21$1'OFF&8YR!C<W%,JAIG4TY))=:,S2M*TGJAQM9=4K2?5*B_P#
M YT/PK;;BKQ^)R=D3&#N+-2L>W$;1H,S,R/1Q+1F>OKV/[ 75RPN&,/I.*[/
MB;&FUU=':0Y,.1+3H[*6Y,;-MR0XI6F]PRT]>FA$1:)(B(:S>).-8/$N$0\(
MKISMC%ANOO(E2$I0X9R'5.F1DCIT-0(G   YCG>'45S);[)J?D*]HY603)$Z
M8U7&F.1G(>6]L,VUI-24FL]-P+J>\1^.F%\2V4O(XLF9?9?.0;3][;.)=?2V
MLR-26R21$G=H6Y1[E'Z;M.@&O7$>"*O$<MS_ "V/<RI,G/CD'+CN-M)1&^9=
M<=_=FDM5;>YH6[Z.H&MCPGP]6\)XM,Q:KLW[6/,GN62GY*$-K2MQEIDT$2.F
MFC1'_:!:TF-^/5/AG+5ARCB5W*JFK@W3M<;;::5 >)].JTD9^Y!=TB>3M^RK
MH7M/:!JO(7A:Q4O3':/DO(:E,YTWY+<%28R5K,S,C432T$9EKTU(#5D<4<'3
MN,;^7>2<\O,H1*AJA% MWE.L(-3K;G=22EJ]Y=O:7U*,#4/RCQ#H9F23\FX]
MRVVP&1:F:K*'4*,HJS69FHD)0XRI"5&9GLW&DOU2(N@&I_PUP5B'"U?,;HUO
MV-W:*)5I=SC2J2\23,TH222(D((S,]"ZF9ZJ,^F@M>?)W!]7R;E^'9?.MI$"
M3ATE,N+&8;;6A]27VG]%FKJ75HBZ :LFTK*^ZK9=1;1FYE9.97&F1'DDIMUE
MU)I6A1'ZD9'H".:'_#&#6R9K>!\AY!BN/6*C5+IHSJG&E$>A&DU(=9W%H6A=
MQ*ST]3,%U;/%/"&%</X_+I,6;=7*LB+[TMY1I<ER%)2:4ZFDDI2A&Y6Q"2T+
M4_4S,S&O#A#A6KX0H;&AJK61:LV,SYY;LI"&U(5VD-;2)'PT1J!:U=5X]T^-
M\P2^6\4NI5.]:&L[>A:;;7!DD^1&\1ZZ*23CB2>^I?4NG0#4/N_$"J;R.QR'
MC?-KG ?O92ESX-4M78,UF:C2WVW65)1J9F2%*42?U="Z$-3_ (9X$Q/AAFPD
M54B3;9';F1VEW/42GW"2HUDA"4]$)-2MRNIJ4?51GH6@M6J"
M
M
M
M
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MQ]M/R)2$$XT<C4_W>])[D[M-2 ;IMQMYM#K2B6TXDE(6D]2-*BU(R/ZP'T
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ME^0<68!)Q7**J*;L6%D%$=24]QE"GB;2AI3:G2,DJ07O+:M1 C[O.99<W L
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M#=HVY3+M?,AL'()M1R%J[S:B+:2]J3UZF1%T,)5S+G%UQQB3&95C,=^MKK.
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M3CFKQB$=9?U!UK.;+L6DQ8U3*);*^[#T*0J0VT9MDE!&@ST5N]4@K>9#&R7
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MVXUY13Q#GO##<9-O5L-ML\>W#TMI+KU:MY#B84@G%$I*XB4[$N*T2M.A%IM
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M=ZB8TVY7O5$%4?M+BJ+N.=U9]#1T274_CH%P@@
M       \G),9EYF.Z\AM^0:B8:4HDK<-!;E;",]3T+J>@#U           !$
M<WXQPGD0H2\JK?F9E::U5U@P\]#F1S<+1?;?C+;<(E:>Y.[0_B0#TP["L(XX
MB?<.*0F*O[P=<E.(4ZIV7+>+JXZXZ^M;KJBUZFI1Z )4  /AYYF,RN1(<2TP
MTDUN.N*)*$I26IFHST(B(!^MN-NMI=:42VED2D+29*2I*BU(R,O4C ?0
M   /*1)CPV%R9;R&(S1;G'G5$A"4E\5*49$1 (OFG&N$<CG5+S&L*V9J73D0
MF%O/(CFI>PS[K3:TH>29H2>UU*D]/K/4):1:="]  !Y2HS$R,]#DH[D:0A33
MS9ZD2D.$:5%TT/J1@-?C>.4N(44'&L>BE"I*ULF(44EK<V-D9GIN<4I1]3]5
M&8#%5CN*S,P1E9L-.YA60E5I24NJ-UF')63W;4T2]I;C3N(U(U^@P&_
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MVHE[7$=%(5H9Z*+XD .RHS+K+#SS;;T@S3';6HDJ<-);C)!&>JC(NIZ /4
M1B+68/C>66=FPJ) R_+SC*L.Y)TDSOD&S88VM..?J(,T_NTE]?4!)P
M  'D4J,<E4,GFSEI03JHY*+N$VHS(E&G770S+34!Z@
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M)[7R3R%68TK5+D,'#X<.0W%D?-PY)%8..)DQG%(;5VEDHBVK22DJ(R/T =$
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M#A,SEO**0VVM?:=-2UF39F9D@B,]#/0!>8(
M                        (%G'$N/YO;P\E.PM,=RR PJ%'R#'Y?R,XX:U
M]PX[BC0XAQK?[B2M!Z'J9::@K8X)QWCO'D*7'I3DRI]F]\U;W-D^N98SI!%M
M)R0^OJHR+HDB(DE\"ZF")8                                     Q
M;&N@V]?*JK-A$JNFM+CRXSI;FW674FE:%%\241F1@/:/'8B,-18K2&(S"$M,
MLM))#:&T%M2E*4Z$1$1:$1 /0
M                                           :#-</J,^Q:RQ"_P"[
M]T6K:697RZ^T[M2M+A;5:'IU27P ;J+';B1F8C.O:8;2TWN/4]J")):G^0@'
MJ         P:ZFJJAR<]60VHKME(5-L'&DDE3\E:4H-QP_52MJ$IU/X$1>A
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M@C; *6O)LU'E'BE>B4\FO<Q2P=<B$XLF%.)E$1*-O7::B+XZ O$OQKE"JR?
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M9]_,W.5C$5#D9I(8B5,1Q7<^7JJ=KY=))/X=R1WUJ(O7H8%7D"
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MF^QRKR5J%'MT./18$V/9-QTNK;:<D0U=QGO)09$XA#A)=)"]4[TI/3H VP
M      #4)QJJ3DR\N4A;EVJ$58VZMQ:FVHO<[RTM-F>U!N+))N*(M5;$Z_9(
M!MP                                 !#^0,&?S2)7N5=]-QK(Z:3\[
M47,#:OMNFDT*0\PY^[>:6D]%MK]?SZAH\.XKM:O+#SW.\J>S#+FHBZVM?.(S
M60H45U9+<)B*RI9;W#(M[BEFHRZ>@*LP$
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ME6%C):;+5;B&FS(B;27JM:DI^OU!&)6\T8398E?Y>2YD1G%D+5D=1,BN1[6
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M>Y*#)U.[:HC21EIH")
M
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M-Y)V%[B,M#5KT] 9;X
M
M                                                  !^*2E232HB
M-)EH9'U(R,!@Q:.D@QW(D*MBQHKJR<=898;;;6LC(R4I*4D1F1EKJ8#UF5E;
M8+8<GPV)2XJR=C*?:0Z;3A>BT&HCVJ^L@%<\B\<Y+G60XQ&CV%?68%36D3(;
M*.B.XJTDV,!Y;J4)62R:2TO5.X]N_74]3] 58D^IJ[5+:+2#'G(95W&4R6D/
M$A9?K))9'H?UD",I3:%H4TM)*;41I4@R(TFDRT,C(_@ Q8=14US33%? CQ&&
M5*<9;890TE"UEHI2221$1F1]3(!D-QV&4K0RTAM#BE+6E"222E+^T9D7J9_$
M!\%#B%&^2*.V4/;L^7V)[6T_AMTTT ?11HZ74OI903R$=I#A)(E$WKKM(]-2
M+Z@'ZW'8:6XXTTA#CQ[GE)2236HBTU49>IZ?2 _&HT=EDHS+*&XY$9$RA))1
MH?J6TBTZZ@/"OJ:JI0MJJ@QX+;JM[B(K2&4J7^T9((M3^L![MQHS+:F664-M
M+-2EMH224J-?51F1%H>OQ >3U972(A0'X;#L!.A)BK:0IDMOIH@RV]/AT 9)
M$22)*2T270B+H1$0#$54U2K!-LJ#'.U2GMIG&T@Y!(]-I.:;M/JU 9!L,F\4
MDVTG(2DT$[M+>2#/4T[O737X /R2T;\9Y@CVFZA2"4?70U$9:@()Q+QHSQU@
MN.8S9JBVEW0,/1T7"&"2O8\^Z]M;->Y:2(G-IENZ@J<S(4.QCKAV$=J7$<Z.
M,/H2ZVHO7JE1&1@CZC1HT-AN+#91'BM))#3+220VA)>A)2DB(B_( QXE-45\
MA^7 KXT67)ZR7V&6VW'3UU]ZDD1JZ_2 \+>DB646<2&66[*5$>AHG*;2IU*7
M4&G3=]K:1GKIJ C?%_'K.!X9C=!8_+6%[0P2@?>Z&22X;>Y2MJ%+U6E/N]-0
M$PFP(-G'5#LHK4R(O3>Q(;2ZVK3J6J5D9& _4PH:8A0$QVB@DCME%)"2:)'I
MMV:::?5H ^G(T9YM++S*'&D&E2&UI)24FCJDR(RT+3X /&PJZVV8*+:PV)T8
ME$LF932'D;B]#VK(RU(!ZKB17&"BN,-KC))))94A)MD2--NB3+3IIT ?2V&'
M'&W7&D+=9,S:6I)&I!J+0]IGU+4OH "CL)>5)2T@I"TDA;Q)(EFE/4B-7J9%
MJ QRJ*E-@=NF!'*U4G8J<3*"D&C33:;FF[33X:@,@F&">5))I!2%))"GB26\
MT$>I)-7KH1_ !^(C1VU.J;90E3Y[GS2DB-9Z::JT+KTZ=0'S$A0X#)1H$=J+
M'(S,F6$);01J/4SVI(BZF _'($%V4W.=C-+FM)-MJ2IM)NI0KU2E9EJ1'KU(
MC ?I0XA1ODBCME#V[/E]B>UM/X;=-- 'Y+KX$^*J#.BLR82B)*HSS:7&C(O0
MC0HC+I^0 ;@06895[49IN E/;3%2VE+)(_9)!%MT^K0![I2E"22DB2E):)27
M0B(O@0##@5%35F\JL@1X2I"M\@XS*&3<7^TO81;CZ^I@/V9455@^Q)GP8\J3
M%/=&>?90ZMI7KJA2B,TG^0!D.L,/[#>;0YVE$XWO22MJT^BBU]#+Z0 X\=3Z
M91M(.2E)H2\:2[A(,]322O73Z@'H
M
M
M
M
M
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ME2!QGS'4L7=;<M=R#E%'&<^794K>23<6VVA&TU(-"TK;0I.I*^R9:ATL"
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MB47PZ%^NUB?94ZIA+B3>26JFR41J(OK+U!EZ
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MI?W^GK\ 7%J9,_D$7'[&3BL:/-R)EE3E=#F+4TP\ZCJ3:EIZIW$6TC]"/UZ
MBK>".?87+./W<B_BM8[DV,O.(OJUQ:DH9CEN-+QFZ232DMBT.$K[*D'KH1D"
MV,7A'F_)>:<CR.774,>#QG3ON1(%RXMWYR8]N(VB)LTD@OW?[QTM=4;D%UUU
M L3OE_.)G&W&]]F\"(U/ET[33K<1]2FVU]Q]MH]5)(S+0EF8)'/U7Y+>05CC
MK.9QN($S\4=95*3+B27#-<=&NY22(G%Z%M/_ *LP:Q:-/Y"4V7<)WW+.*Q-T
MRAB27)M),7HIF9&;)PVEK07N0HC)25I+J1_ ]2(F*NQCR/\ (O,Z2-D>+\21
M[*CF&X4::U*42%FRXII>F]:3Z+2I/I\ 7%H5_,V4XWQ1D'(_,>**Q>93R39C
M4\=PG7)3:TLI8-)F:M#<>=-OKZ$G=Z F*N?\DO(2OQEODNQXIBHXV<0U+)],
ML_FODWS(T._;4LDJ)1&3AQMO77T!<78KG7!VN'V>:'W'6\:?C]UN-H1RE2>X
M;!Q4IUT-SNI-OUV]#5KMZ@F*4/R5\@9="OD2KXD0?&Z4*E)?=?6<M4)&JC>+
M0TJV;2W=PHQHTZZZ=07$XR/R:@%P0GF?#:]$U:93,"74SEFA4>2MPD.MK4WK
MJ:=Q*29?:29'TUT!,0V-Y#^2#]$UE3?#J)&/.Q$V3<IF2L]\-;9.I<2DC4HR
M-![OL&?U N)DSY,Q;S@"ZYFQNI3]YT;C<6=1S'3-#<E3[#:T]U"2-2>V^3B%
M$DM?0].H)C3\@>3>18?Q3Q_R#"Q^',L,S+]_!<>=2VRHV]Z20HBU/7ZP,:R\
M\B?(+"*Y>1YSP^B+C$52"GRH\XC4VA:B01F:#>V]3(M5)TU^(&)ERWY%EA?$
M6-<KXA7-6T+(Y49EF-.4MDVVI$=]X]W;U]Z%,[#+73UZ@8BC'-OE+)8;D,<,
M-K9>0EQM92CZI66I'U<^)&!D;;ESR#SWC#&^/9:\1C.Y3F"'F["F?><2<68V
M4?:R@T:[M5/&74_@0&-!/\G^7,"5%L^6>)WZC$WWDQW[.$^;BF37\=#):#5T
M/:E2T;O@8+CI^FN*W(*F#>T\A,NJLF&Y<*2C7:XR\DEH46NAEJ1^A@RJ;GGF
MFVXBFX7%K*J/9)RB>N ^J2XMLV22IE)*1L(]=>Z?K] +(B_+7E$?$O+]5@MO
M4LNXK*8BR;&W)QSYEAN4XXVI9-D1DHF]A*,O4RUTZ@8E/D%S78</XS09!0U\
M6Z*[L$0D]]Y2&NVXRMU+B%M$K77;Z_0!(N8$<O<F\_\ .W'<G(;)_C%@\'II
MCC$>^>DJV.Q3D=B.\HD*U+N[D=-O0U N-GQ5S7SEG]OC[]IQJU78+=%WEY U
M(4I*(RFU+0XE*E:Z*,B+J7Q Q).!>;;?EZSS:!9U,:L;Q6:S#CKC.N.&\3JY
M"5&LED6FG9+33Z3 L'.;;='D:UPF53&.I<A',.U[KGS!&4-4C39IM^T6W\G4
M#%;N>3?,=SG>78=@7'47(2Q6PDP7W6Y#B5]IF0XPVM9*-)$:^WKH0+BQ^+.1
M.<<HR@ZSD+CE&+4!1G7BLTO]P^^A2"0WIN5]HC5^8$6W?6#E11V=JRVEUV#$
M?E-M+,TI4IEM2R29EJ9$9D".3L1\H>?,ZJ',@Q+BABXIF75QW9$62Y_>M)2M
M2")1[C,B6GT2?J#6)YAOD_&S7BK-<SBTAU^781&<?M*"4XI39K)"U-J)PDH5
MM6;:TF1I)2329'\#,F(9B_DAY%9E21LEQGB1BSHI9N?+S&92R0YV7%-+V[E$
M?12%)]/4@7%I<&^0-=RY67I6M8K&<CQ99)O:^0YN;:;/>7=)Q:6S(DFTLG$J
M3J@RZ^H)8KE/D_RAR)<64?@7CLLAQZJ<-EVZLG#8;>46ID:24MA*-Q>Y*#<4
MO;H9I3KH!B;<.>19Y]D\[C?-\?=Q#DFN0M:ZQY1J9D);(E*[1K)*B423)>T]
MVY'N2HRUT%CRPKG^X=Y?M^'.3:>+C]XPA3M)/BNN+B3D(2;NI&Z1:=QK]X@_
M\%25:*Z 8Q, Y]S+E[,LMK..:" O#<>:>3"R"R=?;3+E[%)C(T;2>B77$FOT
MU2UU/W&23&-SP-SV]RI(R/&\JJF\;SO&9"T3Z<G#47RZ%=M3A;]#U;=(T.%Z
M%JD]?=T%C'XIYVO>7N1LCJ\9IHQ<98\XID\E<<<[TIS0T-$RDBVGW%)4Y]3>
MFNBE$!BXLBOJW%J"SR6X<-JJJ(KTZ8XDMRB9CH-Q6U/Q/0NA?$P1RY$\DN?L
MFHY7(&&<5QY'',?ONMRI$K=+=CQE*2XM"2<0I1IV*W=ME9$9&770&L36)Y!9
M7G7%E9GO$.&G?W;EBJLNZ%]XB5"4TR;BU$X1H):>K1I5H71?4B/4B)BNH/E-
MSS9Y=/P*!Q9&?R^K:^8GU*9+G=99_=^]1FHDZ?O6_P!;]8@7'2N$Y3D$W &,
MJY'J48K<--2I%O7&O>B*S&<<T6:M3Z&TA+A_E!E2G _EBKE[/Y6&6E*S3-OQ
MWY5$\AU:W'_EUZFTLE%IN[6Y>J>GL4"V)]RYGG,F)W$"'QM@*<MK)$8W9<Q3
MW:[3Y.*3V]-R?U2)7]H"E\1\I^>,\1/<Q'BV+;(JW2CSS8DN%VG3U/:>]2>O
M0_0%Q*^2?(SDK%.1:3C;%\)C7616U3&L?D5/N)>3(=;=<?:+31.C9-*ZZ_ $
MQFXWRUY+6.0U-?><1-UU++FQV+*P*3N./%==2EU[3>>NQ!FK3Z@$?Y0\NK?C
M?F*9QZ]01'\>KY->W*M%/.I?3'F,L/.KVD6TC03JMOY 7$Z\D>?Y/!U?CZZJ
MMCV]I>//DF/(<6A*8\5"#6LNWJ>IJ<01?V@DB-9-Y.Y!0\ 8GS$W00W;/(K!
M<!^L4\[V&D)5,(E)61;C,RC)Z'^T8&,1CFWREDL-R&.&&ULO(2XVLI1]4K+4
MCZN?$C R-KS'Y%9EQ%AF#7]EBL;[]R1#IW-3(?<1\F\PAI9MH4@E:_WAEJ?I
MI\0)$[RSF:%"X.D\S8>RU:Q"AL38<:0LVTF;KZ&'&W#1N,EMFI25$7ZR= ,0
MZPYFYHGX?A64X#QXSD2<CK?G[-*)"D-Q'C41);2:E),R,NO4#%?8KY3\\9N_
M:1L5XMBVC]*Z4>U;9DN$;#JC61)5O4GKJVKT^@%QUM0RK*=1UDVXB% MY,1A
MZ? )6\F)+C:5.M;OCL49IU^H&6P <X8=Y)7V2X?RMDLBBAQW^/.X4-AMYU2)
M1MD^9]PS+5/]T7V?I!<1;&/(_P B\SI(V1XOQ)'LJ.8;A1IK4I1(6;+BFEZ;
MUI/HM*D^GP!<=&<;7F79'B$*WSFB+&\E>4\4JH2ON$TE#JD-GNU/[2"2KU^(
M,H;SKS>7$<:CK*>G7D.;91).'0TZ%&A*UI4A!J6I)*/[3J$I01:J,_4M#,%D
M5D]Y,\K<=7E-'YVX^8Q_'+QWLLVU=()[L=2W*6277TJV$>JD;D*V]2(]- ,2
M;G+G[,^-N0,=P/#<8C9'/R&&F1%;=>6VZI];SC1-I).B=-$$>IF!(CC'E1GN
M(9-2TW-7'+F*U%X[V(]NR^;B&U;DI-9I,E)6E&])N$EPE)2>NA^AC&VY8\A^
M0</Y;8XJP;#XV2V4N$W,B(4\MM]PU-N.N$1%HG1*6U*]0,>^,<L^2EGDE177
M_$;=91RYL=BRL2E:G&BN.)2Z]IO/78@S5IIUT ;?F+R&=P7*('&V!X\YF')5
MBA+J:QI1I9C-K(U)-TTD9FHTD:]OM)*/<I1%IJ)$2I/)O/<7S:HPSGG"$8FF
M_6359;PW>Y&):E$@M_O>0I)*4DEJ2[JC4C4G0P,3J?S3;0_(JKX5151UU4^
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MWKH0+BQ^+.1.<<HR@ZSD+CE&+4!1G7BLTO\ </OH4@D-Z;E?:(U?F!%U@@
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M]0'9'CM_L.P/_5$?_P !@E4EX4__ !#S#_KB-_VLX%KKH&0!P)Q5_LI\F?\
MG2?^C,!IM?'VB\HIW%%+(XURC'ZW#E+F% AV+.^4A12W2=WF4-[U<W&GWGT
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M1EK] &&=<W5F#<E8CQM*J),R;ERFDQIS+C:66>\^;'O2KW'M,MQZ? #%I@@
M
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MA?<;7'^;U-2S-]_W;M?B0#OH&0
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MZ^T%J,\>\,91B?/N<\IV,N"[C^31W68,9A;JI:%./1W"-U*FDH(M&E:[5J^
M&G*/#&49MS3Q[R-52X+-)B:V56+$E;J92R;DF\KM)0TI)^T]"W+3U U+ZNCY
M:9Y>N;RSOXC_ !+(AI;IZ!!%\VS+)N.1K6?RZ3T-27C_ +]7VBZ?0%C @
M
M                                #Q^5B_-%-[#?SI-FR4G:GN]HU;C1
MOTUVZEKIZ:@/8
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                        &$[<
M5#%G'I'Y\=NYEMK>BUZW4)DNM-?;6AHSW*2GXF1:$ Q+O+,6QHVDY'>5]0I_
M^Y*PELQ37UT]O=6G7^P!LHLJ+.CMRX3[<F(\DELOLJ)QM:3]#2I)F1E^0![
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M]",]J=3 9P
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MYX_QK+UI)#]Q71Y4A">B4OK;+NI+ZB62B($2H
M
M                    '-7CA7-T6:<U\:6R-SK-Z=DEESH;U?;(<-M7UD;9
M(W?\X%J,8G2<\^-3MSA^(X<GD+ )TQV=0RV928\F,MU))-+R=%*]$HW%L).X
MC-*NID"_4IP_B3EO,>-N087+MZZQ>YYW%UE&;YR8=09F;K>TB4X24FYL(VVU
M&24)+KN,]"(*N#Y(3N)F_'E?'B&)*644[F8KG,_=WW8TLC)>TB/W;"))F2C5
MIUV;NA%2^]X:R>DSK@2+0PG;7'L$8<BW5L1MH0A6UK5Q2%+W$2U)4HB3KIZ
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M$']:5+-/]@)4[!
M                                                         1=>
M 8^>?-\DM)>CY,FO542%LN;&),0U]Q*7F]#)2D*ZI5T/X>A$ E
M                                     UE/CM%CYSU4E>Q!7:RW;*R4
MP@DJD3)!ZN/.'ZJ4K3U,!LP                   :V_H*;*:6;CV0PV["E
ML6C8F0WM=CC:OAJ1D9&1EJ2DF1D?4CU 4_2^)7#5)9PK!,*=/8K7OF8%7/G/
M2(#+I'N(R9,R(^O719F1_'4%U>0(
M (MFW'^/<@(J(^2I>?@4U@S;-04.;([\F-KVRD)T/N(29Z[#/0_CJ E(
M
M
M
M
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MV2_, ;$?LE^8 V(_9+\P!L1^R7Y@#8C]DOS &Q'[)?F -B/V2_, ;$?LE^8
MV(_9+\P!L1^R7Y@#8C]DOS &Q'[)?F -B/V2_, ;$?LE^8 V(_9+\P!L1^R7
MY@#8C]DOS &Q'[)?F -B/V2_, ;$?LE^8 V(_9+\P!L1^R7Y@#8C]DOS &Q'
M[)?F -B/V2_, ;$?LE^8 V(_9+\P!L1^R7Y@#8C]DOS &Q'[)?F -B/V2_,
M;$?LE^8 V(_9+\P!L1^R7Y@#8C]DOS &Q'[)?F -B/V2_, ;$?LE^8 V(_9+
M\P!L1^R7Y@#8C]DOS &Q'[)?F -B/V2_, ;$?LE^8 V(_9+\P!L1^R7Y@#8C
M]DOS &Q'[)?F -B/V2_, ;$?LE^8 V(_9+\P!L1^R7Y@#8C]DOS &Q'[)?F
M-B/V2_, ;$?LE^8 V(_9+\P!L1^R7Y@'T
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MJKB.F2PEPB)Q!GJE;:R(S+<A1*0K0S+4NA@C?@
M
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MK)-H_(:8-VOC*>?>DK8=D),TI<1N-&A:D9EZ]2U)5W @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                 TN8+6WB-^XTM3;B*Z8I#B#-*DJ)
MA9D9&74C+Z0'*OB=R8UBO!67YSGEE.FUE1=DAY]:G9KZ&W68;2$H2I1GIO=+
M73H74P:JQ;#S*X-KU5^EE,EM3FVW77HL-;B(O=+4D/F9D9+(OM(02C($QE7_
M )><'X_<-5*[EZQ;5L)ZTK8ZI4!DW$DHB4ZD_<9$>JB;)>GH?4C(#$VSSF;
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M&!C6X-Y6</Y[D$?&:Z?*K[6<HFZY-I'.,W*<4>B4M.$I:=RCZ))9I-1]"Z]
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MW-C*L7F[5M#;DQ]R0I*?EDGH1N*5H6H+75X,@
M                                   T>:?_  =D/^K)O^;K <"\9_\
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M^ #(\C*B_I?%[B^J?M8MY7U\MMB5:53JY$%Y"&'TPU-N*2DU(2UJ@C-)=?[
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MK?:D1_J_XZ1:%^;4#JVIRN.E^#Z#9^2^[TT+))^QN+(=$DKTZ]_YG=K\=/\
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M0D[B/;IT K??_)_?_ F6?ZW;_P V0!77H,@
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M:$ G8(
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MHJI#9LN&3+JV5:H5U+W-JT^DNH"0@
M
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M;-<K)YQB-#+JFVVW4NI09JV[DND2BU^T1Z:%T!+%R CCCSN_]+XM_P!83O\
MI0@:BQN8^6\TPOFGC+!Z%Z,W0Y3)CLVR'F"==4AR8AE>Q>XMNJ#T+Z#Z@CX\
MA.7LSXYSOC/'\9=CMUV4SE1K4GV">6;928C7L49EM]KR@(T7+/.'*F*\^5/&
M6#PH-JQ;U[*H==,3VR.9))]).NOI/<336PG5I3U-*3(M-=0,8-%R[SC@7.E#
MQ9RZ_57-?E"$KAS*MKM$UW^XALVU;&U&1.MFA:7$:Z=2/TU+CWR#F7ESD?E:
M_P"-^%)%31U>)&MJXR"Y(G"=DM+[2T$1H<(D]PE-I)+9F>TU&HNA F)CX_\
M,^39Q;9/QWR+#C1.0<0=VRWH/_HTIC>;9N)+51$:5;=3(]%$I)D1=2 L6KGF
M&UW(.(VF&6TF5$K;=I+$I^ XEF039+2LR2I25EHK;M41I/5)F0(Y2\C*CB;B
M/A:)PQ1P&K/,[);)TY&RT[:DKYHG%S'G&D)5N7[F4::&O7:DMJ5:&HOCC?B>
MH3Q1A.-\DT4"\N*2N0V;=I&9FG%6^1+6R@W4K(MA;6SV]#V%\- 10O&^%8;S
M9SY<954X[65O%7'CA0JF)7PV(S%E9)6K:\]VD))U.J5.]?U2:29=5:E=H@R
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M #^2"5<P(
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MBK08^Y87^8X]Q:Y@=0ZA4"GMID^<_*GQ%NDX:3CRUK2G;VT*6X@]N[VI,]%
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M9_'Y%CWR74RE&MYGY>0XP6XU-M&>XD;R]A=#!E+P
M
M                                       <SV7 ?-&,9A;Y#Q!R6==4
M7+CKSE-=I<F,QU/K-Q26TN)D-F23/]VKMI42?:9GU,RZEO!?!$OBZQR'+LIO
MCR7/,H7OL[$F^TRA&]3JDH(^IFM9[E&>A=$DE):=1:NL$
M                                                           !
M$97'U;8<@P>0K.9*F3:>*Y%HJUQ22A07))&B1(;0E)*-UU&C9J4H]$^GU!+@
M
M
M
M
M
M
M
M
M
M
M
M
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MH0#];=;>;2ZRM+C2RU0M!DI)D?Q(R]0'T \VY$=Y2D,NH<4CHM*%$HR_+IZ
M/E^7%C=9+[;):&?[Q:4="]3ZF0#V(R,B,CU(^I&0#P7.A-J-#DEI*T]%)4M)
M&1_61F ^VGV'R,V'4.D70S0HE:'_ & /0                !\N.-M(-QU9
M(;3]I2C(B+\IF (<0Z@G&U$M"NJ5),C(_P AD ^@
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MED= >,7^P7!_\A5_V[H)5M @
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M+(F.6$6SLZV6S]Z2(3B'TH1(FQU,-J<;,RU+:XK;KT)6OZP$=T RXEX<NJ+
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MZ>-\FF);24IV\-EUW3W*;9B,*0DS^A)N+,ORF!6JXZOJ>C\T^3'[RSC5K4F
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MVDGN;[*&UI69D1?J_K%J)]7)XQ_[!<'_ ,A5_P!NZ"5;0(
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MREQ*DAXYCL1,"EKT&U#B(-2DMH-1J,B-9J4?4S/J8(V@
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M$20A3BFTK84EQ2U),TZEO0GH"XM $
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M10;#/)D:N?PV2EIEEJ)6J;BF3#O<8)"EI:)WJM"M3,O=]!%P<?,Y@QA=,SR
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M/<?B8IS#R[C%<IQR!2/%6,.O&1N*1$FOLI4O0B+<HD:GT!:[/!D
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M,@
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MKQ+"BBS8[UI 1%2E4B(VZE3S1'\NG0UH(TZZEZ@>.C@0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
*          '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>px_24protalixproxy02-bwlr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 px_24protalixproxy02-bwlr.jpg
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M_\0 NP !  (" P$!              8'! 4" P@!"0$! 0$!
M      $" Q    8! P(" P<,"PP&!0(7  $" P0%!A$2!R$3,11!(@A1,I05
M%E8789'10E(CD].TU)57<8'2,U-4574W&#BQ8G*2<\,D-+5VAG>A0[,E-9:"
MLG3D-@D9HH-E)L'AXF.CQ"=G1(2%1RC"9*2E1CD1 0$! 0$! 0$
M   1 4$A,0(2_]H # ,!  (1 Q$ /P#W\
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M    #!N+JFQVN>M\@L8M54Q]OF)\]YN-';[BB0G>XZI*4[E*)):GU,] $5^F
M?A[]8.-?IF!^. A],_#WZP<:_3,#\<!$T8?9DLMR8SB7H[R4N,O-J):%H66J
M5)46I&1D>I&0#L
M
M                                 !5G-?(^48 WB43$*^#87.5W;%"P
MFT6ZW';7)0HT*4IGUB+<1:]#Z>@%Q +'VA,]Q:+R#39=C]2G-<,JXUW&562G
MI%9(CR'T,FAS<276UIWD9)/0U>X1:&8BS+?G#C;$SIX.99!&J;JUAQYIQ#2\
MZEEN022);RVT+2RV:U;26\:2^J!'?EO-O%N"VC5+E&1LP[)UE$DV4-2)1-L.
MJ)*''EQVG$M(49EHITTD>H$,GYMXNPZ>U6Y!D34>4XRU*/LLR);;4>2>C3C[
ML9IQ#*%_:J=4DC+J70".>5<T<7X3/@UF39+&A3+!E$J,@DNOI*,ZK:A]Q;"'
M$M-*/HEQPTI/W0(E%UD=)CM%*R>XFHC4,)@Y4F=ZSC:6"+7>7;)1J+0^FTC!
M%>N>TKP>VW,<5F$8_))0MQ"&92W'4.:Z+CH2R:GTEH>Y3!+).A[C+0%C;7W-
M_%>-55/=6V2,IK\@95)IU1FI$QV0PA.Y;B6HS;CA)27OE*21)]/@!'"\YTXE
MQRJJ[NXRF+'K+J*Y.J9"4O/%)8:4E*S;)IM1FHC41;--VNO3H>@C15_.M5$R
M7.J_,W(U/0XW/JJVEF))]R1.=MHIR4MDRE*UJ<TTT0VG7374N@$6)D>88YB+
M%?*R2<FNCVDQFL@N/(6:5S)6O:;,TI/8:MI]5Z%[I@C#E\C8/7S[^LG7<>-+
MQ:.S,R$G34A$)B4G>R;KAI)!&LNJ4[MQ^YU :2@YSXHR>GN+ZDR9B16T#)RK
M=2FI#+K$<BW=TV76T.F@R\%)09'Z 6-R[R1A#$BJBNW#27[NN=NZI&UP^_7,
M-$\MY)DC0B)![M%:']0$=&$<J\?\D/SH^$7;=RY6(8<G*8:?2AM,LE*;+>XV
ME)J,DJU21F:=-%$1@.+W+/'<;'[S*9%ZRU18U-<JKR4M#Q'%G,N(:4RMO9O-
M1+6DBVI/77H P,@YSXGQ7(F\4R#)XT"^7V^Y&<0\:6#?(E-E(=2V;;!J)1&1
M/+3T,%C6-<ZXPOF.?Q&Z:8\BOKCFN6+QN)0J2E'F%LZ&WL2EN.1NJ=6X23\"
MZ@1NL4YGXOS9ZQ8QK)(TMVJ87,FDXEV*28C1FE<A)R$-DXRDRT4ZWN07N@D?
M<0YCXVSNV71XM>)F6R6/-HBN1Y,13T8E;>\P<EIHGF]?MVC40$<[G-I%5R/3
MXDM^M;JIU9,LI*'G'BL]8A^^9;2@VS;(O?;E:^X"M?C_ #UQ%E-Y7XY093&F
MV]JA2Z]E+;Z$.F@MRD)=6VEON$74VC5O_O>I 1T<Q<K?14K$),A$4J>\NFJR
MWF3%+046&IM;CCR-GBI)(Z$9'KX 8TV6^T#C[>"LYGQS)BY W\=P:.8S(2_&
M6PJ6Z3:R<:<2VZA9$>J26DOVP(GDGDK!HB<G5(N&D)PTFSR;5#I^3)Y!N(W$
M2#W;DEJ6S<"-3D/./%&*RJV'?Y/&AR+:,S.AD:'G$E$DF1-//*;;4EEM9J(B
M6\:"!8G,B="B07;.5):8KF&E2'I;BTH90RA.]3BEF>TDDDM35KIH"(+BW./%
M.:/6$?&LFCS9%6PY,EM&V^PORK'[X\V3S:#=;3Z5M;B!8V.$<J\?\D/SH^$7
M;=RY6(8<G*8:?2AM,LE*;+>XVE)J,DJU21F:=-%$1@BO:+VE</:R?*\9SZQA
M4$NGR"11U1$4A9.QFMI-OR7"0IMDEJ,TDI:DIU(_<!8D47EMMCD7D#&<B\I6
M8OA,"ML3N''%)4:)[)N+[N[U2))EHDD]3^J9@-IC'-7%^80[6?19&PY%I&"F
M6JI3;\ V(II-9/J3+;95VS(M=Y%M^J!$6O?:,P>3@>69/QW:Q;VZQF%Y]59(
M;DQ5+:-:4DYL>0TXMH]Q??&R-/4NO4")QBG(6/Y--/'V):%Y;"@0Y]W6,H=4
MF'YUI+B$+<-.PE'N]5!JW:== 1JK+DIBASN\I;V=5Q,8I* KZ6O?(7:-$3VQ
M;CC26S1V"3Z4J->[3IU!2DYNXTRR;84V(Y#&M+V%"<L$Q4I>;0ZRVG7<TXXA
M*'4D?17:4K;UU\# C5\4\V5&<X]B/QZ['@9SE4.18,T,1+SQIC1WW6NZ9[5=
MMLR;Z*=41&?1)F!$GSGE+ ^-RAEF5PFO>L.YY*,AE^7(=2R6YQ268S;KFU)>
M^5MT+W01@VW-7&%-34]_,R%IRLOT..TRH;,B<[);8_?5(9BM.N[6_!PS1ZI]
M%:&"Q*L>R.CRREB9'CD]JRI)R#<B36%:MK2E1I5XZ&1I4DTJ(^I&1D?4$13'
M^;.+LIR!G&*'(FI=Q*-Y,%'9D-L2SC:]THLAQI++^S:>[LN*\ 6(7QC[2V'Y
M8Q#K,LLH5-F-A92JV)5LE(4T:F9!LLH4\I!MH==(B-*%K(U:^J74")E<\X<4
M8]E2<+N<HBQ,C-:&7(RR=-IIUTM4(>?2@V6E*+P2ZXDP(S+'EWCBH@6MG:9
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MFJ#^3(!&_
M
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M]QU"3(E&730!Z+Q:!)JL8I:R8DDS(4"+&D)29*(G&64H41&7CU($;8
M
M
M                            8-M2TU]%*!>UT:S@DM+I1IK+<EKN-GJE
M6QQ*BW$?@>G0!F(0AI"6VTDAM!$E"$D1)))%H1$1>!$ Y
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MX7$SG%L5R7)JIQR4S9QZUV3YNL=@I);R)K3LQ';4DC]!G[I=#+4-0SR]QZ>
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M?^+R/ATW\> Q*6MC4F:3:VN4\B"Y5QY"F'9#TA'=\P\C>1/+7H>A:'IX@)B
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M>%<3X7C>94,QAVYLI\.F\K%?4\PVJ2\^MVS2X2.P1N&LD&6I&C:?N@:]* @
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M'&:2L)M4IQEM3RR)YU#*=$)ZGZRT@B&8S[0G&^3W\#&6'K"MM[;<54W;5TJ
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MROYFC?E3X"3             (UR#_P#!UK_DT_\ :) 24
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MZ:>OMW:=-0198(
M    ",M?T@ROYFC?E3X"3             -/E55)O,>L*J$XVU+DM;6%O$HV
MB6DR46_;UT,RZZ ,'N\@_P 5IOA,K\0 =WD'^*TWPF5^( .[R#_%:;X3*_$
M'=Y!_BM-\)E?B #N\@_Q6F^$ROQ !W>0?XK3?"97X@ [O(/\5IOA,K\0 =WD
M'^*TWPF5^( .[R#_ !6F^$ROQ !W>0?XK3?"97X@ [O(/\5IOA,K\0 =WD'^
M*TWPF5^( .[R#_%:;X3*_$ '=Y!_BM-\)E?B #N\@_Q6F^$ROQ !W>0?XK3?
M"97X@ [O(/\ %:;X3*_$ '=Y!_BM-\)E?B #N\@_Q6F^$ROQ !W>0?XK3?"9
M7X@ [O(/\5IOA,K\0 =WD'^*TWPF5^( .[R#_%:;X3*_$ '=Y!_BM-\)E?B
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M$ '=Y!_BM-\)E?B #N\@_P 5IOA,K\0 =WD'^*TWPF5^( .[R#_%:;X3*_$
M'=Y!_BM-\)E?B #N\@_Q6F^$ROQ !W>0?XK3?"97X@ [O(/\5IOA,K\0 =WD
M'^*TWPF5^( .[R#_ !6F^$ROQ !W>0?XK3?"97X@ [O(/\5IOA,K\0 =WD'^
M*TWPF5^( ?::KR'Y02KV]\DWW(;,)AB"IUS][=<=4I:G4H^[(B(B 24
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MA6,9J9#=T[D>0VEUI6AZEJE9&1]2 =R$(:0EMM)(;01)0A)$2221:$1$7@1
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MU$FP8\F(PI*V&'FD.-H6W[U24J(R(T^@R\ &6I*5I-"R)2%$9*29:D9'XD9
M,6+55<!Q3L&%'C.J+:I;+2&U&G770S21'H ^G6UQSRM3AL'9I1V2F]M'?)HS
MUV=S3=M^IJ UJW<2/)G*A:81Y9,@^<>CFVV<QZO9=2UO4>FY3:7#2GJ>A'H
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MU[R>YZQ$O[G: NX$
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M,DK+Z99R\QE(:36-D_)D/IMV)9FXIV2IMY*4LFE*]QFE6U"=0$7XXP+,(,K
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MBB@4_<23;BH,9IA2T$HU$E2D)(U$1F9EJ8#>@
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M,2TFZAM9F25*1KJ1&9'H9D [P
M & JEJ57+>1*AM'>-15P&Y^W[\F(ZXEU;1*^Y-:$J,O=(!G@ #X9$HC29:D?
M0R^H T^,8ICF%U+=%BU:S5U+:UNIC,$9$;CI[EK49F:E*,_%2C,P&Y
M                 !@)I:E-RYD28;17CL5$!R?M^_*B-.*=0T:ON26M2B+W
M3 9X
M
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M((GP(
M
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MW4LNK<6TXA;*VW4FM1:Z&D]#Z!88(
M       #I1$BMR79C;#:9;Z4(>D$DB<6AO78E2M-3).Y6A>C4_= =P
M
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M,M="W=%:=2+W01]
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M)E^+.N/TDU3J([CS:F5F;#BFEZH5U+123!$D
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ML<ZQ:+(LSK,QB3OBF@O&X!7,*"M== @28L13*YD@E::J=><UVD9I3H:B(M#
MB2Y1S+C.*6%C$G5UQ)KZ132;^[A5SS];7F\A#GWY[INV-N(<<[*7-B5$:M (
MQ\DYSP[&+FYIYD.WEGC2HWRDG0*]V3#KF9C*'VWGW4_:;%[E;"4HB(S,M" B
MRD+0XA+C:B4A9$I*B/4C(^I&1@CD
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M%D/R,6L:B142F)4<VS459*[K\>?&22EDI9+WZ$E?@9D07B"
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M$>GU@1D
M           K3VA6W'>$LZ::0IQQ=2^24((U*,S(O BZ@N*BXZ]JGC;%^/\
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M9)4HB)S[8+#\G@')&8S2WGE/5VUMM)K4>D]@SZ%J?@!C3UWM?<5Q*^)%<@Y
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MV36W&^!,7)UE<=:G+-?8<)1*02[.4HB/<1'X'X^D$U=((
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MI<1Y5]"&W#0I)IW*,TNH-.PCW;BVZ@)(DR4DE%KH9:]2T/K]0P'T
M
M
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M;XK2R7']HBGDYLTIU2W%S,3)2H!))U1FXE]780[J1GM8+4_="\P0
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M*)2<WX(Y+F9I7UUQEF&IR+'F\A5"92I]582B1)92HEFPI6J=Z6UZ)=2K;Z-
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M+P*BQ?C<H;TN)4TK:)&0(-"8ARHQMMJ:VJ5W"4X:EN(]70DEH9Z@B<
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M]/M"QV=9)O;#$DR4_$TBR2X3YNN-&V;FU3R2>6T3I-*7ZQH\06L\^),5."]
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MJ7#5MV.&6J-3 ;V9D>/5U:S<V%M"B4\C9V+!^2TU&<[I;D;'5*))[BZIT/J
MV#3K3[2'F5I<9<22VW$&2DJ2HM2,C+H9&0"#<H<J4_%4.DL+N(_(@W%FS5N/
M1]ND5#J5+5(<)1_O;:4&:M.H#GG7*%-@E]B&.38[TNRS&Q360T,&DB9(S2E3
MSFXR]1*G$)T+J>O0%=_(^?'@%;4RF:B1>6-W:1Z2MKHKK+"URI:7%HU<?4A"
M4_>SU,S!&#B_)K]ID:,.RW&9^'Y/)C.3JR-/<BRHTZ-'4E+WEY,1UUM3C6])
MN-'HHDJ)6AEX%6 "/AD2B-*B(TF6AD?4C(P!*4H224D24I+1*2Z$1%Z" ?0
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M:9S)OJRS90^5.J,J'?Q(,ZMA3V925F9(8GEW$.LJ;-+I$M:>J3(^NA#5G @
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M#JDH3O<<7LVZDDB/4!:]%;MW]1#N68LJ$W,;)U,2Q87$EMD9Z;767")2%=/
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MR2AG0E&VE.NFOI!<6AS/QU/Y/Q&/CE=-9@/LV4*Q4])0IU!HAN=PT;4F1ZJ
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M3\>JX%'=IL,DCKLHT=Z*TA<:J)9-MSI7WXR;8=49=OQ6?I00+%D@@
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M^<SWZ-L/Q $5KG'-?''+'+G#$?!K5=@]5W[CDU*XLB-L2^EI*#U?;01ZFD_
M%B_^9[Z?4XG%JJF4N#;Y9:UV,0[!KHY&.VD):=?0?31;;/=4@_0LB,$Q%+SE
MZVQG/OH]K:VLCQ:[R$6#"N[!VOL;=B0EM*G:UZ0WY=WL[MAH6^;CBT*+U3TU
M$:>_]IN+49!=(89K7*''+1=).JW9;J<DEN1W4,29$.*AI39MM+6K8A;FYTD*
M,MOJZB&0>TY%I[^Z2RS6.4&.6:Z:=6.3'"R.8IAU#,B3#BH:4T;;2EJV(6YN
M=2A1EM]7419_*=PS2XY EO,OOH>NZ2(28LMR"LE2[*.RE1N-$9J2DUZJ;\'"
M]4^A@B%)YDS YDFW<QV S@M?EB\+ER%SG#LG%G8IKD3&VB8[9-DXM.YM2]QD
M1F6A::ECLI>9KVYY#EX>B!41NQ82JU5++GN0\@:9CDYV[#R\AEMN1'>[9+),
M9:U);6E6JM%$01+CWE;E$\(PN$N%7W^:9E;Y%$A2YTU]B.VS5/2'#6^I$=:M
M$=I;2$-I]X2.I&9D03EOF.Q^1EYDSM,R4VERPL15$1(4;;FEJQ6*?)9MD9=7
M362=OHTU C(A<B9WD%W9RL5QF+.PJDNG,=G*>F&Q;R'8KR6)<J.VI'9)IA9J
M]1QTEN$A1IT]4C"#X3G61.,4LK.G2F/O9QD4&+,@SY+3#$6MCV+KANMFA/=:
M;*.I#+2BTV[5GHLM $IHN7,M>^2.19+CT.OP7/9+$2@=CRW)%G%7/:6]!5-;
M[1-:2$I+7M+/M*41*W=3(,3#.9\POTX7?7>.P*_#\XE/55:J/.<?L69;34EY
MMQUM3"&S:=**LB2E>Y&I:Z^ $=_%W,UWGV1'53(%5$;4B0N74M3G&[^G<CJ(
MDM3X,MIE:S7NT-Q@C2E73J1DH"/N7VF?,\XP*W"?+RE.8E(??@VLJ1'K&U)L
MF2)Y2&&W34ZHB[23)/0C,]="VF&ELO:48=@XVW6L5M#=W4.9/G_*F8N/"A'6
MS55ST9+D9MQ3SJI"'$H-))+8@UG]R!&L3S:AZ[K>3I:)47'6,'OI\R@:?-UI
MR?77$2&7;TT0O>LS2R\:"U0LCT3J9 1(\BY>Y#P./)1F>,UGQH]4S,@J&*V>
MZXVIBG4R[8Q'ENL)T?:CNFZVM);'#2:?5 CMON?VZBWSBJBTQSBQZ'#=QM]I
MW5%O.EK885'29),D]M^9%;49:GZ^NG@!$AJ["RI.99N,/NK=JLFHDY RTIQ3
MC<6QK7VX4M+)*+5+;J'HZ]OAN2I7BHP%E @             K_F"IM;'&ZZP
MJ8;MHYCUS6WTJFC$E3\Z+7/DZZRTE1I2IPB^^M(,_66A*?$P7$-S[D/%>4\1
ML./L$[M]E&0(1#3$\I)8*LW.)-4R<IYI'ERC:=PB7HLUI2E!&HP%XI(R21&>
MID6FI^D$>8<5S.!QGQK'XMR/+?D%G^.RI29$N96.6)6##LQYY,B&@TZ2"DDZ
ME?WLS6E>J33J"M&XSR#/J,5:N(LJIG\M51XG=,PHGD4P3B6BG6I:H^IDRIRL
M>D^KX[B3KIUT*PWDYS?X-D-^]&E1'<832<>VJG#G+4JNIIF^]E]N(HGG&GR6
MT3JF/OAM-K(C\0'%,-$K$<UC8_9PG\<ES,3COP\/CV4*H:E.7,=+[D20\\LB
M?5'4E,E,70DD2#5Z^H"Z^-\=K<0Y6S['L<AG6XS\74$YF T;GE"F/^>;?=;2
MHS2E:TM-=S9[[0C/J"(OFE-F?*/)N0,8[$JI&+8Q4/8H^5\<IMEV9?MI=L%Q
MEQ"W;D1R8949Z:&I6A@)=P_G7_UITF)YB^MK.:R;*Q"6E;3ZBE6%(R;BG4N*
M1H:7HR$2"<5H2MVA=>@&NOG2AAY0Y@./6<=4BJM,A=A3T((S-+,FELVC7J1'
MH:342DGZ%: 8IMR3D>7?(^_R6#)*TQ/)L0PM:WTFHSM8%B3ES,;T+][>-,=)
M.>!DE1 K!-BX<S665O:U]=R:>7*7%<\C;2\H3'3./RR&-KR6%5RX1$E6B.P3
M2E;OOA& S]MA'NOO#<EML[/EIPTM)=)L]5$IHU$DM#U_ZO7_ -$!EP\:L,7K
M>-K'CN+)AYMD^!7:Y\E!NJ>FVK=1$D1#E*>,TFM,A9FWW--I^J7J] 1W5ZL3
M+#Y+7"C5J?+!XC-.W=A^8)Q$PD(WE:;S)1V)O=WRO0W.YN\$: K N(''=FEZ
M%P['7*QQ>'7JL]8;3*4THFHJ7*SSI/=#L"DI69:_?]-^_IH DG$^#XY6\H8;
M-BTB(SS?'$&P[_;<3MGO2$MN*,U="<-"U$9'UT,$>F00
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MK]\M2EF>NNW0J89)B$?)+?%[=Z2XPYC%@NS8:0E)I>6Y$?B;%F?4BT?-73W
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MY:MLWLF%Q:RJJF\=H$+4DSD>8=3-FR=I=4I-2&&4:]?O:S\#(!/@0
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M&3DIJ[:!,JI+D=)[3<:1,::[B2/WW;UV^G3H FH
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M=U*D))*E;T$7K=/2"-V
M
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M@)7B5?E=)8M8],6Q(Q&JI*V+#E);-IY=BR2VG_MU;D&A#:O MIGIZP(F8
M
M
M #H9A0X[STEB.TU(D&1OO(0E*W#+P-2B+4_VP':M"'$*;<22VUD:5H46I&1]
M#(R/Q(P'Q+32&B82A*64IV);(B)))(M-"+PTT] #J1!@H95'1&:3'61)6TE"
M20I*2))$:2+0R(BT_8 =;M35/RRL'H,=R>31QRE+:0I[LJ\6]YENVGKU3KH
MR&V&634;+:6S7IO-"23KM(DEKIXZ$1$0#'C5-7#3)1$@QV$3%*<EI::0@GEK
M+12G"21;C/TFH!D$PR2T.$VDG&TFAM6TM4I/34B/T%T+H ZIU=7VD<XEG$9F
MQ5&2C8DMI>;,R\#VK(RZ /KL""]".M>BM.5RD$R<1;:5,FV1:$@T&6W;IZ-
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MRCU,]"])F>I@.8
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M/=
M
M                                                        %9>T
M3_0=GG\T2/[A N-KPP6G$& _[NU/Y$T":B_M3?T YM_[*Q^5L N)]@'_ ,"8
MO_-$#\F;!'DG+<7B97[1'*C5AQO+Y(1"31FPU&MSJ$U_=KD;M=7F=_>V]--=
MNT_=!I,7<,Q_.N::[B+*H;\/CS$L0BV--A1RWB9<E.NH;4MYQ#F]_L$?;ZK/
MJG773=N(KGE&/\A<9YVXNQJ;(5@]-&QFRJH3K[D@JN1-GQN[&:<6I2R0X1[B
M0I70B_PC,K=<=8Y7L<Z8S2X5B,OBVVI65V>3P[.X>EN6]8\V:&T,,FXZV\1*
MW;EI,B3X^*>@6W[9']GS)O\ +5OY>P"8NFC_ /!:W_V5C_LT@BC/;+_H9/\
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MX FKJ!
M
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MQ6@"1@
M
M
M
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MA%@N&TP:5,MD:'VD]]IS4MQ$?JZ%J M $
M
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MA*8JU-F3A1T-J6I*2+57JI\=P(]0 @
M
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M2W.TKHO0BZD>W=Z2QZ'BRH\Z*Q-ANI>B26T/,/(/5*VW$DI*B/TD9'J0([@
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M2]#+7]@!]A\KX-\54DV]O:VDL+N+"E-U<R:PB0VJQ:2ZV@R4I)GKNVDK:1&
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MZEIXD R8.:8A95T&V@7L"366<@H-=+:DM*:?EJW$3#:B5HIWU5?>R];H?3H
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MN;/9K]L70&J]55T"+55\2K@M]J#"9;C1FM3/:TRDD(3J?4]"(@99(
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MB4Q O'JRSJ[CMH.$\TQ6QH;K9.)49DZEUM1FA22Z>L LX$
M                                          ?%(0O3>DE:&2BU+70R
M\# ?0
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MXAQ33FFIH623/:HO<,!PC7%3,;D.Q)\:0U$4IN6MIY"TLK3[Y+AI,R29>DC
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MM&T$ZN$3J#?2V?@LV]=Q)/W= '84N*:$ND^V;:U]I"R6G:IS4T[2/7J>I::
M.+4^"_(5$9E,N2D))Q;"'$J<2@S-)*-)'J1:D9:@,@
M
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MCUA?.4;=?E5I<7IV$]V/VIK['QQ*[!+6HB7V^VE!H3[W3UB\=035M @
M
M                                                          "-
M8A%I74V.3T\"96+R*0<BPB3V7X;BI44O)F\<9\DFVIQ#*/6))=Q))5U\0$E
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M0:&]G2(%2U-E.0[B7CTUUN(\;,>= 8)]WNN;=J&]#)*7%>JI9DDNI@)4
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M27(KQ:*ZZ$XTLB/T@-P
M
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M3IM27I]T$U<0(
M
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M([:?,&G8;NTM^S77;N\=-?0 YD1%T(M"
M
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MM/Q+7T'H#+Z
M
M
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MK4V:C4:CW:ZZZ]0$AEP(,\F2G1FI)1G428_>;2YVWVNJ'$;B/:M/VJBZD R
M
M
M
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M=G,. Y6Q[!<A"8;RTNK3Y9];!F:DD1'J:-? $3<
M
M
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M(LE2D%!6Z4A3?E)3L;JX24$>[M;O>]-= 1-0
M
M
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MF1$:5D9?4,#5L@@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M$JIF.2V\C\U\6.-1I)HW0"UD(?5V](ZT&1I-#^Q6XC3IN(R!$G
M
M
M
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MC^?-%^DHWXP"'TS\1_/FB_24;\8!#Z9^(_GS1?I*-^, A],_$?SYHOTE&_&
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M;:E$1F7N@-R
M
M                 /AD2B-*BU(^AD?@9 .KR<3^ ;_Q$_8 /)Q/X!O_ !$_
M8 /)Q/X!O_$3]@ \G$_@&_\ $3]@ \G$_@&_\1/V #R<3^ ;_P 1/V #R<3^
M ;_Q$_8 /)Q/X!O_ !$_8 /)Q/X!O_$3]@ \G$_@&_\ $3]@ \G$_@&_\1/V
M #R<3^ ;_P 1/V #R<3^ ;_Q$_8 /)Q/X!O_ !$_8 /)Q/X!O_$3]@ \G$_@
M&_\ $3]@ \G$_@&_\1/V #R<3^ ;_P 1/V #R<3^ ;_Q$_8 /)Q/X!O_ !$_
M8 /)Q/X!O_$3]@ \G$_@&_\ $3]@ \G$_@&_\1/V #R<3^ ;_P 1/V #R<3^
M ;_Q$_8 /)Q/X!O_ !$_8 /)Q/X!O_$3]@ \G$_@&_\ $3]@ \G$_@&_\1/V
M #R<3^ ;_P 1/V #R<3^ ;_Q$_8 /)Q/X!O_ !$_8 /)Q/X!O_$3]@ \G$_@
M&_\ $3]@ \G$_@&_\1/V #R<3^ ;_P 1/V #R<3^ ;_Q$_8 /)Q/X!O_ !$_
M8 /)Q/X!O_$3]@ \G$_@&_\ $3]@ \G$_@&_\1/V #R<3^ ;_P 1/V #R<3^
M ;_Q$_8 /)Q/X!O_ !$_8 /)Q/X!O_$3]@ \G$_@&_\ $3]@ \G$_@&_\1/V
M #R<3^ ;_P 1/V #R<3^ ;_Q$_8 /)Q/X!O_ !$_8 /)Q/X!O_$3]@ \G$_@
M&_\ $3]@ \G$_@&_\1/V #R<3^ ;_P 1/V #R<3^ ;_Q$_8 /)Q/X!O_ !$_
M8 /)Q/X!O_$3]@ \G$_@&_\ $3]@ \G$_@&_\1/V #R<3^ ;_P 1/V #R<3^
M ;_Q$_8 /)Q/X!O_ !$_8 /)Q/X!O_$3]@!S;:::(R:0E!'XDDB+^X Y@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M
M
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MX731:#5M5]4@1L@
M
M
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MLEHVKV'MW:::!.(,*+6PHU=!:)B%$:1'C,IUVH::22$)+7T$1$0([P
M
M
M
M
M
M
M
M
M
M
M
M
M
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M9N'JA1^JGMM&:?5+T^D$;4
M
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MAVK.11)=7&;;)#A8W?STUR(KAFI6]3L5]I]1]"[B4GH6T@'H $
M
M
M                                                       $;S'!
M<=SJ'&BWK3R7X#WFJRQA/NPIT.0233W(\AA2'$*T/0]#T,O$C :&)POA+%39
MU<M,^T<N7H4BUM+.?)F6,A57(3)BI5(<6:R0TM!&EM.B?'IU,%JN<AX4R7(\
MHE-/5=?7TTO(&+]ZY@6M@TPIN-);?[GQ,>YCXP=0V3+LC?L5JIS;O/0"K8=X
MQQ!ZHN*-<5WXNOK8LALD$^Z2EV*9#,HG$JW:I+N,-GM3TZ:>D$::SX,P2WD6
M*YOQDJOLYAVKM.BREMUS=FMTGU2VF$N$E+JG/7/[7<9GMU,%K(L^&<(M'+YU
MYN8R>038MQ(*--?8*-;0M":GP]BB\O(]5.]QO3?M(E:D!7V!PQ@M>:'$,2Y$
MI-K#R%V7+FR9+[UK7MFTU(=6XM1J,TGZR?>G[@#EDO#V&95:S;6P3.CJMT-M
M9!#@3I,*):ML)V-IFLLK2EW:CU->AFCU5&:>@%;?.\+A9MA%MA:U%#8GQ>S$
M?;3IY9]DTN1G4I29?O3J$+(O[T$8+."P;^',LLQA(3DV14#6.Y,F(^[Y=<<B
M>-Q#)ZI-)&J0Z:5Z$K0RU\ &ZFXE23\1>P:2RI6.2*\Z=V.3BR6<-3/ES3W"
M/=KLZ;M=0&-)P/%YD]BQFPBDNQZF1CI-/*4XPNLF&TIYEQM1FE9*[*-347A^
MR C<+@[!(C$V*\5C8Q959*H(K-C8RIB(%5.;)IZ-#[KBNRE24I3N+U]$D6[0
MM 6N=SPA@5V9D^S-BL/U[-/:QX,Z3$:LH,1HVF&YJ65I[W:2HR0I7K:=#,T]
M *ZN5L(N<DXT/CG$&6$LSRB5CTN:^I!0Z]A2%*>(B0M3RR2V24HU3J9ZFKIU
M#+R+AS"LGN)EO8HFMIM>R=]619LB-7V9QB)+1S([:R0[M2DD^C<DB2K<GH!6
M?*XRP^9:JNGXCASU7$3(S63SB4_&-=#*"PLDDHBVI9+;L]Z?CIJ".B]XGPW(
M6KI,UB0U(O9\.XE3(LIZ/):L:UMIJ-(CN(41M+;2RC0T?_9 1?D#B$KG$K'C
M_%X,=JDS.W5:9;9S9+JGHRG7V9#[\9HT+WNN=K:A.]"4*,E=2U(%J3YAADG)
M9>(T\=+47#Z2P9M[)I"C0MQ541*@16VR29=OO['5ZGX-$G[;H1.
M
M
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M&R
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MCBDM<ERKX\:H418%=RA?V-K$2MAYN)_W"49+BE-J4VMSS)IW&T:MKNO75)F
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M3]T]I!O\YXZRJTC<_P#D:0Y,C+VZ=&/F1LDJ:4.M8:6234HM.VZ2]-^G74R
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MQZ:;-5 +DY.K;&YXVS*GIV#DVUA1V<2!&+;J[)?B.MMH+>9)]92B+UN@(B>
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M&;/)5W-8J\KF:*"Y,<<@-NDRXLR]38;:SVK0O:HC]73=ZH$=M'SAA.0V,6#
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MDE!H-2B)1*-1$G3QU <DWU&NV70(LXBKUM'=75D^V<M+9D1[C9W;R3H9'KM
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M%9-3.KJR;,C*5.?41.QXZW$&9&>A]4ET!*L?V8OZ!<'_ /85?]NZ!JV@0
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M0O2 Y4UO#O:>NO()J\C:1F9D7NIV.&U(;)U&Y)^![3ZD SC,BTU,BU/0M?=
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M$9'J1'X=# =4:)%AI<3$8;82ZXMYTFDD@ENN'N6M6A%JI1]3,^I@.X
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MM0MKB2,O$DJ(TD"H%[)=[1PO9_Q*-,LXD>0CXPWLNR&D+3K923+5*E$9:EU
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M!QC&XODJ.M0;4.+O6[L0:C69;W5*4?51^^48(VX
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M@'*FR.ER%RT:IY92G*6<Y569)2M/9FLH;<6T>]):F274'JG4NOB V@
M
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MQV[?J 8M[A,R.QY6,CU+Y=6)=/=*OKR,$U; (
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MU^4-)21*,W#;-LUHZ*W>)$:E&DTJ(E*+30FO38(
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MU4NCE.6**5V,X[&EK8M2BF@U(G$A"EI>V?\ 6[%(,]W730!L0
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MB]2_@U+Z^JD!:_L1F1\%1-/19S__ %T@FM%[+*DGR_[0)$>IED*=?AMD7_V
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MNTI*DET48)KU0"
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MZURFMPBD?O;J-=UG(7Q7*D6T>&BZK4_$LQ_RYN,]V.^LVE_>Y1$?JK(S3N2
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M7%<TR*?PEE%]+L//6]"C(X4#(FTMH*>BF=DL1YJ4H(V]5DTDU;2VFHC,BTZ
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M6CO:2E!NH+[VX:4EJI.NA'J!JWP0
M   !A3J:HM%M.65?&F.,]65R&6WE(]/JFLCT_: 9I$1%H70B\" 8$JBI)TI$
MZ;6Q9,UO3MR7F&W'4[>I:+4DS+3]D!F.M-/MJ9?0EUE9;5MK(E)41^@R/H8#
MXAAAMDH[;2$1R3L)I*2)!)\--I=- 'R/%C0VB9B,ML,D9F3;220G4_$]$D1
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M%.$6\R\3 9[>'8JU!@UC=/$37UDSXTKHQ-))MB<;BWN^VG31+F]Q:]Q==5&
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M/X=O_'3]D \Y$_AV_P#'3]D \Y$_AV_\=/V0')M]ETS)IQ*S+J9)41_W '8
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M ]$ @
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MI%S$WK<Q5=';B]Y"(2%)2YVDIW$1]2(_ P5= (
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M V8
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M* 598(
M
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MN]5'3T RN%"$-I)#:20A/1*4EH1%]0B <@%?\1?^!WW^\^1?[5D NK !
M                                 !6F:_TN<7?_ +?_ "% *LL$
M
M
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MM/UR .XW]VGZY '<;^[3]<@#N-_=I^N0!W&_NT_7( [C?W:?KD =QO[M/UR
M.XW]VGZY *US1:#Y=XN(E$9_]_\ 0C+^(H!5F @
M
M
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M9 /I$P3YQUWPEO[(!](F"?..N^$M_9 /I$P3YQUWPEO[(!](F"?..N^$M_9
M/I$P3YQUWPEO[(!](F"?..N^$M_9 /I$P3YQUWPEO[(!](F"?..N^$M_9 /I
M$P3YQUWPEO[(!](F"?..N^$M_9 /I$P3YQUWPEO[(!](F"?..N^$M_9 /I$P
M3YQUWPEO[(!](F"?..N^$M_9 /I$P3YQUWPEO[(!](F"?..N^$M_9 /I$P3Y
MQUWPEO[(!](F"?..N^$M_9 /I$P3YQUWPEO[(!](F"?..N^$M_9 /I$P3YQU
MWPEO[(!](F"?..N^$M_9 /I$P3YQUWPEO[(!](F"?..N^$M_9 /I$P3YQUWP
MEO[(!](F"?..N^$M_9 /I$P3YQUWPEO[(!](F"?..N^$M_9 /I$P3YQUWPEO
M[(!](F"?..N^$M_9 /I$P3YQUWPEO[(!](F"?..N^$M_9 /I$P3YQUWPEO[(
M!](F"?..N^$M_9 /I$P3YQUWPEO[(!](F"?..N^$M_9 /I$P337Y1UVGN^9;
M]W3[KW0$DV(^Y+ZP!L1]R7U@#8C[DOK &Q'W)?6 -B/N2^L ;$?<E]8 V(^Y
M+ZP!L1]R7U@#8C[DOK &Q'W)?6 -B/N2^L ;$?<E]8 V(^Y+ZP!L1]R7U@#8
MC[DOK &Q'W)?6 -B/N2^L ;$?<E]8 V(^Y+ZP!L1]R7U@#8C[DOK &Q'W)?6
M -B/N2^L ;$?<E]8 V(^Y+ZP!L1]R7U@#8C[DOK &Q'W)?6 -B/N2^L ;$?<
ME]8 V(^Y+ZP!L1]R7U@#8C[DOK &Q'W)?6 -B/N2^L ;$?<E]8 V(^Y+ZP!L
M1]R7U@#8C[DOK &Q'W)?6 -B/N2^L ;$?<E]8 V(^Y+ZP!L1]R7U@#8C[DOK
M &Q'W)?6 -B/N2^L ;$?<E]8 V(^Y+ZP!L1]R7U@#8C[DOK &Q'W)?6 -B/N
M2^L ;$?<E]8 V(^Y+ZP!L1]R7U@#8C[DOK &Q'W)?6 -B/N2^L ;$?<E]8 V
M(^Y+ZP!L1]R7U@#8C[DOK &Q'W)?6 -B/N2^L ;$?<E]8 V(^Y+ZP!L1]R7U
M@#8C[DOK &Q'W)?6 -B/N2^L ;$?<E]8 V(^Y+ZP!L1]R7U@#8C[DOK &Q'W
M)?6 -B/N2^L ;$?<E]8 V(^Y+ZP!L1]R7U@#8C[DOK &Q'W)?6 -B/N2^L ;
M$?<E]8 V(^Y+ZP!L1]R7U@#8C[DOK &Q'W)?6 -B/N2^L ;$?<E]8 V(^Y+Z
MP!L1]R7U@#8C[DOK &Q'W)?6 -B/N2^L ;$?<E]8 V(^Y+ZP!L1]R7U@#8C[
MDOK &Q'W)?6 -B/N2^L ;$?<E]8 V(^Y+ZP!L1]R7U@#8C[DOK &Q'W)?6 -
MB/N2^L ;$?<E]8 V(^Y+ZP!L1]R7U@#8C[DOK &Q'W)?6 -B/N2^L ;$?<E]
M8 V(^Y+ZP!L1]R7U@#8C[DOK &Q'W)?6 -B/N2^L ;$?<E]8 V(^Y+ZP!L1]
MR7U@#8C[DOK &Q'W)?6 -B/N2^L ;$?<E]8 V(^Y+ZP!L1]R7U@#8C[DOK &
MQ'W)?6 -B/N2^L ;$?<E]8 V(^Y+ZP!L1]R7U@#8C[DOK &Q'W)?6 -B/N2^
ML ;$?<E]8 V(^Y+ZP!L1]R7U@#8C[DOK &Q'W)?6 -B/N2^L ;$?<E]8 V(^
MY+ZP!L1]R7U@#8C[DOK &Q'W)?6 -B/N2^L ;$?<E]8 V(^Y+ZP!L1]R7U@#
M8C[DOK &Q'W)?6 -B/N2^L ;$?<E]8 V(^Y+ZP!L1]R7U@#8C[DOK &Q'W)?
M6 <@
M
M
M
M
M
M
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MF9_6 ;\
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M?=-)=-%%[H*D68X?E..Y#P)A^08LQR!E,"CM&9>,2I3+3,C:A:TLJD/$IO\
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M23-^1&;<</0O#52C!E)0
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MVEW&&2(B0M1)T,R]TP1*
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MO\R /D[>_.ZS_ 5?YD ?)V]^=UG^ J_S( ^3M[\[K/\  5?YD ?)V]^=UG^
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MXDS:BMK+U'%:&E1:& F0
M                        ",2_Z0ZG^9['\IA (#[1_-LKA'$Z^WK:UNSM
M+29Y..V^I2&6TI;4M:U&GJ9EH1$7U?J /+W]?OD#YMUG^.\#7\MY"]L?FZQD
MU<2#QZW(DW:%.T[3;,M2I;:#,E+9T3ZZ2,CU-/0A4C<V'M,^TK507[*RXG>B
MP(J>Y(D.Q)J4-H+Q4H]O0B])@1"OZ_>?_-NL_P =X1?Y=L;V_<X;?0N3BU:\
MP7OVDO/-F?["M%:?6 _E[\C.F_&9?,M#=0E9E[FXB,&7:
M                                                      C& ?\
MP^Y_.5M_M*0 DX   (_AO_A$G^=;G_:LH!(
M                                   :#,?_  B-_.M-_M6* WX
M                                                           "
M,2_Z0ZG^9['\IA /-7M^IW83B22^VM72^NP"XKQGV <Q?9;>1F%9M<2E9?>)
M'@HM07^FW9]B+E:,Y#=C\D,LNUR#:KUMJFH5';5XI9,E$:"/TDG05*SY'L?<
MX2V'(TKEEQ^,\DT.LNR+%:%I5T,E)4X9&1_5 J.?_-^YG\\*O\!($6JOYO\
M9HO>$**MO;:]AVC=E+.$AF*TZVI*B:4YN,U]#+U= ,U^H==_X?%_R+?_ *I
MRR0
M           $8P#_ .'W/YRMO]I2 $G   !'\-_\(D_SK<_[5E )
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M*,KB#E;&8M%E7DOC&ODUCQOQ7FDEN,CW*7IJG4R5O\4FDR(Q!?@   -!F/\
MX1&_G6F_VK% ;\
M                  !&)?\ 2'4_S/8_E,(!YK]OK_X-P_\ G9S_ + %QZQK
M?_#HG^0;_P#4($90   /(O\ \H!_1_BO\\*_)7 7/KUC7?\ A\7_ "+?_JD"
M,D   %/^T;S0YPG@S=W7PT3K^SD% JF7M?+H<-"G%.N[3(S2@D^]29&9F7@6
MID7%"8KD?MQ9IC\7/\?F5S]+/2J1!K5MUC9O-),T^JE2"41&9'IO=)0IX]&\
M8Y[E4GC21E?,=>WBUQ4+E%<(4VXPTB/$+7O;5J6>BD]?44HC^U]P1'F6Y]JO
MFKE7*)..\!8^;5>P:NW).,B5-4UKM)YY3QFPPE7H2HNGW1@L=LGD3VX>.4?'
M664)7E*R9.2FSBPI24MD>BM3JU$XCI]L?0O$4\>VV)2%PFYCQI;;4TEYQ1GH
ME)&G<9F9^@O=$1^=V6^V=S ]E-Y.PZ3';PN-.4BO0Y!:>247>:6>ZZ:=Q&ZE
M!JZJU\=/ &H]^85E=;G.)TV7U"M:^YBM2VDZZF@W$^NVH_ND*U0KZI R\?>T
M![3O*?%W--CC5#*B.XQ7^0?36OQ6U&XAV,TZZVI[3N%O-2NI'J6O0%S'JKBW
MD[&N6L1BY;C3OWIS[U.A+,C?B2DD1K9=(O26NI'X*29*+H8(\[\2<]\EY=[1
M]SQS=V##N*P9=TRQ&1%9;<V0''$,D;B4DKH22UZ]06/7@(\B7\[VY*LK6S0J
MI12PO,24K,JY2RBL[ED>GB9["_9%%=\9<W^UMRZ_91\(G5LMVJ0TY,)^-!C[
M4OFHD:=Q):Z[%> +N/4''>1\EXAQ]D&3^T3)B1)%4\Y*0_$)@T)KT,MF1:1N
MBEFYO2E/OC,R+W!$><G/:5]HKF>_FU_!N/E IXAEHX3+$A]*%*/:J1(EGY="
ME$71"2]W0U::@L?'O:&]IWA2U@ES30ILJ&6O9W'&8S*EET4HF)4'[SW"3UVK
M(_\ [($>S\+S&@S_ !BNR[&9/FJ:S;[K"S+:M)D9I6VXG4]JT*(TJ+T&0(WP
M    "L?:*??C<(YM)C.K8D,URW&GFE&VM"TK09*2I)D9&1@//7'?-'M"X)A-
M+E^<4+F?\;V<<I*+F"K?:PVMQI/S!DG56A^EU.A_P@JO2G&_-7''*T4G</N6
MWYQ)W/U,C[Q/:\==S*CU,BT]\C<GZHB)^
M    ",8!_P##[G\Y6W^TI "3@   C^&_^$2?YUN?]JR@$@
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M'_PB-_.M-_M6* WX
M                    ",2_Z0ZG^9['\IA /-?M]?\ P;A_\[.?]@"X]8UO
M_AT3_(-_^H0(R@   >1?_E /Z/\ %?YX5^2N N?7K&N_\/B_Y%O_ -4@1D@
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MKKA^"4))6IF?N$ W&8_^$1OYUIO]JQ0&_
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MT_P06N]_@_VP>2$?$W(&9HK<><Z2T*EH43B---#9@(2EW77WKBB(4\23VAN
M>6N6,FQFJIO)MX)C<)B"S)>DDVZIUW84J1V=#TT2A"4IU^T\>H&;%PL^S%P.
MRRVS\B8+G;0E'<<-TUJVEIJH]Y:F?I,1%'O^S-R%Q[SS&Y#XBAP4X='DM2$5
MCDORZDQWFR;F1=%$KU5$:]A]=-4_<BK6SY$]GSDG)?:9K^4ZR/"/$XEE2REN
M.2B1(-FO3')X^WM\2-"]I:]>GNB%>D\^P3'>2<5GXAE$8I%9.1H2RT)UAY/O
M'FE&1[7$'U(_VCU(S($>6> /9?Y%XFYD3DMNN%+Q:*U.BLSF']'G4/(-+2S9
M,M4FKIN3KZONF"[KV6"-1E4"5:XQ=U<(DJF3H$J-'2M6U)NO,J0@C5UT+4_$
M!YS]DO@G/^';/*)69M1&V;9B(W$.+()\S4PMTU;B(BTZ+(%W7I'(*"HRFDGX
M[?143:>S97&F1G/!;;A:'U+J1EXDHNI'U+J"/%LWV5.<.*LBEVW ^5;JR9ZI
MLN2$Q)?;(]4H?0XDV'MNI[5]/\$M06NK^K![1'+5S#?YKRM+%-$5KL\PF6\2
M3/UB8882EA"E%TWF?N=%> %>SL0Q*BP7&J[$\:C%$I:MHF8S6NJCZFI2UJ^V
M6M1FM:O2HS,$;L    !5OM(?T%YU_-;G_K) =/LS?T#X-_-_^>< 6P  *0Y'
M]EOCK.91WU*EW#<S0KNL7M'_ *.?=^[<90:4J/W5(-"S^Z 5E8<M<X>S8]$@
M\P-Q,YPF0YY>#D,-]MFT\#5HIM9I4LR+QWH_^FF*KT;QQR9B?*N/IR7#Y#K]
M?O-ETI##D=QMY)$:D&2R(E&6OBA2D_5$1+P
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M6*(-^
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M1I4IG4NOK.G^P#*T@%<8/_2=RE_[73?[*9%%CB
M                K7F/]ZP7_?&D_P"U6+@E>8_^$1OYUIO]JQ1!OP
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MCQH\-AN+$90Q&922&F6DDAM"4]")*4D1$1>X0([0
M        $8P#_P"'W/YRMO\ :4@!)P   1_#?_")/\ZW/^U90# G\5<8VDV1
M96>&TDRPEN*>E2I%=%=>==6>JEK6ILS4HSZF9F Q_H;XC^8F/_HN'^* /H;X
MC^8F/_HN'^* /H;XC^8F/_HN'^* /H;XC^8F/_HN'^* /H;XC^8F/_HN'^*
M/H;XC^8F/_HN'^* /H;XC^8F/_HN'^* 0[D>DX"XSH_C:YP2CE3GU=FII8=3
M#=L)\E7O68[1-ZJ/[H_!)=3%'D61[/?-/-V0OY(C$*_ *!Q:4PJUUDJN.Q&/
MJDT1T(WK7M]^LT)W*]SP*+8O_CWV'>-L:)F9F4N1E=HV9FII?^B5YEU(B[*#
M4L^AE[YWQ] %>A\:PW%,-AE7XI2PZ>'J9FU"80R1F>FIJ-)$9F>G4S!&\  %
M<8/_ $G<I?\ M=-_LID46.(
M"M>8_P!ZP7_?&D_[58N"5YC_ .$1OYUIO]JQ1!OP
M                                            $8E_TAU/\SV/Y3"
M>:_;ZT+#,0,^A?&SG7_Z0"X]&P.0\!;@14*RFH)1,MD?^G1_N"_OQ49'TB\?
M_.JH^'Q_W8@^%R/Q\9F1974&9>)%/C=/_HP'WZ1>/_G54?#X_P"[ >5?;JRC
M&KW!,88I+F%9/MVZUK:B2&GUI0499&HR;4K0M3(NON@N/8]=_P"'Q?\ (M_^
MJ0(^MP834MZ>U&:1.DI0W(E)0E+SB&M=B5K(M5$G<>TC/IJ ZE4]0MV2^N!&
M4_-1VICILMFMYO33:X>FJBT+P4 QH^+8Q$?;E1:6 Q):,E-/-164.)47@:5)
M21D8#/7!A.RV9[L9I<Z.E;<>4I"3=;0[IO2A9EJDE;2W$1]= 'SR$$YQ69QF
MOC(FCC%,[:>^3!J)9M]S3=L-1$K;KIKU =C[#$IER-):0]'=2:'6G$DM"DJZ
M&2DGJ1D?U0'!J%#8B% 9CM-P22;91D(2EHD'XIV$6FAZ^&@#%BT%%!>;DPJN
M)&D,I-MEYEAIM:$*U,TI4E)&1'J?0O= =\BMKI<EB9*AL/RXIZQI#K:%N-'X
MZH4HC-/[0#ZFNKTS56:8C)62T=M<PFT$^:.GJFYIN,NA=-0&+-QS'K)\Y5C4
MPIDE1$2GI$=IUPR3T(C4M)GT <VJ*D8**3-9$;*":E0B0PVGL*</51MZ)]0U
M'U/;X@.,G'J":\](F54.1(D$1/NNQVG%N$G3:2E*29GIM+37W &1&K*V$\])
MAPV(\B1IYAUEI#:W-OAO4DB-6FOI =+]%22GGY,JMBOR)*":DO.,-K6XV6TR
M2M2DF:B+:GH?N$ ZHF,8U D(EP::#&E-Z]M]F,RVXG4C(]%)21EJ1Z .4'&\
M=K);D^MJ(4.<[J3LJ/&::>61^.Y:$D9Z_5,!W6=14W4<H=S CV,0E$LF);*'
MV]Q>![7"46I:^(#@U14;$AB8Q61&I<5!-1GT,-I<:;(C22$*).J4Z'IH7H 9
M"X,)V6S8.1FESXZ%ML2E(2;S:'=-Z4K,MQ$K:6XB/KH XV%96V\8X=K#8G1#
M,E''E-(>;,R\#VK(R](! K:ZJC%#JXC,&(DS-,>,VAELC/Q,DH(B ?45U>W-
M<LFXC*+%Y)-O2TMI)Y:"TT2I9%N,BT+H9^@!A2L7QF:^N5-IH,F2X>YQYZ*R
MXXH_#4U*29F V,>-'AL-Q8C*&(S1;6F6DDA"4EZ$I21$1 (9S#BMMF_&638E
M1DT=M;PSBQ?,+[;1+6I/52B)1D1$1GX *=XS]C/"\<*'8\BS7<VNHC:6H\64
M:TU49"349-ML*49K26X^CA[/3L(%KTK%BQH4=N)"9;CQ&4DAEAE)-MH27@24
MI(B(B]P@1V@                               C& ?\ P^Y_.5M_M*0
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M\5_/>A_2D3\: ?2WQ7\]Z']*1/QH!]+?%?SWH?TI$_&@'TM\5_/>A_2D3\:
M?2WQ7\]Z']*1/QH!]+?%?SWH?TI$_&@'TM\5_/>A_2D3\: ?2WQ7\]Z']*1/
MQH!]+?%?SWH?TI$_&@'TM\5_/>A_2D3\: ?2WQ7\]Z']*1/QH"#<DY[@^1R,
M%K<>R6KMK$\OIG"B0)K$EXT(<6:E;&EJ5HDNIGIT%%F9C_X1&_G6F_VK%$&_
M
M     1B7_2'4_P SV/Y3" >:?_E "/Y#8F>AZ?&CI:Z=-3CGTU_:!<^OS_!M
MM,9;I7LCJ&<D<6UCSDR.BU=:Z+3$4ZDGE)\>I(U!->S_ &C,9]F"KXC3,Q)-
M1'R1]#+F,.TSB5R9!D:=W>V&HU-[%F:C=\%:>GH*SCPX(V /VTKO_#XO^1;_
M /5('-D@
M                (Q@'_P /N?SE;?[2D ).   "/X;_ .$2?YUN?]JR@$@
M                 &%*IJB<[WYM?&DO:$7<>9;<5H7@6JB,P'1\FL<_DB%\
M&:_<@'R:QS^2(7P9K]R ?)K'/Y(A?!FOW(!\FL<_DB%\&:_<@'R:QS^2(7P9
MK]R ?)K'/Y(A?!FOW(!\FL<_DB%\&:_<@'R:QS^2(7P9K]R ?)K'/Y(A?!FO
MW(!\FL<_DB%\&:_<@'R:QS^2(7P9K]R ?)K'/Y(A?!FOW(!\FL<_DB%\&:_<
M@'R:QS^2(7P9K]R ?)K'/Y(A?!FOW(!\FL<_DB%\&:_<@'R:QS^2(7P9K]R
M?)K'/Y(A?!FOW(!\FL<_DB%\&:_<@'R:QS^2(7P9K]R ?)K'/Y(A?!FOW(!\
MFL<_DB%\&:_<@'R:QS^2(7P9K]R ?)K'/Y(A?!FOW(!\FL<_DB%\&:_<@'R:
MQS^2(7P9K]R ?)K'/Y(A?!FOW(!\FL<_DB%\&:_<@'R:QS^2(7P9K]R [&**
MDBNI?BUL5E]'5#K;#:%D?U#))&0# S'_ ,(C?SK3?[5B@-^
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MK"/G+5?#H_[L ^76$?.6J^'1_P!V ?+K"/G+5?#H_P"[ /EUA'SEJOAT?]V
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MBB8"
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M+_)L7\ W^Y /B.E_DV+^ ;_<@'Q'2_R;%_ -_N0#XCI?Y-B_@&_W(!\1TO\
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M25%X&1D70P&:
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                              ,6SFE6ULRQ-!NE
M#8=D&V1Z&HFD&O0C/PUT >/V/;^K)!_>N/YSA$9;S;G(7IK^Q'!J)YQ=[9&
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MRG8
M
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M.&T3K2S,DF9.+T4G5*O09Z&":OH$
M
M                                            :G*/_AFZ_P#897_8
MJ >%_8CXXP3/H6:KS*@AW:X#M<4-4QON&T3R9.\D^YNV)U_8!K7MK%N/L'P@
MG?DACM?2K?+:^Y!C-LN.)+0R):TI)2BZ>!F#+QM[7Z6W/:+XW;=2EQM46L);
M:R)25).V>(R4D]2,C]PP:Q:/M1>SQ695BBLTX_JVJW.\<+S:45K28ZYL5KUE
MHT:))F\WIO947K=-A>^+0F:Y>R[S,GFO [/ LSDF_E];%7%FNJ47=G5DA/9*
M1]5:-W;=/3QVJ,]5@;BB.',ZG>R5R;DN"<EPI"<>LS;)4YAHUZG&4LH\QE)G
MZ[+B%J)9)/<73[9)I!=]6=SW[7G'MM@%MB/&TI^ZO,ACKKERBC/QF(T>27;>
M,^^AM:G%(,T()"=-3U,^FAC,27V=Z!GV=^!+3-.1"56R)RU74Z(X6V0TR:$,
MQ8VQ1E]^<,NB#T,E.$D]#(P3?5%\9\:W_M=YYEG(^<R'J_'4)=BQ'(Y[B;EJ
M;TBQF=Q$1MQD&EQSP-1Z:]7#,%^)+[+W(EUPUR+:>S]R.KRL:1--JK<<4?:C
MV:]-B4*5I]YEI-*FS^Z-)D7KJ,#7MZ\_\%LO_97_ /LU R\7_P#R>FG_ .4,
MNFO_ '/^S_\ IH-:]O@R&1&6A]2/Q(!^57*3-[P;R%R3Q]2Z,4.2->62@R/3
MXLDO-S6-AD9%JA.K!G[AK(&WO_V;\#^COAW&Z5YKM6DMCXUM",M%>:GZ.FE7
MU6T&AK_T 9UY,ERK;V2_:2LLBM*Y^5@.2+E=M]A.O=KISJ9&UI2C))O1G"22
MD*,C,D^@EDH%^KNSGVV.)ZS%94K"IK]UE+S"DUT$XC\=MF0I.B52%OH0G:@S
MU,D&HSTT].H)$?\ 8;XRO*&FO.2,B8<C/9*33%2T^1I=7$:4IQR09'UVNK4G
M9KXDC=[U23!==OM_?T<XQ_/?_P"*/ 8O[ACKQ!@)E\W:G\B:!G7DO%#_ /X_
M++_VFP_V0L&N-G0__P#0&W_R;O\ L1L#B*>U_P 8VO&F72.3<+6Y"QW-6Y%?
M?MQ_50B7*0??;67@;<I)&YZ?OB5'T]4#%G>S?AK?(7LF6V%K<)E5P[:1F'E:
MFEN1N2IE:B+J9)<)*C+W -^JZ]G+G*/[/[UWQ+R_"E4[+$Y<F/*[*WCC/K2E
MMU#B$:J4TLD)6VXT2B/J?4E$9#<1SVA\[]FV^I7JWBC'TOY=82T27\@8C/16
MTD:][B='S2M2G#/30F]/J@97LGV:ZNSIN#<-KKB&] L&HCBG8DE!M/()R2ZX
MC<A74M4J)77W034)]MS^@J7_ #G _P#74!BJ\H_L!TW_ .J_[74"]3_$N*J_
MF#V1,8Q21L;M$P%2Z.:O_J)[+SW;,S(C]59&;;G3WJCTZZ G7E;@N1DO]8O!
MJ?*UO_&F/2CI2C2OWR,W!:?04?\ 8;,U)(O1X> -:](<O\]\G\+\ZP(V2J\S
MP].V/QV8\1DG'(RVB;>)+QIW&ZP\9KV;RU3MUT)1 D13VD.:O9NS[ )S5!&:
MNL\E]OXMG-5[L.3$<WH4I;LAUIHS3M(TF@C7N/T?;$,Q=GL?4-]C_!M.S?-.
M1US9$J? C/:DM$.0O<V>T_ EGN=+ZBM?2":HGVK#_P#XI>-O\A2?[8D N?'N
MX&7@7V'J6EO<MY BW5=$LXWEF-&IC#4A&BGW2/0G$JZ&7C[H-:Q^6L;R3V2^
M7(/(G'1.-X#?.ZKK"4HHIF1[GZ]WQ+:9&;D=1EJG[74VS,Q]7/[3:F>8?9K9
MR_"$JLJYMZ)?(0V6YXH[1.,ODI*==%L]Q7=+[78KW 3$9X%]K#B?'.*J7&<Q
MGOU%YC\;R:F?*OR424-&KMK:6PA9=4Z$9+V^MKZ.H+N(9[.4B5RE[5&2\IU4
M%YC&V//2S==+384M/EH[:S+5).+29KVD?VJO< WX[>>JN]X)]HZJYVAP')V*
MV;Z'Y!M=$I>5'\I+C*5X)6XV9NMFKH9J/37:8&+*S_VU^+V,&G/X--E3LQFQ
MG&JV&N(ZP<20XG:EU];J>V9-F>[1M2]QEIX'J1(G'LO7_*N5<<HR/E*03[TY
MTCHC<CHC25P$)(B>=[9((^XK78>PC-);NI*(#5&__*%__N\+^>/_ ,2!<>T*
M/_P2M_\ 96/^S2#+P[[,W]KGD;_B'_:S0-;\:1N?:^R/[1MK:75<_)P+(E24
MLR&$Z]VMEO)?2;)J,DF]&624+09D9D1^!+28'U=W('MK\55V)S'L&FOW6528
MZT5T7RK\=MA]Q.B7'UOH06U!GN-+>XU::=-=Q$B/^Q9Q?=8QAF2<@9#'<BR,
MG92U5,/D:73@L)6LWS(^NCRU^IKXDC=X*(P76B]@NLK[O$^1Z:UCHEUD]R%%
MFQ72U0ZP\S)0M"B]Q23,@-><>;L$R7A[*+/C*1+?=Q!V4FZI4K/5I]I:%M-/
MZ:$7=0DU,N&6FJD^YM!<>R.?<YY;XXXHPG*^-I*&*EJ%&CY LXC4M;7=CLG'
M=^^I624:DM"CTTU4GW09QT2?:G]FW.<*:?Y"BHDVBHQ%,QZ76.3'DO[2WH8=
M-LV]#5^]K[J#])[3 B ^P=2V;F59ME<"(["PMYE,*,AQ2E(-\W^\VV2C_?%,
MM:DI7HWE]T"Z]S R
M
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M$Q75D9.R/"B-(88;3KKHE""))=3]! C,
M
M
M
M
M
M
M
M
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M6DR-)D?I(R <@
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M>(+NM<D/UN00)4>) NF5FLUQEO&X2$.M]#1OZJ/W"21$UZJ!
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MD&U)TZZSK%K-TF'E,^N@TK,U)41>.FNFT@'3C>*<U9#G5=F/)-W$HZ*D;=3
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M(6DN/12@56&T3TCXEBM;]YO.D[M[T@_#>:>FI]=-I)"UP0
M
M   =4F.S,C/1)*.Y'?0IIY!ZD2D+(TJ+IUZD8"'<=<28#Q5&F1L(JB@'8+2N
M=(<==DR'>WJ3:5./*6K:@E'M3KH6I^DS 38               '5*BQIT5Z%
M-9;DPY+:F9$=Y).-.-.$:5(6E1&2DJ(]#(_$!44?V6N$(T]$Q..*=C-.G)9J
MGILQZM0\9F9J**MXVS+J?JFDT_4!:N%*4H2E"$DE"2(DI(M"(BZ$1$0(^@
M                                   #JDQV9D9Z))1W([Z%-/(/4B4A
M9&E1=.O4C 0[CKB3 >*HTR-A%44 [!:5SI#CKLF0[V]2;2IQY2U;4$H]J=="
MU/TF8";                     (-GW$''_ "6[#F995=^TKR-,&TC//0YK
M2#U,TD]'6A1IZGZJC-/4STU 9.!<6X+QG&E,8;4H@N3E$Y/F+<<DRY"DZF1N
MOOJ6XK0U'H6[0M3T(!,  !&,]X_Q?DO'UXQE\5<RH6ZW([;;SD=9.M:[5$MI
M25>DR\?2 V>.8Y1XC20L<QN"W6TE>WVH<-DC)"$ZFH^IF9F9J,U*4HS-1F9F
M9F8#:                             (_\B,8^6GTA>1_^N_R'Q/\8=UW
M_4>YWNWV]_;]_P!=VS=]4!(
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M5]C)2<=<5]:EN$HD$6NI(VF1]#(S!7JP$
M     >?N6O[27!?_ !#^1(!>/0((
M                  "ON=?Z%\__ )@LOR98#)X9_HAP+_=ZI_(F@-3@
M  4(]_;*C?\ +T_]KK!>+[!
M              4/[9']GS)O\M6_E[ +B]6OWI'^"7]P$<P     !Y^XF_M)
M\Z?\/?D2@77H$$
M    !0_M+?Z[P_\ \P*7_.@N+X!                                '
MG[EK^TEP7_Q#^1(!>/0((
M           "ON=?Z%\__F"R_)E@,GAG^B' O]WJG\B: U.      !0CW]LJ
M-_R]/_:ZP7B^P0
M    %#^V1_9\R;_+5OY>P"XO5K]Z1_@E_<!',      >?N)O[2?.G_#WY$H%
MUZ!!                             !P<>::+5UQ*"]U1DG^Z X(E17#T
M;?;6?N)6D_[A@.X                  4/[2W^N\/\ _,"E_P Z"XO@$
M                             >?N6O[27!?_ !#^1(!>/0((
M                  #!MKFHH8+EG>3X];7-=79<QU$=E/37JMPTD7A[H"JK
M#VJ^ :U\X[V9QW7"Z&J+'ER4?X[+*TG^T8$;;'?:&X5RIYJ-3YI7')>,R:8E
MK5!<49>@DRDM&9^X0"S$J2M)+09*0HB-*B/4C(_ R,!]
M  %?<Z_T+Y__ #!9?DRP&3PS_1#@7^[U3^1- :G       H1[^V5&_Y>G_M=
M8+Q?8(                                                  "A_;
M(_L^9-_EJW\O8!<7JU^](_P2_N CF      //W$W]I/G3_A[\B4"Z] @@
M                       ,2QLH55%5+G.DTRGPUZJ4?H2DO$S/W %<7&<V
ML]:FZ\S@0_!.W0WU%[IJ^U_8+ZXU$1AU;CZC6^M3RS\5.*-9_P#T1F X$A*>
MJ2(C^IT_N C:UV17569>5EK4T7_4/&;K9E^PKJ7[1@JPL>S&%=*3$?3Y6R,N
MC1GJAS3QV*]/[!]1()*(H              *']I;_7>'_P#F!2_YT%Q? (
M                              \_<M?VDN"_^(?R) +QZ!!
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MBG+>+LY1BD@ULF?;FPG=$R8D@BU-IY)&>A^DC+HHNI&#*:
M   *^YU_H7S_ /F"R_)E@,GAG^B' O\ =ZI_(F@-3@      4(]_;*C?\O3_
M -KK!>+[!
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M^ 0                               !Y^Y:_M)<%_P#$/Y$@%X] @@
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M O\ =ZI_(F@-3@      4(]_;*C?\O3_ -KK!>+[!
M    8\B?!B?ZU):8_P JXE'_ *QD P?E1C/\LP?A3/[H!W,7M')/2-9Q'C\-
M&WVU]2_848#/(R,M2/4O=(!]                      %#^V1_9\R;_+5O
MY>P"XO5K]Z1_@E_<!',      >?N)O[2?.G_  ]^1*!=>@00
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M>_5SF+"/^^L*W;?NDGT4D_V2 77$E,S8S,N.K<R^A+B#^HHM1E7<
M     H?VEO\ 7>'_ /F!2_YT%Q? (
M \_<M?VDN"_^(?R) +QZ!!                   >8>;B.O]ISA"U]Z4E<R
M#N]W4R1I_P#AQ1M>?D]KF;@67O,M+J<QM(M?WU,8O_M /1(@      #\:^3#
M,^2,P,SU,[NR,S/_ -K=!O/BZ?;94ISE&A>4G:3N,5RB]SJ])UT/Z@:GY>;0
M:?H+["?)3][B-IQS9O&Y+QM:955O/51U\M1[D%Z3)IW7]@G"+T QKUP"
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MYDW^6K?R]@%Q>K7[TC_!+^X".8      \_<3?VD^=/\ A[\B4"Z] @@
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MZJAN>I_DW?6+ZQ[A-,3 10           %#^TM_KO#__ # I?\Z"XO@$
M                            >?N6O[27!?\ Q#^1(!>/0((
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MH           "A_:6_UWA_\ Y@4O^=!<7P"
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M_;<;6#&IT"               H?VR/[/F3?Y:M_+V 7%ZM?O2/\ !+^X".8
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MM2C3J1J:0E1%TU40K&KSQAY:,CKG5GJXX^9.*]TW241_7,Q65R#*@
M    *']I;_7>'_\ F!2_YT%Q? (                                \
M_<M?VDN"_P#B'\B0"\>@00              'E/VW^4[;#\1JL)H)*XD[*5/
MJL9+)FAQ-?&))*:)1:&7=4X1'I]JE1>D%Q^=P-@"_O8RG(B<^4C"ST*=%L(V
MA^D_*K=T_P#P8,ZK>IC?%'+T&(2324')&FB2GH9=F>2="^L'3C]AP9
M!^/7,_\ 2]GG^\%I^5N WBX/;,_\?X\_W0@_]JZ&L_EYG!L ?L;Q/.*SXNPJ
MPUU.11UKBCUU]8XC>O\ T@YI@              *^YU_H7S_ /F"R_)E@,GA
MG^B' O\ =ZI_(F@-3@      4(]_;*C?\O3_ -KK!>+[!
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M ]O>SEDT;+^(:.^A44+&X4A<Q$:GJT=N(RAF6ZWZI>DU&DU*/TJ,S!G5J@@
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M+CGK.I5;+FN7]S):_P#6(478,J            H?VEO]=X?_ .8%+_G07%\
M@                               #S]RU_:2X+_XA_(D O'H$$
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MMWH+HM9]/\876?R\SB-@#]?."FS;X8P%"B41_$-<9DKQZQD'Z?V>@.:P0
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MO\M6_E[ +B]6OWI'^"7]P$<P     !Y^XF_M)\Z?\/?D2@77H$$
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MRX6BT.-K4E25%[I&6ABZS^7F$1L ?LIQI"*MXYQ&O(M/*TM<SI]5N*VGT_L
MYI2              *^YU_H7S_\ F"R_)E@,GAG^B' O]WJG\B: U.
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M7\B;V1OR[%6D-I6X>KDJK+1#+O7J:FCT:<_] S/50,;CTN"
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M&?Z(<"_W>J?R)H#4X      %"/?VRHW_ "]/_:ZP7B^P0
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M"B,@8;H                  4/[9']GS)O\M6_E[ +B]6OWI'^"7]P$<P
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MY:M_+V 7%ZM?O2/\$O[@(Y@     #S]Q-_:3YT_X>_(E NO0((
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M80?[&JE?W2$TQ/A%            4/[2W^N\/_\ ,"E_SH+B^ 0
M                      !Y^Y:_M)<%_P#$/Y$@%X] @@
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M28K%K(JJM7C]\FN)GR=/<VI4R7_I&*R]0B(              "ON=?Z%\_\
MY@LOR98#)X9_HAP+_=ZI_(F@-3@      4(]_;*C?\O3_P!KK!>+[!
M           !YI]N:V>K^$T0FE&2+:XA1'B+P-MM#TK0_P#TF$F"X_-@&P
M        7%[*LUZ!S]A;C)F1NR)$=9%Z4/Q'FS(_K@FOU;!@
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MB^ 0                               !Y^Y:_M)<%_\ $/Y$@%X] @@
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MO]"^?_S!9?DRP&3PS_1#@7^[U3^1- :G       H1[^V5&_Y>G_M=8+Q?8(
M                /+'M[_T0TW^\,;\BF N/SI!L          %L^S'_ $]8
M/_[<K_L'037ZR P                 *']LC^SYDW^6K?R]@%Q>K7[TC_!+
M^X".8      \_<3?VD^=/^'OR)0+KT""                 ",9AC17,;S<
M-)?&D<O4]'=1XF@S]W[G_P"V+B*L,C(S2HC2M)FE25%H9&70R,C\#(4    9
M<"SL:M>^OE.,==30D]6S_90>I?\ 0 SK>QQK,H)57(>-PKZ#X$MQE"UHZZ[D
MDOJD_JH41A!2N6^QEQ?EW<E\9Y ]CMDKJFIG:RHNIG[TMYI>3^SO<_8$C6:\
MV9_[,?,?'G=D6- Y:5+74[2GUFL;==-5)01.H+ZJVTD(U50&1I,R,M#+H9'X
MZ@KMBQ9$Z4Q"B-F]*DN)98:3U4MQPR2E)?5,ST ?J@G'V,!P3$N.8AD::>$T
M<Q2=-%R"3ZZ^GW;BG%BXY:UHHSJ:M5;VD:O27J.JU>/W&D=5G];H NM*4H22
M$EHE)$22+P(B&5?0            %#^TM_KO#_\ S I?\Z"XO@$
M                       >?N6O[27!?_$/Y$@%X] @@
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MD?9 I_\ -^9C\\:SX/(^R!3_ .;\S'YXUGP>1]D"G_S?F8_/&L^#R/L@4_\
MF_,Q^>-9\'D?9 I_\WYF/SQK/@\C[(%/_F_,Q^>-9\'D?9 I_P#-^9C\\:SX
M/(^R!4RXH]C#*..^1,?S69D\"9&IY!R'8K3#R7'$FVI&B34>A'ZP%>R09
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M+B^ 0                               !Y^Y:_M)<%_\0_D2 7CT""
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MT?*N1%,7V6-FAV' 2G?7P7"T42O7+[\ZD_!1D24^@C/10,[KU,"
M        "ON=?Z%\_P#Y@LOR98#)X9_HAP+_ '>J?R)H#4X      %"/?VRH
MW_+T_P#:ZP7B^P0
M     %#^V1_9\R;_ "U;^7L N+U:_>D?X)?W 1S      'G[B;^TGSI_P]^1
M*!=>@00                   !H,AQ2#>I-[_5[%):(DI+QT\"67VQ?](M%
M:VU'9TCFV>UHT9Z(DHU4TK]OT']10J-<       #DTXZPONL.*:<\-[:C2>A
M_5(!QZ$7N$ E6(XJNU=18V"#35MF2FD*Z=]1'[GW!?\ 2&BT"(B+0O 94
M           %#^TM_KO#_P#S I?\Z"XO@$
M      >?N6O[27!?_$/Y$@%X] @@              ,>?!AVD*36V+")4"8T
MN/*C.I)3;C3J32M"B/H9&1Z& \<Y[[ ];8VKUAQ]D95,![UBJ;%E4A#:CU,^
MV^A1*V>&B5(,R^Z,%JLFO8/Y?5/*.[8TK<#>:3F%(?49(^Z[?8(_VM06K9XX
M]@_'Z2T:M>0[SY0,L*);=1#:5&C+6E1&7><4I2UH,BT-"21^R"5Z_:::8:0P
MRA+;+:20VV@B2E*4EH1$1="(B!',!P=:;>;4R\A+C2R-*VUD2DJ2?B1D?0R
M5AE7LY<*9BMUZWP^$W+>ZKE0"57NFK[HSC*;(S_PB,!65G["/#DQ6^#.NZ[^
M\:E,.H__  T=9_\ T0+6 W[ O%:7$J<R"_<01ZJ1W8:=2]S4HO0"ISC7L@<$
MXV\4A5"Y<OI]ZJVD.24%_P#2D[&S_P#208%7155%31PFZVE@QZZO:Z-1(;2&
M&4]-.B&R(B\/<!&:                   "ON=?Z%\__F"R_)E@,GAG^B'
MO]WJG\B: U.      !0CW]LJ-_R]/_:ZP7B^P0
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M7P"                                //W+7]I+@O_B'\B0"\>@00
M                                               %?<Z_T+Y__,%E
M^3+ 9/#/]$.!?[O5/Y$T!J<      "A'O[94;_EZ?^UU@O%]@@
M                                        *']LC^SYDW^6K?R]@%Q>
MK7[TC_!+^X".8      \_<3?VD^=/^'OR)0+KT""
M     #J?BQI*=LEE#R?<<22B_P"DC :MW$\<>4:EUS1*/Q-!&C_U3(6CH^1.
M,ZZ^1+]CN.:?^L%2,J/C&/Q5;V:YDE>ZI.\__HM1*K:I0E"20A))070DD6A%
M^T ^@                 "A_:6_UWA__F!2_P"=!<7P"
M                 //W+7]I+@O_ (A_(D O'H$$
M                              !7W.O]"^?_ ,P67Y,L!D\,_P!$.!?[
MO5/Y$T!J<      "A'O[94;_ )>G_M=8+Q?8(
M                           "A_;(_L^9-_EJW\O8!<7JU^](_P $O[@(
MY@     #S]Q-_:3YT_X>_(E NO0((
M                   "A_:6_P!=X?\ ^8%+_G07%\ @
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M))J(B(]-?'0!(0                    %#^TM_KO#_ /S I?\ .@N+X!
M                              'G[EK^TEP7_P 0_D2 7CT""
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MI^L?0#%@0^=_:1?F1V)'"4AF.XZA#KQNO>HA2B)2NJ-.A DQZ@!
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M^ 0                               !Y^Y:_M)<%_P#$/Y$@%X] @@
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MXTXKSG"+Y^VR7DVUS* [%7&;J[!KMLMNJ<;63Q'WG/622#273[8Q!:X
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MB      *']I;_7>'_P#F!2_YT%Q? (
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MUQ>?B4AF8[#36VI*2^M#2&UD\1*0V>U1K-)>KXI,03@   %#^TM_KO#_ /S
MI?\ .@N+X!                                'G[EK^TEP7_P 0_D2
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MXUEM7\EB*;L^'6N3)2E.-LNIZ:GL+>9="/T:[B+UK,>8@SO:"XORC'7<PO\
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MMS;1[5&LT^]\4GU$$W   !0_M+?Z[P__ ,P*7_.@N+X!
M                'G[EK^TEP7_Q#^1(!>/0((
M                            "ON=?Z%\_P#Y@LOR98#)X9_HAP+_ '>J
M?R)H#4X      %"/?VRHW_+T_P#:ZP7B^P0
M        4IR;[/S_ "ME3$[)\TL58$R]'E'A++:$1E/1T$@S[Q+UT7ZVNJ#4
M6Y6U1>@M72A"&D);;22&T$24(26B2270B(B\"($<@             !0_MD?
MV?,F_P M6_E[ +B]6OWI'^"7]P$<P     !Y^XF_M)\Z?\/?D2@77H$$
M                              !#.3<"?Y&QU- QD=GC!]XG79U,[V7W
M6NVMM;#A^EM9+U,O=20#LXSXWQOBG$HN'XLAPJ^.I;SLB0HER)$AW3>ZZI))
M(U'H1="(B(B(O !+P            %#^TM_KO#__ # I?\Z"XO@$
M                        >?N6O[27!?\ Q#^1(!>/0((
M    *N]HO(KS$^%\KR'&YSE;=068ZXDUG:;C9JELH5IN)1=4J-/AZ0&FQWG+
M%,2XZXTF<FWIQKG+J=F2FPD-J-MUYJ.RX^MU:$[4=74^.FIGT ;3$/:,XJS:
M;;5M-9OHL:>*[8R(DR(_%><B,)WK=:0XDC61)T5M]]H>N@"!<"^TQ%Y1S3*J
M.YEML%YAQW%8;49;3154-*M[SSRM=%K+:I1.*+3T$0I$N@>U/PI99 WC\:^7
MJ])\BQ:N1GT5CDKIHVF2I)(ZZ]%'HGTZZ"#=YUSUQCQO>.XYE]LJ!;MU_P :
MH8-AU9.L&I2$H;4E)I4XI2%$E&NH#7R_:3XCK6::1:V[L!N^JSO*PI$5]*G(
MF];:2(B09FXM3:B0V6JE=--=2 ;CC?FOC[E55BQB=@XJ?4G_ -X0)C+D22T@
MSV[S0X1:IU(R,R/H?CIT 1MOVJ.$G;\J%&0F:%/^33<^7>*J.29:]OS>W9_Z
M7O/3NTZ@(7RY[4$/ .9J'!52TQ,7@'WLTDE$=?DI-V/WH[31Z&1H42VU*4VD
MSZZ:EH9&6+HD\HX;$SZIXT?F+3EUW".SKHG9<V+C$EY9F;FFPCT8</:9Z] 1
M,@                 !7W.O]"^?_P P67Y,L!D\,_T0X%_N]4_D30&IP
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M<;/H2D&2BZ?5(!S          %#^V1_9\R;_ "U;^7L N+U:_>D?X)?W 1S
M     'G[B;^TGSI_P]^1*!=>@00
M                 %#^TM_KO#__ # I?\Z"XO@$
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MGOB-)&1]#(@82@       %#^V1_9\R;_ "U;^7L N+U:_>D?X)?W 1S
M 'G[B;^TGSI_P]^1*!=>@00
M             %#^TM_KO#__ # I?\Z"XO@$
M        >?N6O[27!?\ Q#^1(!>/0((                 .F7$B3XZXDYA
MN3%<T)QAY"7&U:&1EJE1&1Z&6H#H.GJ%>4-4",?Q?_J&K+9^7TT_>NGJ>!>]
MT\ '8JNKUS462XC*K%M';;F&VDWTH/7U27IN(NI]-0&.W0435HN\:JXB+IPM
MKEDF.T4I2=--#=).\RTZ>(#K3C&-HM#O$TT%-T9FH[(HS)2C,_$^[MW_ /2
MRU5M<N<BS7$959-I[:)AMH-]*.OJDYIN(NI]-0'U==7N36[)R(RNQ92;;,M3
M:3>0@]=4I69;B(]3Z$?I $5U>W-<LFXC*+%Y)-O2TMI)Y:"TT2I9%N,BT+H9
M^@!AGC&-G:?'ATT$[HCU*R.,SYK7W>[MW_\ 2 [;6BI+Q#3=W6Q;)MA6]E$Q
MAN02%_=))Q*M#^J0#M^*ZPY;5@<)CS[".TQ*[2.\AO0RVI7IN).AGT(_2 RP
M                 !7W.O\ 0OG_ /,%E^3+ 9/#/]$.!?[O5/Y$T!J<
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MC2FB?84;FBV]WOD]2ZET!=;_ -K"@EY!P+EC$))K?@ML61H(M=6H4AMYX_\
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M;J95[<*81/XXXLQG#+5U+UG61E><4V>Y"7Y#JY"T)/TDA3AH(_3IJ":GP(
M    "A_;(_L^9-_EJW\O8!<7JU^](_P2_N CF      //W$W]I/G3_A[\B4"
MZ] @@                                                  *']I;
M_7>'_P#F!2_YT%Q? (                                \_<M?VDN"_
M^(?R) +QZ!!
M  5]SK_0OG_\P67Y,L!D\,_T0X%_N]4_D30&IP      *$>_ME1O^7I_[76"
M\7V"                 #JD1V)<=V)*:2]%?0II]EPB4A;:R-*DJ(^AD9'H
M9 (QQQ@-=QGB[6(4TR5+IHCS[M>F:M+CD=F0X;O82M*4FI"%*5MW:GU\0$L
M  !A7$!VTJ9U8Q,=KWID=V.B?&V]]A3J#03C>XE)WIUW)U(RU :? ,&H^-\1
MJ\,QQ"TU=6V:$..F2GG7%J-;CKAD1$:UK4:E:$1=>A$6A )*
M           "A_;(_L^9-_EJW\O8!<7JU^](_P $O[@(Y@     #S]Q-_:3Y
MT_X>_(E NO0((
M   "A_:6_P!=X?\ ^8%+_G07%\ @                               #
MS]RU_:2X+_XA_(D O'H$$  !YXRWDKE'..5K/B7AI^!3LXRPV_D^4V+7FNV\
M\DC2PRT9&DS]8BZEU,E=4DGUJ-_QM/\ : I\YEXAR?&B9%BRHOF:_-*YMN(E
M+VO[R\R1IZGH9:)1JD]#U,E= V5[[2?"N-Y*YB=OE;#-NPYV)6QI]V.P\1F1
MH=D-MJ:0HC(R41K]7TZ""T$RXRXI3FG4NPU-D\A]LR6A39IW$I)IU(R,NI:
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MNK<>J=22?4C!%E  "ON=?Z%\_P#Y@LOR98#)X9_HAP+_ '>J?R)H#4X
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MTF9@.0#$LK2MIH+UG<3&*^MCD2I$R6ZAAALE&22-;CADDM3,BZF RR,C+4O
M   &) M:NU*2=7-CSBAON0Y9QG4/$S)9T)QES89[7$:EN0KJ7I 98
M "A_;(_L^9-_EJW\O8!<7JU^](_P2_N CF      //W$W]I/G3_A[\B4"Z]
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MM -D Z(TV'-)TX<AJ03#BF'S96ES8\W[Y"MIGHI/I2?4@'>
M      "A_:6_UWA__F!2_P"=!<7P"
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M[U:%KN46H@L4!0_M+?Z[P_\ \P*7_.@N+X!
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MTZ>Y3UQ?W 'SZ(.8M-/IPM?T/7@'T0<Q::?3A:Z?S/7@'T0<Q::?3A:_H>O
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M0:C4I)L=5;B,BZ^X()V  *^YU_H7S_\ F"R_)E@,GAG^B' O]WJG\B: U.
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M-DQ3-!DM6AH929[?3U+507 " "A_;(_L^9-_EJW\O8!<7JU^](_P2_N CF
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M6O[27!?_ !#^1(!>/0((
M          "ON=?Z%\__ )@LOR98#)X9_HAP+_=ZI_(F@-3@      4(]_;*
MC?\ +T_]KK!>+[!             !#L'XOP_CU^TF8Y%>*PN7$NV,Z9(>FR7
M";U[;?<?4M1(1N/:DC 3$    !P>>9C-+?D.):8;+<MQQ1)0DB])F>A$ X19
M<2<RF3"?;DQU^\>96EQ!_L*29D8#L;<;=(U-+2M)&:3-)D9:ET,NGN .0
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MI61I/W $G(B21)21$DBT(BZ$1$ ^@*']I;_7>'_^8%+_ )T%Q? (
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MO,NI0XVLM?>K21B"1 *^YU_H7S_^8++\F6 R>&?Z(<"_W>J?R)H#4X
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M5]%$U*:2Z@C^KHHM1!L0%#^TM_KO#_\ S I?\Z"XO@$
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M9)42E;M-VX]=0%PV-G$IN9,RMYT-=E"@<8QY4FN9ZNR&F),E:VD?561;2_9
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MCCV,9CR=/Y2Y!/'YE!'NL-D8=B-5:I3&L9?<;>>4^^P:OO)*=62&R6>NG4]
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M05PBN\SM[6JWJ0KOP9+;"6GD[%*T)6P^BM#^H(.WV<L9OL.X7Q;&\G@KKKR
MW+3+A.*0M39N37W$ZFVI2>J%)5T/T@-'8PLPXPY4RK-Z?&)F78KG+%<J8S4K
M8\_!LZME49!=F0XT2F76S(S62]4J+P]VB%+XCY#SW!N5:_)JB/1Y-D61,9!1
MP9#R)<-:8K,9;3#KC)Z*(R;-AQ73UM3+H ZJ;C^';VU%$H^ X&*V4>4P]DEQ
MD"([\",PT9*<* <63OD.J,OO2]J4EXJ+0!+)5!R)3<O\EOT%0^ECD&GA-T.6
M(6RJ'6V%57264>90:NYU=4C;M0KZVN@5%8<3V]MQK88Y!X=F/<MKKNW>9GD<
MN-*0[+;(E//0I#DA]QUUXTF3))0V2-W56A=2K@FT^9X+F]+RC3XU+R.KL<9A
MX_DE'"6PFUA/Q%=]I]M#KB$.EZRFG$)7J1^MJ9 C5YS5\P\CX9:2K.A.#&E9
M!12<9Q4S8.QAU\"0A<F1+>0X:#4Z9;^T1F;9%IJ9@)URAC-]=YUQ9:5,)<J!
M1W4B7;/H-)%'87#6VE:B49&9&H]/5U ;;FRCMLEXFR^AHHJIMQ85K\>'$0:2
M4XZLNB2-1D7US$$"GT68XYR5QQF$7&I5S6L8T6,VZ8;C"7($AYV.LW74N+3N
M;225:[-?#]C6BS,2S23DM_E]#+JE5KV+6#<!+AO)?*2T_'1(;>T2DB1N2LCV
M&9F1::B"NN>\9R.]N\3E/T5AEW&$/S?RFQ6FDE&E/R%I3Y5Y;9NL>8:09&1M
M=PO=/4A1'^+, MZ3FMO+Z[CU&#8%*QF150HC:HQRO,IFLOD[/2PM9)=<21D@
MM[FB4D1F1]"#88-@685GLHVN!6%4Y'S"14Y%&:JE+;-PWI[TQ;"-R5FCUR<1
MIZWIZB*ZH>+9UQ]98!R17X[(OCAX5!P_+L=AN,E8QO+=N0V]'2XM#;RD.[VW
M$=PNG4M?142#C*#GEARSF6=Y7C;F.U%W5U,>DCO/L/ODU$5(W)?[*E$E[56]
M2.NTE$G4S(P&YYBQJ]R*;QN[20E3$4V8UUK9F@T)[$)AF2AQT]YEJ236GHG4
M_J""*\W\8JN\SQ[D1S$FL]J*V$_4W>,*4VF5V'7">:E1"=6A"G&U[B4A2B-2
M5=/=*C[Q)@Z6<GN+^MXTK^.\77 .!6>991\HI+[RB4ZXX;#[K;3!$DD]HR-1
MJ+=NTZ (53X+R=(]GEGCA>*.PLPP6PA2X34F0QY2X\E8+F&49Y*CVD:"TU<(
MBU,B_8"5V4CD?D?D3C7(3P2=CN*XU92G;-VU>C%--V1!<:)26&7%Z,H/U=YJ
MU6:BT21$8"9<+8W?8Y](?Q[ 7!^-LUN;6MWJ0KOP)79[+Q;%*T)>T]"5H?3P
M$$,P; LPK/91M<"L*IR/F$BIR*,U5*6V;AO3WIBV$;DK-'KDXC3UO3U!5N\<
M5TZGX\Q*IM&#C6<"FKHLV,HR4II]B*VAQ!FDS(S2HC+H>@(DP"A_:6_UWA__
M )@4O^=!<7P"                                //W+7]I+@O\ XA_(
MD O'H$$ &#74U14+F.54"/!78R%S9ZHS2&C?E.:;WG301;UJT+52NI@/J:>I
M1;+ODP8Z;MQ@H;ED32"DJC)5O)HW=-QH)1[B3KIJ CD/BCC&OL)EK"P^G8L;
M!#K4R0B#');B)!&EU*O4\'",R67VWIU ;U_':"32%C4FKB/XZ32(Q5+K#:X?
M8:TV-]E231M3M+:6FA:$ SCBQCC'"-E!PS1V3CFDNUVM-NS;IIMTZ: (YCG&
MW'V(37K+%L7JZ:PD$9.RH,-F.Z:3\4DI"2,D_P!Z70!O+9=HW537*1IE^Y0P
MZJO8E+4U'<DD@S;2XM!*4E!JT)2B2>A>@!7_ !5A&24]EE&=YX4).=9A)87+
MC5IK7%AP(#78B1D.+(C6HD[E.+T+<H_J$ D^3\>8)FKT:1EV-UMW(B%I&>GQ
M6I"VTZZFDE+29[3/J:? P&UE45).IUX],K8K]"XT49=6ZRVN(;!%H39M&6S:
M6GO=- &IHN.\"Q<HOR=QFLJU0G'7XBXD1EI;;TAOM.+2M*242EH]12M=33T\
M &ZK:BJIVWVJF$Q!:DON2Y"(S2&4N2'SW..K)!%JM9]5*/J8"#\T8/<\@8A'
MHJ-4=$UJUK;!1RU&AHV84I#SA>JE>IFE/0M.HN"18_@6$XI.FV>,X]75%A8F
M9SI4**TPZ[J>XR4I"2/37KIX:]1!M:^HJJI4M=7!8A*L)"YLY4=I#1ORG"(E
MO.;2+<M1)(C4KJ>@#1S.-./+#($97.Q6JD9(A1+3:.PF%R=Y>"S6:=347H4?
M4O0 W*:*D3=+R--=&+(%L%#5:=I'FSC$K>3/=TW[-WK;==->H#29)53ZF-;9
M)@%%5R<\G)CH><F?Z&4Q#*B227Y#2%+5VT&KM[M?<Z$8#6\1X',P+&)#-T\Q
M*RV^L)=_DTN(DT1G+*Q<[CA-$K0R;0G:VG7Q).NA:Z )XI*5I-"R)25%HI)]
M2,C]!@(S0\<X!B]G(NL<QBLJK:5KWYL*&RP\HE=5%N0DC(C/J9%T/T@.'T9\
M=GD:LN/%:H\G4KNJMCALG)-T^AN;]NN\_N_??5 ;&)B.*P&ZQF#208S5(IU=
M,AJ,TA,-4C=W3CDE)=LU[E;MFFNH#[DF)XQF-?\ %655$2YKMQ.)C3F4/H2L
MO!2261[5?5+J Y4V+XUCF[Y/T\*JWLLQEG"CM1S4Q%)1,MGVTIU2V2E;"/PU
M/0!]R'&<=RVM73Y151;BK6HEJB3F4/M;T^"B2LCT46O11=2 851@.$4!5_Q'
MCE;7'4F\=8J+$9:5'.4DDO&VI*2-)N$1$LR]]Z0&S.DICN"R$Z^,=\F/Y(K3
MLH\V44U]SL]W3?V]WK;==->H#49-QW@>:2(TO+<;K;N5#+;&>GQ6I"T)UUVD
MI:3/;KUV^'U &2O"<.<8L8KF/URHMNAANU8.(SVY2(B22PEY.W19-D1$@E:[
M2\ &>BEIVK%=PW CHMG(Z83DY+2"D*BH4:DLFYIN-!*,S).NFH".PN)^,*V5
M.FP,.IH\NS;<8GNMP(Y&\R^6CK:O4]XO[=/@KT@,VUX_P6\C>3N<;K9\;RK5
M<3<B(R[I#CJWM,D:DF9(0KUD)+HD^I=0&5$Q+%H% K%85+!CXRMM3*ZAN,TF
M&IM?ODJ9).PR5]MJ77T@/EYA^*Y-4(H,AI85G2M$DFH$N.V\RWVRVIV)41DD
MTET(TZ: .['\:Q[%*U%/C%7%IZM"C6F'!91':WJ]\HTMD1&H_29]3 ;0!7W.
MO]"^?_S!9?DRP&3PS_1#@7^[U3^1- :G       H1[^V5&_Y>G_M=8+Q?8(
M           BG(.#(Y!I$T+U[:T44W=\IVDD)BO2&%(6VN.ZI2'-6UDOJ1$1
MZD74!O:6FK<=J(%#31TQ:FL8:B0HR-32VRPDD(3J>IGH1>)]3 9P
M                  B/(>!-<ATR**3>6M'"-PSFG2R$Q7)4=:%-N1WE*0O5
MM9*ZD6A_5 2*HJJZBJH5)41TQ:JN8:B0HR-=K;#""0A!:ZGT21%U 9@
M H?VR/[/F3?Y:M_+V 7%ZM?O2/\ !+^X".8      \_<3?VD^=/^'OR)0+KT
M""        ,6!65U6VZS6Q&HC3[SLIY#"$MDN0^LUN.*VD6JUJ,U*4?4S 90
M                    #%A5E=6^9^+XC44YCZY<LV4);-Z0[IO=<-)%N6K0
MB-1]>A>X R@                 !0_M+?Z[P_\ \P*7_.@N+X!
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M'6'T$MM:3]Q23(R$&4 H?VEO]=X?_P"8%+_G07%\ @
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M+Y__ #!9?DRP&3PS_1#@7^[U3^1- :G       H1[^V5&_Y>G_M=8+Q?8(
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M<01]UOH>IIZ$?0C*S8)<=YOEF&UF-9MG7)5C%N8=N[7RI;:(=.<)9K\W--Z
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M*2DW20?J[]I;M-=!!( %#^TM_KO#_P#S I?\Z"XO@$
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MR(M"T(!(,EQF@S"FDX]D]>S:4LPB*1#D)W(5L42DGZ#(TF1&E1'J1^ "&U?
MG$M.N,_$QQ#DZ'*CSXEA+D2IDUJ1"4:V#1(D.N.I2@S,^V2]A^E)@,S+^&.-
M,[M2N\GHD2K8VRCORF7Y$-<AA/@U(\LZT3R/1M=W%IT\ &PR#C+ LGQV%BES
M11GJ"L[?Q7$:)4;R9LIV-JC+8-"VC270C;41@.6,<;8-A]--H*"E88J[,U':
M-O;Y:YAN)VJ.2Y(4XMW4C,OOBCZ -+C?!7%.)73&046.MLVD,U' <>?DRVXA
MN:[O+-2'7&V==?\ JDI <LIX.XMS.Y>R#(*!+UM*2E$Z1'DRH7FT((DI3)1%
M=:2\1$1)^^I5TZ> #99#Q7Q]E%%6XW<4,==13;2IVH^^&N%L222\N[&4VXUT
M(B]11:Z%J S,-P#$./X+]?B-8BO9E.=^8[O<?D2'=--[S[RENN'[AK6>@#CG
M''N'<D53=+FM4W:US+R9+"%K<:6V\DC22T.,J0M)Z*,O54 RZC#\;HK>TOZF
MO1&N+I$1JTEI4M2WT5[79CDO<HR^]H]4C+]L!BQN/\+BU5Y1M4L8ZC)9<BQO
M83B3=:ERYNWO.N)<-756U/AX:=- &GP_A;C/!+0KO&:),>V0T<>/+??DS7([
M"NAM1SE.N]E&G3:UM+3IX )T\RS)9<CR&TO1WDJ;=:<22D+0HM%)4D]2,C(]
M#(P%91/9TX7A'()O%&'&)#;S11)#TF3%93))1.>78>=6VPI1*5ZS*4J+7H9
M-KD'#'&64KBO7N/LRI<&"Q509O=?;E1XD59K:0R^VXEQLTJ4?KI42CU,C,R
M;K%<%Q'"J-6-XS5,P:9PUKD1_6=-];I:+6^MTUK=4HNBE.*49D C5)P-Q)CM
MVQD-1C+#%A$<4_!0IV0]%BO*ZFN/%=<4PRK7KN;;29'U(!*LGPW&,S8@QLHK
M&;-BMF-64%#^NC4MC4D.%M,O#<?0^A^D@'/*<3QO-J9_'LKK&+:FD&1NQ)*=
MR=R>J5),M%)47H4DR,@&GPKBO ^/7Y4O%*@HMA.2EN78/O/S9CC:/>H-^4XZ
MYL+0O4)6WH73H F(   *^YU_H7S_ /F"R_)E@,GAG^B' O\ =ZI_(F@-3@
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M-7<+H6F@# XVSZLY-Q&)F5/'=BUTYV4W'9D[2?V1)+L;<M*3,DFHVC5MUZ$
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M=O)KD8OE+T)R%#GEY]A3J6'T+4MO>P3BD]]#?<3KMU%'J$0
M     !0_M+?Z[P__ ,P*7_.@N+X!
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M]E^TH[M/*%QC1)^(9V:3Y->M"#;0XR['CJ)Q*3(C)*]=Z2,BZ'X :OT$
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M@D                   H?VEO\ 7>'_ /F!2_YT%Q? (
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M"Q)KGD[CK'KIO';W*JJNO7=I)KY4QEI\C7ILW)4HC3NU]7=IKZ 1*R/7J7@
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M 2I*DK22DF2DJ+5*BZD9'Z2 ?0%#^V1_9\R;_+5OY>P"XO5K]Z1_@E_<!',
M     >?N)O[2?.G_  ]^1*!=>@00
M                  %#^TM_KO#_ /S I?\ .@N+X!
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MV1_9\R;_ "U;^7L N+U:_>D?X)?W 1S      'G[B;^TGSI_P]^1*!=>@00
M                                                 %#^TM_KO#__
M # I?\Z"XO@$                                >?N6O[27!?\ Q#^1
M(!>/0((            KB#PUCD#EV=R^V^\JVFQ#C%6JV^4:DN(:9<E(+34G
M5M,I;4?I+777T!T9+Q+82<KFYM@&62\*R*X::8OS8BQK&).*,G8RXY'E$:2>
M;2>U+B3\/$CZZAC/<!XQ(XTR#CN1/FR'<H?^,;O(GUI<L)%GW6WBDJ/:22VK
M:1M0DB222T]TP"UX<M;)K'KM&:SHO)V/,OPV\T:BQ27+B2'#<./+A[>RXT7J
M[4]#(RW:ZF8#<X#QD>(6UOE-Y?3,IS.]2TU/N)B6X[:8\<OO;$>,R1-M-D9F
MHR+4S/J9@,/G'+<0QS [*KRYB3.:R2-*JJ^KA1GY+\R4ZPK8P@V4+)"U?:*7
MH1'UUZ ,7B/BN)C7#,' LIC%+DVT1YW*FGE&M3\NS(UR4N+(]5*22NUO(]?5
M(P&G+V?["97Q</R+/K:ZXNA+:[&*/L16W'6(RB4S'DSFT$\\R@TI]7U3/3J?
M0M*-[EW$D^URYO.L)RR7AF2K@HJ;%V+%C3HTJ$TLUMI4Q)2:$K09GM67@7H$
M&E_JYTQ8+F>#)R*S>8S2P8M9]K+[4B:F2RN.ZM6XTI2LW5L;E:I+3=T+H0"Z
M0%9Y-Q7<2\KEYK@F8S,/O;9AF->)1%CV<.8B*DT,K-B41DAUM)FDEH5X>)>.
MH:]' -$UC])3(MIBY=;E;&=6EJZ32Y%G;M*4MQ3Q$E*4I<,R+[V1:$DB]W4)
M9?X!$O\ /</SQV:ZQ+P]%FB/#0E!M2"MF$L+[AGU+8224G;Z0$!J?9\G4M._
M@M;GUK$XJ>5)VXO'CQ&Y*&)BUNN1TV)H4\3*E.'J1%O,M2W=3 ;S'N%8-"YQ
MJZ5S)DJXUCV42"2FFD%+;LV"C_?="]4VTD6W;X^D!GYMQ<YD60P\VQ;().(Y
MU#C*KSMXK+,MJ3 4ON>7DQGR-#B4K]9!ZDI)^GPT#5P^"*1_'\JK,NN;'([W
M-28+(,@>6F+(,X1[HI1FF"2TPEA1;D)2DRU]]J70!PKN'+V7<T=CR#G<[,:[
M&)2+&AJWX<."VB<RE2&I$ER.G>^XV2E;3,T]>NFNNH3JMQVR@Y7=9"_?S)M;
M:-QFXE"]L\G!..V2%J9T+=JZ9;E;C\0$@           !7W.O]"^?_S!9?DR
MP&3PS_1#@7^[U3^1- :G       H1[^V5&_Y>G_M=8+Q?8(T\[%<?LL@J<JG
M04/9!1HD-U,Y2EDMA$U!(>))$HDGO26GK$?U &+5X)B5+C,K#JRK;CXS-3*3
M*KDJ<4VM,\U'((S4HU>OO5KH?IZ -1><.\;9'0TV-V]"V[58\VEFC)IU^/(A
MMH2E!)9D,N(>26B4DK[YZVA:Z@,NAXNP'&<;L,2IJ*.Q06Q.E:Q7#6^J7YA.
MQPY#KREN.&I)Z:K69@,;'N(>.L531(H:-$4L9>F2:(S?D/*BNV2.W)-!NNK,
MR<3TT5J1>C0!D9SQ?@O)"819C4)GO5RE+@2D.OQ)3!N:;B;?C.-.))6A;D[M
M# =F)\9X%@J9R,1H(M2W9LQX]@W'2>Q]N&A:&B<2HS)1D3B]RCZJU,U&9@-)
M0<#\2XQ?,Y)28RQ&M(JUO0=79#L:*XYU4N-&==4RRH_=:;3]0%K/L.(>.+3(
MK7+)M"TN_O8#U1<2TNOM^:A26B9<;<0AQ*#,T))._;O(O P2NW(^*./LLI*K
M'KZC:D5E&AMNFV./1Y$-#*$MI)B0RM#R/50DCVKZZ%KKH [*+B[ <:QFQP^D
MHV(N/W#;S5M&W...2TR6S:=-]Y:E.N*4DS2:E+,_J@,FRX_PZWPUKCZRJFY&
M',L1HC=2I3A-DQ!-"F$;B42]$&VC[;T=0&LS3B#COD&>Q;953%)MHS?EVK&-
M(DP)78,S/M*>B.LK4C51GM49EU 2+&L8Q_#J6-CV+US-72PR,H\..G:A.XS4
MHS\3-2C,S4I1F9GX@-5DG&N$9;?TF4Y!4-R\AQUU+]/8$XZRZRMM9.)ZM+1O
M22BW;'-R?J=3 :._X%XDR>\D9%=8RR_9S%H=L#;>D1X\MQL]R528[+J&7E$?
M75U"OJ@M6''CL1&&HL5I#$5A"6F66DDAM#:"VI2E*="(B(M"(@1ILBPS%\M?
MJ).1UC5@_13$652X[NU8EM=4N)VF6NFG@K4NA=.@!EV&8MGE,N@RZK9M:E:D
MN=AXC(T.(UVN-K0:5MK+4R):%$KJ?4!KL)XPP7COS:\1J$0I4\TG.FN.O2YC
MQ(]Z3DB2MUU24^A)KT(!CTG$/&V.-Y$Q3X]&8B989*R"&HW'HLG3?T-AU:VT
M%]\5T;2DNO[ ##Q+@[BS![AN_P ;Q]$>W80IJ))?D2IAQFUZDI,=,IUU+)&1
MF7WHD]#T\ 6II<RY\"IG3:N JTLHS#CL2M0ZAA4EU"34EHG'/40:S+:2E="]
M((K3B#"KR%>YER=F%0S199F\J.HZ9EUN3Y*OKV"880MUOU5.N&2G'30>AGM]
M):$5NLPX4XPSRV.]R>@1)MUME'D2V'Y,)R0RG0B;D'%=:[R="(MKN[IT\ *W
M5EQ]A-OB18'8441W#TMH9;J";)N.A#9[D;"1M-!I/J2DF1Z]=01I,6X1XMPR
MQA7..XZU&NJ]3ZXMFX[(DS".2T3#A*??<<6M/;+:E*U&22]Z1:@M2G'<8H<2
M@NUN.PDP(+TA^:XRA2U$<B4LW'5ZK4H_64>ON>X"..58EC>;TK^.Y76LVM-)
MT-V)((S3N2>J5),C)25%Z%),C+W0&AQ#B#CO!7)TC&Z4F)EDSY:;-DR),Z4Y
M'_@N_+==<2WT+U$J)/0CTU(!L6N/<-9PH^.VJIM.%G'7#.I);O;[#BC6I._?
MOZF9GKNU :W*N(..LT9JF<AI$O*I&BCU,F._(A2H[!)V=M#\5UIW9MZ;37H
M^5?#?&-(Q.C5&-183%G6+HK)#'<04FO=-2EMO:+]=2C6K<ZK5P]?? 5)&\:H
M&L<:Q J]E>,LPT5B*MU/=8\DVV3*65)<W;DD@B3ZVH"(8IP7Q5A5RUD&.X\B
M/;QDK1"D/R)4SRJ7-2449$EUU+)&2C+[TE/3IX M<<FX'XGR^ZD9#?8ZAZUF
M[?/NL29<-$KMZ;?,MQGFD/::?]8E0%2*QP'#;5./HG4\=;6*/M2\=:02FFX3
MT=)):-I#9I3H@B+:DRTZ> (D@"A_;(_L^9-_EJW\O8!<7JU^](_P2_N CF
M    //W$W]I/G3_A[\B4"Z] @@
M                *']I;_7>'_\ F!2_YT%Q? (
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MY7SG.N-Y&.G79@J!O;N2DN.H37QB:3H3)HVZJ->O4]>@*V6WVP/X;!_P,_\
M&@>&WVP/X;!_P,_\:!X;?; _AL'_  ,_\:!X;?; _AL'_ S_ ,:!X;?; _AL
M'_ S_P :!X;?; _AL'_ S_QH'AM]L#^&P?\  S_QH'AM]L#^&P?\#/\ QH'A
MM]L#^&P?\#/_ !H'AM]L#^&P?\#/_&@>&WVP/X;!_P #/_&@>&WVP/X;!_P,
M_P#&@>&WVP/X;!_P,_\ &@>&WVP/X;!_P,_\:!X;?; _AL'_  ,_\:!X;?;
M_AL'_ S_ ,:!X;?; _AL'_ S_P :!X;?; _AL'_ S_QH'AM]L#^&P?\  S_Q
MH'AM]L#^&P?\#/\ QH'AM]L#^&P?\#/_ !H'AM]L#^&P?\#/_&@>&WVP/X;!
M_P #/_&@>&WVP/X;!_P,_P#&@>&WVP/X;!_P,_\ &@>&WVP/X;!_P,_\:!X;
M?; _AL'_  ,_\:!X;?; _AL'_ S_ ,:!X;?; _AL'_ S_P :!X;?; _AL'_
MS_QH'AM]L#^&P?\  S_QH'AM]L#^&P?\#/\ QH'AM]L#^&P?\#/_ !H'AM]L
M#^&P?\#/_&@>&WVP/X;!_P #/_&@>&WVP/X;!_P,_P#&@>&WVP/X;!_P,_\
M&@>&WVP/X;!_P,_\:!X;?; _AL'_  ,_\:!XT=UQ[[1N>7N&.9U)Q9%'C.0P
M,@<^*TRVY*O)+/<DC=4LCU0I6A=.NG4!Z5!
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
0                  ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>sg_eyalrubin-bw.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 sg_eyalrubin-bw.jpg
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M%!04%!04%!3_P  1"  \ , # 1$  A$! Q$!_\0 >    @(" P$
M      <%!@@) 0,$ @$! 0                    $0  $# P," P<# P,%
M 0    $" P01!08 $@<A"#%!$U%A(C(4%0EQ@2-"8H)2DQ:QHK(D&#01 0
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MO)"T+2H="E22"#H/1H#0&@- :"'RG*L>PFPS<HRNXLVJP6Y'JS)T@D(0DD)
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M&O\ JD%83^B !H&C9,6QC&6U,XW98%G:7\S=OBLQ$FGM#24UT$MH#0&@- :
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!V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
